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Abstract
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease with unknown aetiology. 
The prevalence of RA in South Asian Indians is 0.75%. Compared to the general 
population; RA patients have a reduced life span which is mostly due to cardiovascular 
disease (CVD). The increased risk of CVD, observed in RA, may be due to a 
combination of RA disease activity, medicines used to treat RA and traditional 
cardiovascular (CV) risk factors. Much of the published work exploring these 
associations has been conducted in North American and European RA cohorts. South 
Asian Indians are known to have an increased prevalence of traditional CV risk factors 
and metabolic syndrome as well as premature CVD events compared to Caucasians. It 
is not known, in South Asian Indian patients, whether having RA increases this CV risk 
further. In addition influence of increased RA disease activity and treatment on CV risk 
in Indian RA patients is not well studied.
Aims
The aim of this thesis is to measure the prevalence of traditional risk factors for CVD in 
urban Indian patients with (RA) and to compare these risk factors with age and gender 
matched normal controls from similar geographic location. The effect of treatment by 
biologic disease modifying anti rheumatoid drug (DMARD), etanercept and newer 
traditional DMARD leflunomide on traditional CV risk factors are also studied.
Methods
Consecutive South Asian Indian RA patients attending a rheumatology clinic in the city 
of Hyderabad, India, who fulfilled 1987 ACR criteria, were included in this study. Age 
and gender matched controls from the same geographic location were recruited. 
Traditional CV risk factors were measured and composite coronary heart disease (CHD) 
risk scores for the probability of a CHD event in next ten years were calculated. 
Metabolic syndrome criteria were applied to all participants. Prevalence of CV risk 
factors was explored in the RA patients. Prevalence of CV risk in RA cases was 
compared to that in the control group using logistic regression adjusting for age and 
gender. Within the RA cohort, associations between disease activity and measures of 
CV risk were explored. In addition, the influence of initiating drug therapy with 
leflunomide and etanercept on CV risk was evaluated in small subgroup analyses.
Results
Eight hundred RA patients and 800 controls were recruited. RA patients had increased 
prevalence of almost all the traditional CV risk factors. The cases and controls 
displayed increased prevalence of increased BMI. Co morbidities were more frequently 
observed in RA cases and RA was associated with increased prevalence of diastolic 
hypertension, elevated fasting blood glucose, high waist hip ratio, elevated total 
cholesterol and a trend for lower HDL cholesterol. Almost half of the cases fulfilled
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criteria for metabolic syndrome. RA patients had a four times increased odds of having 
elevated CHD risk scores when compared to controls.
RA disease activity was not associated with traditional CV risk factors. Leflunomide 
did not cause hypertension; interestingly the patients with pre treatment elevated 
systolic BP had a reduction in BP after treatment with leflunomide. There was a modest 
improvement in atherogenic index. No significant change in metabolic syndrome was 
observed. A short course of etanercept treatment did not have a sustained effect on CV 
risk factors. It was encouraging to notice a sustained reduction in disease activity even 
after etanercept therapy was withdrawn.
Conclusions
South Asian Indian patients with RA have a very high prevalence of traditional CV risk 
factors despite their young age and predominantly female population. In particular, 
marked elevation in CV risk factors associated with the metabolic syndrome were 
observed in RA patients compared to population controls. This increased prevalence of 
CV risk does not appear to be associated with high RA disease activity. The effect of 
treatment to reduce disease activity has not demonstrated significant changes in CV risk 
factor profiles in patients with RA. As the background rate of CVD events is high in 
this population, the RA patient appears to be at greatly increased risk. Targeting CV risk 
factor reduction in these patients may substantially reduce CV event rates in RA.
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Chapter 1 — Introduction
1.1 Background
Rheumatoid arthritis (RA) is a chronic, systemic, immuno inflammatory disease of 
unknown aetiology. The term Rheumatoid arthritis was coined by Garrod in 1859 
(Garrod, 1859).
RA is characterized by bilateral symmetrical polyarthritis with a chronic fluctuating 
course, resulting in disability due to progressive joint destruction and deformity. The 
clinical features are articular and extra-articular. Extra articular features are given in 
Table 1.1
Table 1.1 Extra articular manifestations seen in rheumatoid arthritis
General and systemic features
Anaemia, fever, fatigue, weight loss, cachexia,
Rheumatoid nodules
Vasculitis
Raynauds phenomena 
Secondary sjogrens syndrome 
Feltys syndrome
Organ involvement
Eye - scleritis, episcleritis, kerato conjunctivitis 
Lung - pleuritis, interstitial lung disease 
Kidney - Glomerulonephritis, amyloidosis 
Neuromuscular - neuropathy,neuritis, myopathy
Cardiovascular - pericarditis, endocarditis, atherosclerosis, coronary artery 
disease, stroke
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1.2 Diagnosis of RA
Diagnosis of RA is mainly clinical as there is no definite diagnostic test. In patients with 
a short history of joint pain, the diagnosis can often be difficult.
1.2.1 Rheumatoid Factor
Rheumatoid factors (RF) are autoantibodies (Ab) against Fc (fragment crystallisable) 
portion of IgG. The RF can be detected by latex agglutination, enzyme linked immuno 
assay (ELISA) or nephlometry. Latex agglutination method is routinely used in clinical 
practice. RF is positive in 70 — 80 % of patients with RA (Masi et ah, 1976). Twenty to 
thirty percent of patients with established disease may be negative for RF; this group of 
patients are classified as having RF negative arthritis which has a relatively mild course 
and better prognosis. RF has limited specificity and can be present in rheumatic 
conditions other than RA like systemic lupus erythematosus (SLE), acute and chronic 
infections and neoplasms, in these conditions the RF is nonspecific, of IgM type and of 
low affinity (Martinus AM van Boekel, 2002). RF is positive in 5% of general 
population and the prevalence increases with increasing age. Some studies have 
demonstrated that the prevalence of rheumatoid factor decreases after the age of seventy 
years (Gran et ah, 1984). The presence of RF in high titres is associated with severe 
erosive arthritis and presence of extra articular features (Scott, 2000, Lindqvist et ah, 
2005). Features present at disease onset which have a correlation with better disease 
outcome are: negative for rheumatoid factor, less involvement of upper limb joints, 
acute onset of arthritis below the age of thirty years and male gender (Masi et ah, 1976).
17
1.2.2 Anti CCP
Anti cyclic citrullinated peptide (anti CCP) antibodies against citrullinated residues of 
protein are found in the serum of RA patients. These antibodies were defined in 1998. 
Like RF they have a sensitivity of 70% but their specificity is up to 95% (Schellekens et 
ah, 1998). This test is useful in individuals who test positive for RF due to infection or 
as part of the normal population variation. More than 30% of patients with RF-negative 
arthritis are positive for anti CCP antibodies, these are better indicators of erosive RA 
but do not predict extra articular disease (Rantapaa-Dahlqvist S, 2003). Patients with 
positive RF and anti CCP Ab have a strong possibility of radiographic erosions (Meyer 
O, 2003). Indian patients with RA demonstrate anti-CCP antibodies in 80% of 
established RA and predict erosive disease in RF positive and RF negative individuals 
(Shankar et ah, 2006).
1.3 ACR classification Criteria
The first criteria to aid classification of RA were published (Ropes et ah, 1958) by a 
committee of the American Rheumatology Association (ARA; 1956) that were widely 
used for the next thirty years. Later, the American College of Rheumatology (ACR) 
revised the criteria in 1987 for classification of RA and not for diagnosis (Table 1.2). 
The criteria are helpful in classification of RA and have a sensitivity of 94% and a 
specificity of 89% (MacGregor, 1995). They are widely used in epidemiology studies 
and clinical trials. Flowever, it is difficult to identify early RA using these criteria 
because two out of the seven criteria (subcutaneous nodules and radiographic erosions) 
are frequently not present in early disease. At least four of the criteria listed below must
18
be fulfilled to classify a patient as RA. The ACR criteria have been developed for 
Caucasian patients but are found useful to all populations. However, there are no studies 
reporting validity of the ACR criteria for Indian populations.
Table 1.2 The 1987 ACR classification criteria for rheumatoid arthritis 
(Arnett et al., 1988)
Criterion Comment
1. Morning stiffness Duration > 1 hour lasting > 6 weeks
2. Arthritis of at least three Soft tissue swelling or exudation lasting > 6
areas weeks
3. Arthritis of hand joints Wrist, metacarpophalangeal (MCP) joints or
proximal interphalangeal(PIP) joints lasting > 6
weeks
At least one area lasting > 6 weeks
4. Symmetrical arthritis As observed by a physician
5. Rheumatoid nodules As assessed by a method positive in less than
6. Serum rheumatoid factor 5% of control subjects
As seen on anteroposterior films of wrists and
7. Radiographic changes hands
The ACR criteria have been used widely over past two decades. Recently, another 
revision of the classification criteria for RA has been undertaken. These new criteria 
were jointly developed by the ACR and EULAR (European League Against 
Rheumatism) (Aletaha, 2010).
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1.4 Epidemiology of Rheumatoid Arthritis
1.4.1 General incidence and prevalence
Rheumatoid arthritis is prevalent all over the world covering all ethnic groups. Based on 
the classification criteria several studies have observed a worldwide prevalence of 0.5 — 
1% in adult population. Studies have shown that geography, climate, (Spector, 
T.D.1995) genetics and environment play a role in the development of RA. Onset of 
disease is between fourth and sixth decade of life and the incidence increases with 
increasing age.
Table 1.3 Prevalence of rheumatoid arthritis
Population Size Prevalence (%) Reference
South Africa
Rural 801 0 (Beighton et ah, 1975)
Urban 964 0.9 (Solomon L, 1975)
Nigeria 2000 0 (Silman et ah, 1993)
Europe and N America
UK 2234 1.1 (Lawrence, 1961)
US Adults 6672 1 (Engel 1968)
US Whites 4552 0.9 (Cathcart and O'Sullivan, 1970)
National Sample, Denmark 19,100 0.8 (Sorenson, 1973)
Heinola, Finland 8,000 2 (Ahoetah, 1989)
Hanover, Germany 11,534 0.5 (Man, 1991)
Belgrade, Serbia 2184 0.2 (Stojanovic etah, 1998)
Holland, Sweden 3928 0.5 (Simonsson et ah, 1999)
Brittany, France 2740 0.6 (Sarauxetal., 1999)
Norfolk, UK 6593 0.8 (Symmons et ah, 2002)
Madrid, Spain 2998 0.5 (Carmona et ah, 2002)
Izmir, Turkey 2887 0.5 (Akar, 2006)
Native American
Inuit, Eskimos, Canada 2055 1.8 (Oenetal., 1986)
Southeast, Alaskan, Indians 5169 2.4 (Boyer etah, 1991)
Pima Indians, USA 2895 2 (Jacobsson et ah, 1994)
Inupiat, Alaska 1651 1.4 (Boyer etah, 1998)
Yupik, Alaska 2135 0.6
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In a prospective population study in Norfolk, United Kingdom, Symmons et al (1994) 
observed an incidence of 3.4 in women and 1.4 in men per 10,000 subjects that 
corresponds to a threefold increased prevalence observed in women. The gender 
difference in prevalence becomes narrower as age advances. Many prevalence studies 
have also been conducted in American, Asian and African populations as given in Table 
1.3
1.4.2 Prevalence in Asia
The prevalence of rheumatoid arthritis varies due to changes in geographic location, 
ethnic groups, methods of survey, definition of the disease and the classification criteria 
used. The overall prevalence of RA in Asians is less than that seen in Caucasians (Table 
1.4). There is difference in the occurrence of RA in rural and urban areas (Chou et al., 
1994). There is trend for rheumatological complains to be more frequent in urban areas 
the reasons are not known and their differentiation into type of disorder was not done 
(Das, 2005). However, a study in Indians from Pune has reported RA to be more 
common in rural populations (Chopra, 2009).
The mean prevalence in Asia is about 0.3 with an exception of Middle Eastern 
countries where it is higher. It is proposed that this difference may be due to variations 
in genetic, environmental and socio-economic factors, like social class (affluent and 
poor), level of education, type of work (manual labourers) described later 
(Section 1.5.3.3).
A comparative study between British and Malaysian patients concluded that, whilst the 
disease activity and functional disability were similar, differences existed in pattern of
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disease and distribution of joint involvement (Veerapen, 1992). The British patients had 
more severe involvement of feet and had extra articular manifestations whereas in the 
Malaysian patients wrist and cervical spine were more commonly affected and sicca 
syndrome was common. There is not much published literature regarding difference in 
RA patients from countries in Asia.
Table 1.4 Epidemiology of rheumatoid arthritis in Asia, Middle East and Far East
Population Size Prevalence (%) Reference
Japan —Kamitonda 2276 0.3 (Shichikawa etah, 1981)
China
Kinmet 5629 0.3 (Beasley et ah, 1983)
Shanghai 7603 0.3 (Dai et ah, 2003)
Hong Kong- Urban 2002 0.3 (Lau et ah, 1993)
Taiwan - Rural 3000 0.3 (Chou et ah, 1994)
Urban 6000 0.9
Indonesia- Java 4683 0.2 (Darmawan et ah, 1993)
India - Rural 39826 0.75 (Malaviya et ah, 1993)
India Pune Urban 4092 0.3 (Chopra, 2009)
Rural 0.6
Pakistan - Urban 2090 0.55 (Farooqi and Gibson,
Malaysia Rural 2594 0.15 1998)
Vietnam — Urban 2119 0.3 (Veerapen, 1992)
Iraq 6999 1 (Minh Hoa et ah, 2003)
Oman 1925 0.8 (Al-Rawi et ah, 1978)
(Pountain, 1991))
1.4.3 Epidemiology of rheumatoid arthritis in India
Prevalence of RA amongst the Indian adult population that forms the basis of this study 
is in the range of 0.2- 0.75% which is less than that described in Caucasian cohorts 
(Malaviya et ah, 1993, Chopra A, 2001, Das SK, 2004) but relatively higher than other 
Asian countries. In comparison, the natural history of the disease is similar to 
Caucasians but with some differences. The disease onset is earlier - between third and 
fifth decade (Chandrasekharan AN, 1994), course of the disease is milder, involvement
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of the wrist joint and the forefoot is reduced . Extra articular features are less frequent 
and less severe (Chandrasekharan AN, 1994). Rates of RF positive RA are lower than in 
Caucasians. HLA DR 4 may not correlate well with RF positive and severe disease 
(Chandrasekharan AN, 1994). RA has a polyarticular onset, the disease activity is 
milder but severe crippling disease is also seen.
Differences are observed in the disease characteristics in North and South India. In 
South Indians RA has a predilection for involvement of PIP joints whereas involvement 
of wrist joint is seen in North Indians. Hip joint is less affected in South Indians. Knee 
joint involvement is common in both the regions. Forefoot is less commonly affected 
and subtalar arthritis is common in both Asians and Indians. The extra articular features 
are uncommon and less severe, isolated eye involvement in the form of episcleritis is 
seen. Sicca syndrome is more prevalent in Asians and North Indians when compared to 
South Indians and Caucasians (Malaviya et al., 1983, Smith CR, 1993, Veerapen, 1992, 
Veerapen et al., 1993, Chandrasekharan AN, 1994).
A cohort of 400 RA patients attending a hospital in Mumbai (formerly Bombay) in 
western India was studied. The median age of onset of RA was thirty six years and 88% 
were females. Majority of the patients were educated, married and were found to be 
non-smokers. At the onset of arthritis 39% of the females were postmenopausal and the 
age at menopause was found to be 45.7 years. Smoking history was observed in 4% of 
individuals. Onset of RA in post partum period was observed in 1% of the cohort. 
History of tuberculosis and hepatitis in the past was reported by 11.5% and 13% of the
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participants. Positive family history of RA was reported by 10%. Majority of the 
participants reported a history of using alternate therapy in the past and one fourth of 
them were already taking GCS at the time of presentation to the rheumatologist. It was 
also observed that the 15% of patients had extra articular features in the form of 
anaemia, rheumatoid nodules, vasculitis or episcleritis (Kundu AK, 2004).
According to a survey conducted in North India looking at the prevalence of RA in a 
rural population that comprised mainly manual labourers, RA was found at a prevalence 
of 0.75%. Close to 40,000 individuals were screened and about 3,400 persons had 
symptoms suggestive of RA but only 0.75% (299) fulfilled ACR criteria. The male to 
female ratio was found to be 1: 9.3 and maximum cases were observed in the age group 
25 - 29 years. The number of non-responders to survey questionnaire was 10.5% 
(Malaviya et ak, 1993). Urban Indians (west region) in Pune demonstrated 0.2% 
prevalence of RA which is lower than the rural population (0.5%) (Chopra, 2009). In 
another study of 213 RA patients, average age 37 years the incidence was maximum in 
second and third decade followed by fourth and fifth decade. Less than 1% of the 
patients had a disease onset after 60 years. It was noted that RA in Indians is more 
aggressive at onset (Akerkar SM 2004). Among rural and urban individuals (North 
India) it was found that rheumatological complaints were more common in individuals 
from urban areas. No differentiation studies of the symptoms into the type of arthritis 
were undertaken (Das SK, 2004).
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1.5 Risk factors associated with the development of rheumatoid arthritis
The exact aetiology of rheumatoid arthritis is unknown. Risk factors implicated so far 
include genetics, smoking, infectious agents, oral contraceptives and in some instances 
due to neglect from a possible lack of education. The disease probably develops due to 
contribution, combination and interaction of these factors. Oliver and Silman (2006) 
summarized that one third of the susceptibility of RA can be explained by 
environmental risk factors and RA mostly develops due to gene environment 
interactions eg smoking and HLADRBL
1.5.1 Genetics
Rheumatoid arthritis has a genetic predisposition. First-degree relatives of an individual 
with rheumatoid arthritis have two to four times’ higher risk of developing the disease. 
Studies in monozygotic twins have suggested a concordance rate of 15 - 20 % (Jarvinen 
and Aho, 1994) whereas the concordance rate in non identical twins is only 4 %. There 
are many ethnic differences in the genetic susceptibility of RA.
Genetic studies have identified a role of Major Histocompatibility Complex (MHC). 
Molecular genetic studies (Gregersen et ah, 1987) confirm an association between the 
occurrence of rheumatoid arthritis and polymorphism of genes on chromosome 6 which 
code for a hyper variable region of the b chain of FILA DR molecules. MHC class II 
alleles especially HLA DRB1 have the strongest genetic association in RA patients but 
account for less than 40 % of the genetic contribution to rheumatoid arthritis. Statsny et
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al in 1978 observed an association between rheumatoid arthritis and HLA DR4 in
Caucasians (Stastny, 1978).
Subtypes of HLADR have been identified - DW4, DW14, DW1, coded by DRB1* 
04041, * 0101. These subtypes differ in the primary sequence of amino acids but are 
similar at positions 70 - 74 in the third hyper variable region of HLA DRB1 chain 
called the shared epitope (SE) (Gregersen et ah, 1987). It is hypothesized that the shared 
epitope has a positive association with rheumatoid arthritis. HLA DRB1* 04, when 
present, correlates with RF positive, erosive and extra articular disease. In Indians, the 
association of DQw7 with RA has been observed whereas other studies have reported a 
disease association with DQw8, hence the DQ association with HLA DR 4 positive may 
be race dependent and not related to severity of disease (Taneja et al., 1992).HLA DR 4 
subtypes DW 10 and DW 13 coded by * 0402 and * 0403 genes are negatively 
associated with rheumatoid arthritis.
Studies from Birmingham and Manchester in the United Kingdom have found a strong 
association of HLA DR 4 with evolution of early disease to definite RA and that shared 
epitope facilitates persistence or severity of disease (Thomson et al., 1993). Weyand et 
al from the United States observed a phenotype and dose effect of shared epitope — 
vasculitis was associated with homozygosity and rheumatoid nodules were associated 
with heterozygosity for HLA DRB 1 * 0401 (Weyand et al., 1992). Studies from India 
(Agrawal S, 1995), Spain (Moreno et al, 1996) and Taiwan (Yen et al., 1995) have 
demonstrated a link of severity with shared epitope. Studies in Asian patients (Chinese,
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Malay and Indians) observed an association of RA with DRB1*1001 and DRB1 *0701 
may be protective (Kong et ah, 2002). In Indians, HLA DR 4 did not correlate well with 
RF positive and severe disease (Chandrasekaran and Radhakrishna, 1995). But another 
study demonstrated an association of HLADR 4 and RA. Indians residing in Varanasi 
(north eastern region) reported an association of HLA class 1 antigen A 2 more than B 
40 (Agrawal et al., 1996). Susceptibility to RA is related to DRB 1*0401, 
*0404,*0405,*1001 and *0101 in 60 — 70 % of patients and 25% of studied subjects did 
not show shared epitope. RA did not have a significant association with HLA-DRB1 in 
Indian patients from the community and hospital referred from Maharashtra (Chopra A, 
2000). On the other hand, researchers from Finland (Mottonen 1988), Switzerland 
(Seitz et al., 1996), Greece (Boki KA 1993), Sweden (Eberhardt K 1996), Canada 
(Suarez-Almazor ME 1995) and Australia (Saudan A 1996) were unable to show a 
relationship between HLA status and disease severity. The shared epitope is 
hypothesized to contribute in disease pathogenesis by influencing CD4 + T cells and 
molecular mimicry.
As the HLA genes account for less than 50% of the genetic component in RA, T cell 
receptor genes may also contribute to the susceptibility of developing RA. Recent 
studies have demonstrated a controversial role of HLA DR genes in RA and that the 
shared epitope may not be an independent risk factor for RA but may be a marker for 
immune reactivity and anti CCP antibody (van der Helm-van Mil et al., 2006). 
Recently non MHC related susceptibility loci have been identified which include 
protein tyrosine phosphatase non-receptor 22 (PTPN 22), signal transducer and activator
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transcription (STAT) 1 and STAT 4, oligodendrocyte lineage transcription factor 3 
(OLIG3) and TNF alpha induced protein 3 (TNFAIP3), cytotoxic T lymphocyte 
associated antigen (CTLA4), peptidyl arginine deiminase, type 4 (PAD 14), Macrophage 
migration inhibitory factor (MIF).
PTPN 22 gene located on chromosome Ip 13 has shown a linkage with RA and is 
considered the second largest genetic risk in development of the disease. It has 
regulatory activity for T and B cells. Studies in Caucasians have confirmed the 
association of this gene with RA. An association with RA and this gene polymorphism 
has not been shown in Japanese patients (Ikari et ah, 2006).
Recently a gene signal transducer and activator transcription (STAT) 1 and STAT 4 on 
chromosome 2q has been identified in North American population (Remmers et al, 
2007). The effect of this association was found to be weak in a Swedish population with 
a recent disease onset. Subsequently, a Korean study has confirmed the association (Lee 
et al., 2007a) with RA. This is the first non-HLA gene that has shown association with 
RA in two different ethnic populations.
The advent of genome wide association studies has resulted in innumerable single 
nucleotide polymorphisms (SNP) to be genotyped in many samples. A collaborative 
work in British population by the Wellcome Trust case control consortium (WTCCC) 
has studied 1860 RA and 2930 controls and observed two well known RA susceptibility 
genes HLADRB1 and PTNP22 (2007) (The Wellcome Trust Case Control Consortium
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Genome-wide association study). Nine variants were found associated with RA. These 
variants were studied in a subsequent study by WTCCC in a large case control cohort of 
UK population and identified a SNP in the intergenic region of 6q23 to be strongly 
associated with RA and this association was independent of HLADRB1 and PTNP22 
genes (Thomson et al.5 2007). SNP in gene CD244 is associated with RA in Japanese 
(Suzuki et ah, 2008) but not in other populations. The SNP was linked to two genes - 
oligodendrocyte lineage transcription factor 3 (OLIG3) and TNF alpha induced protein 
3 (TNFAIP3). The same was observed by a study in US population (Plenge et al., 
2007b). Another gene identified to be associated with RA is the TRAF1 and C5 this 
study was done in anti CCP positive RA patients from North America and Sweden 
(Plenge et al., 2007a). PAD 14 gene studies have shown an association with RA but 
this was confirmed in only one study in Asian — Japanese population and not in studies 
in Caucasians. A meta analysis of Asian and European studies (Lee et al., 2007b) has 
demonstrated that Asians have an association of PAD 14 polymorphism with RA. PAD 
14 is the second most important locus after HLA DRB1. There is paucity of published 
data in genetics of RA in Indian patients.
1.5.2 Hormones
A greater incidence of RA among pre menopausal females suggests an influence of 
reproductive and hormonal factors. Hormonal risk factors exert their effect by 
endogenous and exogenous hormone effects.
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Amongst endogenous hormones, androgens have a protective effect. Men with RA 
show lower levels of testosterone whereas women display lower levels of testosterone 
and dehydro epiandrosterone sulphate (DHEAS) (Brennan and Silman, 1995). 
Oestrogen level in serum of patients with RA is normal, and their role in development 
of RA is controversial (Masi, 1995). Earlier studies demonstrated a protective effect of 
oestrogen in the development of RA. Contrary to this, oestrogen is found to be 
protective against the development of rheumatoid factor but not for the development of 
RA (Bhatia SS, 2007 ). The role of oestrogen in autoimmunity has also been studied 
(Lang, 2004). Studies have demonstrated that pregnancy can influence the timing of 
disease onset. During the post partum period there is an increased risk of development 
of RA especially after first pregnancy. This effect is seen in the first twelve months after 
delivery (Alan Silman MD, 1992). Pregnancy improves the severity of RA by 75%. 
However, an Indian study has not found any association between the onset of RA and 
pregnancy (Tembe AG, 2008).
Breast feeding for more than 12 months led to an inverse relationship with the 
development of RA (Karlson EW, 2004). Compared to women who have never breast - 
fed, breast-feeding for thirteen months or more had a fifty per cent reduction in their 
risk of development of RA. This risk reduction was twenty five per cent when the 
duration was less than 12 months. The researchers observed that being multiparous and 
not breast feeding did not offer the same protective effect. (Pikwer et ah, 2009). This 
study also emphasized that use of oral contraceptive pill did not have similar effects as 
breast-feeding.
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For exogenous hormones, oral contraceptive pills give a protective effect probably due 
to progesterone (Wingrave, S. J. (1978). The Rochester study demonstrated a fall in the 
incidence of RA in women taking contraceptive pills (Linos et al., 1980). Recently it 
was observed that oral contraceptives are protective for the development of rheumatoid 
factor but not rheumatoid arthritis (Bhatia SS, 2007 ). A study by Wallit et al in 2008 
did not find that HRT use influenced the development or progression of RA (Walitt et 
al., 2008). However, a study performed in 2009 found that HRT use reduced the risk of 
developing RA only in those carrying the shared epitope (Carine Salliot, 2010).
1.5.3 Environmental Factors
Studies on population and those involving twins suggest that non- inherited factors such 
as environmental factors are important in the development of RA. The environmental 
factors that may influence the development of RA include: infectious agents, smoking, 
diet and other factors. The role played by these factors is described below,
1.5.3.1 Infection
It was proposed that infection could act as a trigger in the development of RA for 
genetically susceptible individuals. The infection may be viral or bacterial. Polyarthritis 
may be caused by viruses like Epstein Barr virus, Parvovirus B 19 and Retrovirus 
(Blaschke et al., 2000). Immune hyperactivity to viral antigens and their potential in 
initiating RA has been investigated and their exact role in the development of RA 
remains to be defined. Bacteria involved in aetiology of RA are Mycobacterium
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tuberculosis, E coli and Proteus. Immunizations may also trigger RA in a small number 
of patients.
1.5.3.2 Smoking
Smoking is the most important and established environmental risk factor in the 
development of RA. Smoking is a risk factor for the development of RA (Criswell et al., 
2002, Hutchinson D, 2001). Cigarette smoking adversely influences the severity of RA 
in a dose dependent manner (Saag et al., 1997) and it was observed that individuals with 
a family history of RA had a smoking history similar to controls and lesser than those 
with a negative family history of smoking (Hutchinson D, 2001).There was an increased 
association between pack years of smoking and RA. Current smokers have an increased 
risk of RA which continued till ten years after cessation of smoking. Increased duration 
of smoking and the number of cigarettes smoked increased the risk of developing RA 
(Criswell et al., 2002) but association of passive smoking with RA was not observed. 
Case- control studies have shown an increased risk of developing RA in male smokers 
compared to females (Krishnan, 2003).
An association exists between smoking and RF positive RA in both genders. Smoking is 
also associated with increased production of anti CCP antibodies and the risk increases 
with the number of pack years. The risk of anti CCP positive RA is more in smokers 
with a single copy for SE and even higher in the presence of double copy. (Klareskog et 
al., 2006). Smoking was found to be associated with an increased severity of RA in a 
dose dependent manner (Saag et al., 1997). PTPN 22, HLADRB1 shared epitope and
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smoking have a high independent association with the presence of anti CCP antibody 
and RF is independently associated with smoking and HLADRBL Smoking is 
associated with increased risk of RF and anti CCP positivity and is also related with 
heavy smoking (Morgan et ah, 2009). Samples of bronchoalveolar lavage in smokers 
have shown citrullinated peptides in individuals susceptible to RA (Linn-Rasker et ah, 
2006). This is mostly seen in patients with HLA- DR shared epitope (Klareskog et ah, 
2006). There is a gene environment interaction between SE and smoking, anti CCP 
antibodies and RF (Lundstrom et ah, 2009, Oliveira et ah, 2008). It has also been 
observed that heavy smoking is strongly associated with RA in patients without a 
family history of this ailment (Hutchinson D, 2001). Cigarette smoking is associated 
with severe arthritis and it was demonstrated in a cross-sectional study that smoking is 
associated with erosive disease (Wolfe, 2000b). Extra articular manifestations are 
increased in Caucasians and Koreans who smoke (Nyhall-Wahlin et ah, 2006, Kim et 
ah, 2008), and presence of sub cutaneous nodules has been observed in RF positive 
smokers. A study in African Americans demonstrated a two-fold increase of 
subcutaneous nodules in smokers (Mikuls et ah, 2008).
Smoking is also associated with interstitial lung disease and premature death due to 
CVD. However, a study by Wallberg Jonson et al failed to identify smoking as a risk 
factor for CVD mortality in a RF positive RA cohort (Wallberg-Jonsson, 1997). In the 
Norfolk Arthritis Registry (NOAR) it was demonstrated that inflammatory poly arthritis 
patients that smoked at inception had an increased risk of death which was higher when 
anti CCP antibody was positive and two SE alleles were present (Farragher et ah, 2008).
33
For individuals without RA, smoking may be associated with production of rheumatoid 
factor. And RF has been identified as a risk factor for mortality in the absence of RA in 
a Finnish population study (Heliovaara et ah, 1995).
Rates of smoking are low in Indian men when compared with other Asian countries like 
Japan, China etc and smoking in South Asian Indian women is negligible.
1.5.3.3 Other factors
The exact role of diet in the development of RA is not clear yet (Pattison et ah, 2004). 
Increased intake of fruits, vegetables and nuts or reduced intake of meats and processed 
foods may help in better symptom management. The association between RA and 
dietary factors like fish consumption which has a protective effect has been (Pedersen et 
ah, 2005) studied and it was found that it modifies the risk of RA. Use of caffeine is 
reported to moderately increase the risk of RF positive and not RF negative RA (M 
Heliovaara, 2000). Tea consumption has an inverse relation to onset of RA due to its 
anti-inflammatory and anti- oxidant properties (Mikuls, 2002). There are studies which 
did not find an association between RA and the consumption of these beverages 
(Karlson EW, 2003 ). Increased intake of red meat was associated with increased risk of 
development of inflammatory arthritis (Dorothy J. Pattison, 2004) but no relation 
between the amount of protein, red meat, poultry, fish and the modification of RA risk 
was observed in other studies (Pedersen et ah, 2005, Benito-Garcia et ah, 2007). 
Alcohol has a negative association with RA (Hazes et ah, 1990). Women above 55
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years did not demonstrate an association between alcohol and the risk of RA (Cerhan et 
ah, 2002).
The development of RA has an inverse association with socio economic status, level of 
education and occupational class (Bengtsson C, 2005). The difference in the risk of 
developing RA may be attributed to changes in life style, socio economic status and 
access to health care (ERAS study group (2000). There is an inverse association 
between RA and the level of education. A population based case control study 
demonstrated an increased risk of RA in persons doing manual labour and having a 
lower level of education. This association was more with RF positive RA (Bengtsson C, 
2005). Adverse socioeconomic status is associated with worse disease outcome. Low 
level of education reduces the presentation of self reported arthritis and is associated 
with poor clinical state and increased mortality.
Previous studies stated that obesity is linked with the development of rheumatoid 
arthritis (Voight, 1994). However, in the light of recent results obesity has no effect on 
the risk of development of RA. BMI was inversely associated with radiological damage 
during three years of follow up (van der Helm-van Mil et ah, 2008). Another study 
found no association between obesity and risk of RA (Cerhan et ah, 2002). In 
established RA, obesity was found to be associated with active disease and not 
erosions(Antonios Stavropoulos-Kalinoglou, 2007). A study of Indians with RA 
reported an inverse association between high BMI and erosive joint damage (Velpula U, 
2008).
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Variation in latitude may influence the onset of RA. In individuals from northern 
latitudes the disease onset is earlier (Vieira VM, 2010).
High birth weight has been shown to be associated with increased risk of RA in one 
study conducted in Sweden (Lisa A. Mandl, 2009).
1.6 Co morbidity in rheumatoid arthritis
Patients with RA have an increased risk of death compared with age and gender 
matched normal controls from the same community. Reports of RA related mortality 
have been published as early as 1950 (Spector and Scott, 1988). In chronic RA the 
median life expectancy is less than controls. The life expectancy in men with RA is 
reduced by 7 years and 3 years in women (Spector and Scott, 1988).The reasons for this 
increased mortality may reflect the increased co morbidity associated with RA.
A co morbid condition is another medical condition that is present in association with 
RA.' Studies have demonstrated that 27- 54 % of RA patients have a co-existent disease. 
Co morbidity independently predicts mortality (Vandenbroucke et al., 1984). The 
number of co morbidities is an independent risk factor for premature death (Gabriel et 
al., 1999b). The major co morbidities recognized in RA are cardiovascular disease, 
infection, malignancy, gastro intestinal disease and osteoporosis. The system specific co 
morbidities in RA are elaborated in Table 1.5. These co morbidities are major 
determinants of disease-associated outcomes.
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Co morbidities are also common in Indian patients with RA. One co morbidity has been 
reported in 44% of established RA patients and 15% had two co morbidities. The most 
common co morbidities observed in this study were hypertension and diabetes and 2.5% 
of patients had diagnosed CVD (Tembe AG, 2008).
Table 1.5 Mortality in rheumatoid arthritis (Pincus and Callahan, 1986)
Cause of death RA (%)
Cardiovascular 42
Infection 9.5
Cancer 14
Renal 8
Respiratory 7
Gastrointestinal 4.2
1.7 Cardiovascular disease
Cardiovascular disease (CVD) is a leading cause of mortality in patients with RA and 
accounts for nearly half of all deaths (Symmons et ah, 1998). Symmons et al studied 
the United Kingdom National Health Service Central Register and reported a 
standardized mortality ratio of 2.2 (95% confidence interval 1.8-2.6) for CVD in RA 
patients (Symmons et ah, 1998). CVD accounted for 34% of excess deaths in this 
population.
Cross-sectional studies of mortality in RA include individuals irrespective of the disease 
duration and during follow up individuals in remission may be lost. Patients with active 
disease continue to attend rheumatology follow up and therefore these studies will tend
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to include patients with more severe or active disease. Inception cohorts tend to include 
individuals with early disease and follow them as the disease evolves over time. This 
study design provides a better estimate for comparing mortality with the general 
population, whereas cross-sectional studies of standardized mortality rate (SMR) will 
observe mortality at a given point of time.
Studies involving inception cohorts showed mixed results, some studies did not show 
increase in incidence of CV mortality (Kroot et al., 2000) while others demonstrated an 
increased CV mortality (Goodson et al., 2005a). A recent meta- analysis of cohort 
studies investigating the effect of RA on CV mortality has documented that though RA 
disease activity has reduced in past five decades the CV mortality in RA patients 
continues to be unchanged and is 60 % more when compared with the general 
population. It was pointed out that the effect of RA disease severity, treatment and 
traditional CV risk factors should be considered in accounting for the increase in CVD 
mortality (Meune et al., 2009). The risk of CVD is falling in the general population. It 
was reported in a meta-analysis that there is a 50% increase in CV mortality in RA 
patients when compared to general population and no gender difference in mortality 
was observed (Avina-Zubieta et al., 2008). The studies included in this meta-analysis 
were from Europe and North America and majority of the studies were clinic based.
The World health organization (WHO) has reported that CVD mortality in Indians in 
1990 was 1.2 million and by 2010 it is estimated that 100 million Indians will have 
CVD, which amounts to 25% of CVD all over the world. The CVD mortality is 
predicted to reach highest in the world by 2020 (Murray and Lopez, 1997, Reddy and
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Yusuf, 1998). Till date no data on CV mortality in RA patients from India has been 
found in the literature.
The pathogenesis of CVD in RA is multi factorial and can occur in the form of coronary 
heart disease, cerebrovascular disease or peripheral vascular disease. There is a strong 
association between chronic inflammation and CVD. C reactive protein (CRP) is a non 
specific inflammatory marker which is an independent risk factor for CVD (Goodson et 
al., 2005a). A study involving apparently normal physicians followed up for eight years 
concluded that level of chronic inflammation predicts the risk of CVD in normal 
individuals (Ridker et ah, 1997). It has been demonstrated that mortality is increased in 
patients with RF positive disease (Wolfe et ah, 1994, Heliovaara et ah, 1995, Wallberg- 
Jonsson et ah, 1997, Goodson et ah, 2002, Gonzalez et ah, 2008a).
The traditional cardiovascular risk factors can be classified as modifiable and non- 
modifiable (Table 1.6). The modifiable risk factors are directly proportional to the risk 
of CVD which can be reduced with proper identification and intervention. The 
traditional risk factors are linked to CVD in general population and have also been 
implicated in the setting of RA. These interact with each other to give a composite CVD 
risk score (Dessein and Joffe, 2006b). The QUEST RA study confirms the association 
of traditional risk factors in the development of CVD (Naranjo et ah, 2008).
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Table 1.6 Traditional risk factors for CVD
Male gender Non Modifiable
Increasing age
Family history of CHD (coronary heart disease)
Hypertension (HTN)
Diabetes Mellitus (DM)
Smoking Modifiable
Physical inactivity
Obesity
Increased T Cholesterol
LDL Cholesterol
Triglycerides
Decreased HDL Cholesterol
In addition to traditional CVD risk factors novel risk factors like homocystine, 
thrombotic markers such as elevated fibrinogen, impaired fibrinolysis, platelet reactivity 
and markers of inflammation like elevated CRP and elevated Lipoprotein 'a' are also 
important in the risk of CVD. Plasma homocystine levels are independently associated 
with CVD in Caucasians and Indians (Chambers et ah, 2000). But homocystine levels 
are not associated with CVD in South Indians, as studies have not demonstrated a 
difference in patients with and without CAD. High plasma fibrinogen levels are 
associated with CAD this is also reported in south Indians (Deepa et ah, 2002). 
Lipoprotein ‘a’ levels are genetically determined and high levels are associated with 
CVD. Indians exhibit high levels of lipoprotein ‘a’ (Enas etal., 1997).
It is difficult to know the exact cause of death in RA as the increased mortality could be 
due to the effect of the disease or the medicines used to treat the disease. Medications
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used to treat RA may have an effect on the CVD risk. Methotrexate is found to decrease 
CVD mortality (Choi et al., 2002). In a recent study evaluating published literature 
regarding methotrexate (Mtx) and CVD it was observed that Mtx use in RA was 
associated with a trend for reduced CVD morbidity and mortality. This benefit was 
observed especially when Mtx was started in early disease (Westlake SL 2009). 
NSAIDs and glucocorticoids tend to increase the CV risk but their effect is 
controversial (Souverein et al., 2004, Goodson et al., 2009, Gislason et al., 2009). 
Goodson et al explored the association of CVD mortality and NSAID use in an 
inception cohort of inflammatory polyarthritis in the NOAR. The patients were 
followed up for an average of 10.7 years. Mean NSAID use was 4 years. Reduced CVD 
mortality was observed in baseline NASAIDs users and in patients with a history of 
ever use of NSAID. When gender was taken into consideration death rate in males was 
twofold higher compared to females. Overall the NSAID users had more than two-fold 
decreased risk of CVD mortality. The authors concluded that the reduced CVD 
mortality in NSAID users might be attributed to the doctors avoiding NSAIDS in high- 
risk patients, the effect of unmeasured confounders and the possibility of anti platelet 
effect of NSAIDS. In contrast Gislason et al studied the effect of NSAIDs in patients 
with heart failure and observed their risk of death and hospitalization due to myocardial 
infarction and heart failure. In this high-risk population the authors demonstrated a dose 
dependant increase in death and gave a word of caution for the use of NSAID in 
patients with heart failure. The effect of various drugs used in the management of RA is 
described in chapter 2.
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1.8 CVD in Indians
CYD in Indians is two times higher than Caucasians and four times higher than Chinese 
(Miller et al., 1989, Lee et al., 2001) and it occurs one decade earlier, is more severe, 
aggressive and has a malignant course (Enas et al., 1992). The prevalence of CAD is 
high among Indians living in India and continues even if they live abroad. The KAISER 
study demonstrated that Indian patients had a four times increased rate of 
hospitalization for coronary interventions like angioplasty and bypass surgery when 
compared with American patients (Klatsky et al., 1994), This increased prevalence 
agrees with the results of CADI study (Enas et al., 1992).
The prevalence of CVD is found to be similar in vegetarians and non-vegetarians. 
Residents of urban areas have a two-fold increase in CVD when compared to rural areas 
and marginally higher in south Indians when compared to north Indians (Mohan et al., 
2001, Chadha et al., 1990). Earlier it was assumed that Indians had a high prevalence of 
CVD despite having lower prevalence of CV risk factors -“Indian paradox”. This theory 
is not applicable now as it has been established that India is emerging as the diabetic 
capital of the world (Zimmet P 1992, Shashank R Joshi 2004) and may also become the 
hypertension capital of the world (Ramachandran A 2001, Mohan V 2007).
Metabolic syndrome is emerging as a major health problem in Indians mainly from 
urban areas. The prevalence of overweight, obesity and abdominal obesity in 30 - 60 % 
of adult urban Indians was demonstrated (Misra A 2004). This has a direct correlation
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with occurrence of obesity related co morbid conditions like hypertension, diabetes, 
dyslipidaemia and CVD (Gupta R 2002).
The CVD rates in India have doubled in the past three decades and it is predicted that an 
epidemic of CVD is fast approaching (Reddy and Yusuf, 1998, Enas, 2000). 
Traditional CVD risk factors remain the main focus of attention in the prevention and 
treatment of CVD. In the general population these risk factors are strong predictors of 
CVD outcome including mortality and morbidity. All the CV risk prediction scores 
utilize traditional CVD risk factors for the estimation of 10-year risk of CHD. 
Cardiovascular co morbidity in RA forms the basis of this research in patients from 
Hyderabad in South India. A historical review of the literature is given in chapter two.
In summary, although the aetiology of RA is not completely known, it is thought to be 
caused by the interaction of several risk factors. The presence of coexistent disease 
plays an important role in the outcome of RA. With the above background, considering 
the lower prevalence of RA in India and consequently fewer studies reported, my work 
was undertaken. The important aspect is that CV risk in RA has been extensively 
studied in large populations but these studies were done for Caucasians. Moreover with 
the current trends amongst the Indian population, their genetic orientation and increased 
susceptibility towards cardiac and ischemic complications, it was felt worthwhile to 
examine and correlate the prevalence of CV risk factors in Indian patients with RA. The 
effect of disease modification on the CV risk factors is also studied.
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Chapter 2 - Background Literature Review
2.1 Introduction
This chapter provides a review of literature pertaining to mortality in rheumatoid 
arthritis and its associated morbidity. Traditional cardiovascular risk factors in 
rheumatoid arthritis are described in detail The 10 year risk prediction of a 
cardiovascular event is discussed. RA disease parameters contributing to increase in 
CV risk and the cardiovascular effects of medicines used in the treatment of RA are 
elaborated.
2.2 Mortality in Rheumatoid arthritis 
2.2.1 Cardiovascular mortality
Rheumatoid arthritis (RA) is associated with disability, deformity and reduced life 
expectancy. Increased mortality associated with RA has been recognized for fifty years 
(Cobb et al., 1953). Mortality in patients with RA is increased when compared to the 
general population (Sokka et ah, 2008), (Sihvonen et ah, 2004a), (Watson and Fisher, 
2003), (Gabriel et ah, 2003). The lifespan of RA patients is decreased approximately by 
3-18 years (Van Doornum et ah, 2002). One of the major causes of death in RA is due 
to cardiovascular disease (CVD) (Reilly et ah, 1990, Wolfe et ah, 1994) which is 
responsible for about fifty percent of premature deaths (Van Doornum et ah, 2002, Naz 
and Symmons, 2007). This increased CV mortality is multifactorial and is attributed to 
traditional CV risk factors, novel risk factors, systemic inflammation due to RA and
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medicines used in treatment of RA (Avina-Zubieta, 2008). Despite advances in 
treatment, mortality in RA has not changed over the past 50 years (Meune et ah, 2009).
A meta-analysis of 24 observational studies from the UK and USA reported that RA 
patients had a 50% increased risk of CV deaths when compared to general population. 
The increased mortality was due to excess deaths coded as Ischemic Heart disease 
(IHD) and cerebrovascular accidents (CVA). Higher mortality was seen in patients 
fulfilling American college of rheumatology (ACR) criteria. No gender difference was 
observed (Avina-Zubieta et ah, 2008).
Kumar et al compared cause of death in 257 RA patients, 374 same gender siblings and 
matched 485 osteoarthritis (OA) patients, by reviewing death certificates found that 
there were 54% deaths in RA versus 28% in siblings and 32% in OA. More deaths in 
RA and OA group were due to IHD. Interestingly, RA patients had a 40% reduced 
cancer related death than expected compared to their siblings (Kumar et ah, 2007).
Rheumatoid factor (RF) has an impact on mortality (Heliovaara et ah, 1995, Wallberg- 
Jonsson et ah, 1997, Goodson et ah, 2002). A study of 1010 RA patients by Goodson et 
al reported that mortality was higher in RF positive women when compared to RF 
negative women and both RF positive and RF negative men. The increased mortality 
trend in RF positive patients was further confirmed by another study reporting increased 
deaths in RF positive patients compared to RF negative patients and the general 
population. The mortality trend in RF negative patients may be similar to the general
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population (Gonzalez et al., 2008a). Anti cyclic citrullinated peptide (CCP) was found 
to be strongly associated with mortality (Farragher et al., 2008, Mackey, 2010).
In an autopsy study of 369 RA and 370 non RA patients the leading cause of death in 
RA patients was CVD and infection. Over more recent years, a decline in CV related 
deaths was observed in the non RA group and not in the RA group. The autopsy based 
deaths were similar in the RA group irrespective of RA treatments. The authors 
concluded that coronary deaths were less accurately diagnosed in RA which may be an 
indicator of unrecognized coronary artery disease in RA (Koivuniemi et al., 2008). RA 
patients have different presentation of IHD when compared to general population 
(Maradit-Kremers et al., 2005). They may have unrecognized silent IHD and no typical 
chest pain before sudden death (Douglas et al., 2006).
An article discussing the importance of study design, in interpreting studies of CV 
mortality, mentioned that inception cohort studies are able to capture a CV event after 
the onset of disease compared to prevalence cohorts which include survivors of an event 
and do not provide information on patients who may have died from CV prior to being 
included in the prevalence cohort. Therefore, when assessing rates of CV events, use of 
prevalent RA cohorts may lead to an underestimation of the true mortality rate. There is 
also a relation between onset of RA and the time of CV death (Ward, 2008). An 
inception cohort study reported increased mortality in patients with RA but the rate of 
hospital admission in RA patients for CVD was not increased. This may be either due to
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CVD being under recognized in RA or due to higher fatality rates in RA (Goodson et 
ah, 2005a).
2.2.2 Other causes of mortality in rheumatoid arthritis
In addition to CV mortality, RA patients are at an increased risk of death from various 
other causes. These include infections, respiratory causes, urogenital, gastrointestinal 
and cancers. The rate of death from these causes is higher when compared to the general 
population (Sihvonen et ah, 2004a).
After CVD, infection is the second most common cause of mortality in RA. The risk of 
infection increases with the duration of RA (Symmons et ah, 1998). Respiratory 
infections in the form of pneumonia and chronic pulmonary obstructive disease and 
pulmonary fibrosis have been observed (Hakoda et ah, 2005, Young A, 2006).
Not many studies have found increased risk of cancers in patients with RA compared to 
general population. Indeed, Kumar et al reported a lower rate of cancer related deaths in 
RA patients compared to age and gender adjusted population rates (Kumar et ah, 2007). 
However, when site specific malignancy rates have been explored, higher rates of non 
Hodgkin’s lymphoma and lung cancers have been observed (Naz and Symmons, 2007).
In a study looking at renal disease in RA including 604 RA patients and 457 age and 
gender matched controls it was observed that nephropathy is associated with increased 
mortality in RA (Sihvonen et ah, 2004b).
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2.3 Studies in non Caucasian populations
Most of the mortality studies are conducted in Caucasian RA population. There are very 
few studies reporting mortality in RA from Asian countries. One study following up RA 
patients for forty years in Japan observed that RA patients had increased mortality when 
compared to non RA population. Mortality due to CVD was the highest (34.9%), 
followed by respiratory causes (15.7%), cancer (14.5%), gastrointestinal (6%) and renal 
(2.4%) (Hakoda et al, 2005).
We are not aware of any published study addressing mortality in South Asian Indian 
patients with RA. Many studies have been published that study the general population 
and have observed CVD as a major cause of death in South Asian Indians (Mohan et al., 
2001, Enas et al., 1992). The mortality rate in South Asian Indian RA patients is still 
unknown. It is not clear whether having RA further increases CVD mortality rates 
above the high level observed in the Indian population.
2.4 Co morbidity in Rheumatoid Arthritis
Co morbidity is defined as a medical condition that coexists with the disease of interest. 
An RA patient is said to have an average 1.6 co morbidities and the number increases 
with the patient’s age (Gabriel SE, 2008). In the literature co morbidity in RA usually 
refers to presence of CVD, infection, malignancy, osteoporosis etc (Gabriel, 2008, 
Michaud and Wolfe, 2007).
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2.5 Traditional CV risk factors
Mortality from CVD, among the general population is predicted by traditional CV risk 
factors. Many studies have observed increased prevalence of these risk factors in RA 
(Brady et ah, 2009, Erb et ah, 2004, Serelis et al., 2011, Naranjo et ah, 2008, Innala et 
al., 2011) and others have found the occurrence similar to the general population (del 
Rincon et ah, 2001, Solomon et ah, 2004). A recent meta-analysis has confirmed the 
role of traditional CV risk factors in increased CVD observed in RA (Boyer et ah, 
2011). The modifiable and non modifiable traditional CV risk factors are given in Table 
1.6.
2.6 Modifiable traditional CV risk factors
2.6.1 Hypertension
Hypertension (HTN) is one of the modifiable traditional risk factor and a major 
contributor in the development of CVD. A systolic reading above 140 mm of Hg 
and a diastolic reading above 90 mm of Hg is considered as hypertension in accordance 
with guidelines from the British Hypertension society and National cholesterol 
education programme - Adult treatment panel (NCEP ATP)(NCEP, 2001, Bryan 
Williams 2004). However, it has been documented that as little as a 10 mm of Hg rise in 
diastolic BP doubles the risk of development of heart attack, stroke, renal failure and 
heart failure. In individuals aged less than 50 years of age, diastolic BP is the most 
important predictor of an adverse outcome (Perry et ah, 2000). According to the 
Framingham Heart study the CV risk was weakly associated with diastolic BP but a
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much stronger CV event association was observed with systolic BP above 120 mm of 
Hg. (Kannel, 2000). It is also shown that obesity and advancing age are strongly 
associated with HTN.
McEntegart et al (McEntegart et at 2001) found that a cohort of established RA patients 
had higher diastolic blood pressure than age and gender matched controls. Most of the 
patients in this study were using NSAIDs to treat symptoms of RA. However, previous 
research has suggested that NSAID usage is more likely to lead to an increase in 
systolic BP rather than diastolic BP (Frishman 2002). It is possible that there is some 
other mechanism associated with RA that may have caused this rise in diastolic BP. 
Hypertension was reported in 33% of participants in the QUEST-RA (Questionnaires in 
standard monitoring of patients with RA) study which was conducted in 4,363 RA 
patients from 15 countries across Europe and America (Naranjo et ah, 2008) . Many 
studies reflect that hypertension may be present in patients with RA as a co morbid 
condition or evolve in the course of the disease (Goodson, 2002), (Kroot et ah, 2000, 
Serelis et ah, 2011, Panoulas et ah, 2008) for which the use of NSAIDS and 
glucocorticosteroids may be responsible. Recently it was reported that hypertension in 
RA was similar to the general population (Boyer et ah, 2011). There is a possibility of 
hypertension being unrecognized or under treated in RA.
A meta-analysis addressing the global burden of hypertension stated that nearly 1 
billion of the general adult world population had hypertension in year 2000 and this was 
anticipated to increase to 1.56 billion by the year 2020. Hypertension was found to be
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more common in developed countries (37.3%) when compared to developing countries 
(22.9%) but due to increased population of developing countries, the individual affected 
is larger (Kearney et al., 2005). Hypertension in urban north Indians was 25% in males 
and 22.3% in females and the prevalence in west Indian urban population was found to 
be 30% in males and 33% in females (Kearney et al., 2005). The prevalence in Indians 
in rural areas was found to be less than that seen in urban regions (Mardikar and 
Mukherjee, 2007). Kerala, South India has reported a prevalence of hypertension of 
37% in 30-64 year old individuals (Zachariah et al., 2003). A study of hypertension in 
the UK observed that the blood pressure in South Asians and European adults was 
similar (Agyemang and Bhopal, 2002). However, another study has reported that South 
Asians have a higher prevalence of high diastolic blood pressure (Ajjan et al., 2007).
2.6.2 Diabetes
Diabetes is another modifiable risk factor for CVD. Diabetes is also an important 
constituent of the metabolic syndrome. Not many studies have explored the prevalence 
of diabetes in RA. Most of the published literature reports diabetes as part of the CV 
risk assessments. The QUEST RA study reported an 8% prevalence of diabetes in 
Caucasian RA patients (Naranjo et al., 2008). However, prevalence of diabetes was 
reported to be increased in RA when compared to general population (Boyer et al., 
2011). Prevalence of type II diabetes may be increased in RA due to reduced activity in 
active RA and the medications used in treatment of RA. Chronic use of glucocorticoids 
may interfere with glucose metabolism and insulin sensitivity as well as being 
associated with adverse body fat accumulation (Dessein et al., 2004). When compared
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to low grade inflammation, high grade inflammation in RA was found to increase 
insulin resistance and reduce beta cell function resulting in impaired fasting blood 
glucose and diabetes (Dessein PH, 2006).
The thrifty gene hypothesis may be applied to individuals from developing countries. 
The thrifty gene hypothesis suggests that genetic variations are favoured in harsh 
environments where famine situations occur. It is hypothesised that these genetic 
variants enable an individual to efficiently collect and process food to deposit fat during 
periods of abundance. Therefore this induces these individuals to develop obesity when 
they reside in food rich environments. In addition as intra uterine growth retardation 
results in a tendency to catch up growth in infancy and causes an increased tendency to 
develop obesity and type 2 diabetes in adulthood. South Asian Indians are more prone 
to develop diabetes which may be due to increased susceptibility to insulin resistance 
(McKeiguePM, 1991).
Diabetes is seen in South Asian Indians about a decade earlier when compared to other 
Asians and Caucasians (Mather HM, 1998). India has the highest number of diabetics in 
the world (Gupta R, 2007). In India an estimated 32 million people suffer from diabetes 
and the number is projected to increase to 69.8 million by the year 2025. The diabetes 
epidemiology and study group in India (DESI) reported prevalence of Diabetes in urban 
Indians is 11.6% and a study has reported that one in four urban Indians above 20 years 
have either impaired glucose tolerance or diabetes (Ramachandran A, 2001). The 
highest prevalence of diabetes was observed in Hyderabad, India (16.6%) in the same
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study. According to a survey published in a leading national daily — The Hindu business 
line (21 Oct 2005) Hyderabad, a city of over eight million inhabitants is emerging as the 
diabetic capital in India. There are no case control studies addressing the prevalence of 
diabetes in South Asian Indians with RA.
2.6.3 Smoking
Smoking is an important constituent of CV risk assessment and is a modifiable CV risk 
factor. As discussed in the introduction chapter, smoking has been shown to be related 
in the development of RA. When compared to controls in a UK study, smoking was 
found to be increased in RA (Hutchinson D, 2001) in a dose dependent manner. 
Increased mortality is associated with smoking in RA and the general population 
(Goodson et al., 2008). In a study of 603 RA patients and 603 non RA controls followed 
for 15 years it was found that male gender, smoking and personal cardiac history all had 
a weak association with CVD (Gonzalez et al., 2008b). However, another study 
confirmed an increased prevalence of smoking in RA (Boyer et al., 2011). The 
QUEST-RA study described a prevalence of ever smoking in RA to be 43% (Naranjo et 
al, 2008).
Studies of smoking have reported lower smoking rates among South Asian Indians 
compared to European populations (Yuen, 1986, Agyemang C, 2010). Similar reports 
are there from South Asian Indians from United States of America (Cristine D. 
Delnevo, 2011). Data regarding smoking in Indians is limited. Smoking is almost
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nonexistent in South Asian Indian women but they have CVD comparable to men (Enas 
EA, 2001).
2.6.4 Lipids
Dyslipidaemia is an important risk factor for CVD in the general population NCEP 
ATPIII (III, 2002). Dyslipidaemia is observed in RA patients ( Situnayake RD (Kitas, 
1997). When compared to the general population, hyperlipidaemia is less frequently 
observed in RA (Gonzalez et ah, 2008b). However, dyslipidaemia was observed in 14% 
of RA patients enrolled in the QUEST-RA study (Naranjo et ah, 2008). Lower total 
cholesterol and LDL cholesterol in RA were found to be associated with CV risk 
(Elena Myasoedova and Patrick D Fitz-Gibbon, 2011). The abnormal lipid profile 
especially low HDL cholesterol was associated with RA and reduction in RA disease 
activity was found to improve dyslipidaemia (Urowitz, 2009). Active RA is associated 
with dyslipidaemia. The characteristic change being low total cholesterol , low density 
lipoprotein (LDL) cholesterol and disproportionate lowering of high density lipoprotein 
(HDL) cholesterol which results in an unfavourable atherogenic index (ratio of total 
cholesterol to HDL cholesterol). Lipids have an inverse relationship with disease 
activity (Situnayake RD (Kitas, 1997). In active disease there is increase in the 
circulating pro inflammatory cytokines which promote the development of rheumatoid 
cachexia wherein there is increased fat mass and reduced lean muscle mass (Kitas and 
Gabriel, 2011). There by active RA patients when compared to normal controls have 
increased fat mass at a lower BMI (Stavropoulos-Kalinoglou A, 2007).
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When compared to Caucasians, Indians tend to have lower HDL cholesterol and higher 
triglycerides (McKeigue PM, 1991). South Asian Indians are known to have a high 
prevalence of dyslipidaemia in the usual lipid pattern with elevated total cholesterol, 
high triglycerides and low HDL cholesterol (Anand et al., 2000).
2.7 Non modifiable CV risk factors
Increasing age, male gender and family history of CVD are non modifiable traditional 
CV risk factors. The risk of CHD increases with increasing age (NCEP, 2001). Male 
gender is an independent risk factor for CVD (Pekka Jousilahti, 1999). Most of the 
studies in RA have addressed prevalence of traditional CV risk factors in women 
(Solomon et al., 2004, Roman et al., 2006, Dursunoglu D, 2005) ; very few studies 
mention the occurrence of CV risk factors in males with RA (Mikuls et ah, 2011) and 
this reflects reduced prevalence of RA in males. Whilst there is some comparative data 
looking at CV risk factors and CV risk scores in males and females with and without 
RA, some of these studies have reported conflicting findings. Family history of 
premature CHD is defined as CHD in first degree relative male less than 55 years and 
female less than 65 years (NCEP, 2001). Family history of CVD was more frequently 
reported in RA patients when compared to controls from the general population 
(Feldman, 1991). South Asians Indians have a strong family history of premature CHD 
(Enas et al., 1992). The family history of CHD in the context of RA has not been 
studied in this population.
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2.8 Metabolic Syndrome
Metabolic syndrome (MS) is a cluster of cardiovascular risk factors. The clustering of 
metabolic abnormalities occur in the same individual and increase CV risk more than 
the sum of the individual components (Reilly and Rader, 2003). The MS is also called 
insulin resistance syndrome, syndrome X and Reavens syndrome. This syndrome was 
first described in 1988 by Reaven who found that multiple risk factors like 
dyslipidaemia, hypertension, and hyperglycaemia cluster together in CVD and called it 
syndrome X (Reaven, 1988). However, abdominal obesity was not included. There are 
different definitions of metabolic syndrome. The most commonly used definitions are 
provided by 1) world health organization (WHO), 2) the national cholesterol education 
program adult treatment panel III (NCEP ATPIII) and 3) the international diabetes 
federation (IDF). It was demonstrated that the odds ratio using different definitions of 
metabolic syndrome NCEP ATPIII (OR 2.00), WHO (OR 1.73) and IDF (OR 1.69) was 
almost similar in predicting incident CHD which was independent of ethnic origin, age, 
gender, family history of CVD, smoking, T2DM, CHD, and non HDL C (Lorenzo et ah, 
2007). The NCEP ATP III is simpler and the most widely used in clinical practice. The 
criteria are similar. The WHO requires evidence of insulin resistance. But according to 
NCEP ATPIII measuring insulin resistance should not be included as this is so strongly 
associated with type 2 DM.
Three out of the following five criteria are to be met for an individual to be classified as 
metabolic syndrome NCEP ATP(III, 2002).
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Table 2.2 Criteria for metabolic syndrome
Risk Factor Cut off point
Waist circumference >102cm(>40 inches) in males
> 88cm (>35 inches) in females
Triglycerides >150mg / dl
Low HDL Male < 40mg / dl, Female <50mg / dl
Blood pressure >130/85 mm of Hg or an antihypertensive
Fasting blood sugar >110 mg/dl or diabetes
The presence of metabolic syndrome increases an individual's risk of type 2 Diabetes, 
and also the risk for CVD. Individuals with MS are at an increased risk for CHD (Lakka 
et ah, 2002). The increased prevalence of CVD in RA has led to an association with 
metabolic syndrome. Inflammation is an important feature in obesity, type 2 DM and in 
patients with chronic inflammatory diseases like RA. High prevalence of MS (44%) was 
observed in middle aged RA case control study and there was a correlation observed 
between increasing level of RA disease activity and MS (Karvounaris et ah, 2007). In a 
recent case control study in persons without a history of CVD, RA was more likely to 
be associated with MS (Crowson et ah, 2011). Dessien et al examined 79 RA patients vs 
39 patients with osteoarthritis (OA) and found an association between CRP, insulin 
sensitivity, HDL cholesterol, triglycerides and hypertension with RA and not OA 
(Dessein et ah, 2002). In a later study the authors reported the association of high grade 
inflammation with high insulin sensitivity when compared to low grade inflammation 
(Dessein and Ioffe, 2006a).
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Studies have correlated insulin resistance and atherosclerosis in RA patients. Significant 
association was found between carotid intima media thickness and insulin resistance in 
45 RA patients compared to 45 controls (La Montagna et al., 2007). Another study 
found that hypertension, insulin resistance and triglycerides were associated with 
carotid intima media thickness and presence of plaque (Dessein et al., 2006). High 
prevalence of metabolic syndrome was observed in RA: patients with long standing 
disease had higher occurrence of MS (42%) when compared to early RA and controls 
(30% and 22%) (Chung et al., 2008). Other studies did not have an association of MS 
with disease duration (Karvounaris et al., 2007, Crowson et al., 2011).
Increased waist circumference is an important constituent of MS. RA patients 
demonstrated 4 times increased likelihood of having high waist circumference even 
after adjusting for BMI (Crowson et al., 2011). Another study measuring body 
composition found that RA patients, compared to controls had increased fat mass and 
decreased muscle mass (Giles et al., 2008). Rheumatoid cachexia is an abnormal body 
composition with increase fat mass and reduced muscle mass. These changes can occur 
with a normal or increased BMI. Active disease is frequently (30%) associated with 
rheumatoid cachexia (Engvall et al., 2008, Giles et al., 2008). Loss of muscle mass is 
attributed to increased circulation of pro inflammatory cytokines especially tumour 
necrosis factor alpha (TNF) resulting in increased disease activity and reduced physical 
activity which further reduce the muscle mass and increase the fat mass (Summers et 
al., 2010). In an article reviewing metabolic syndrome in rheumatic disease the authors 
found high prevalence of traditional CV risk factors and MS and have advised
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assessment of MS and 10 year of CHD risk in patients with rheumatic diseases 
(Sidiropoulos et ah, 2008).
Most of the published literature addressing MS in RA is based on studies performed in 
Caucasians. Caucasians from a general non RA population have a lower occurrence of 
MS when compared to South Asians (Misra and Khurana, 2011). The prevalence of 
abdominal obesity was high in young South Asians, even at a BMI <25 kg/m2 (Vikram 
et ah, 2003). Lower insulin sensitivity index and lower glucose disposal was seen in 
Asian Indians when compared with Caucasians (Misra and Khurana, 2011). South 
Asians with metabolic syndrome had higher diastolic blood pressure, triglycerides, 
HDL-Chol and fasting insulin when compared to Caucasians (Ajjan et ah, 2007). South 
Asian Indian migrants have high prevalence of MS compared to native populations and 
other ethnic groups (Misra and Misra, 2003, Tan et ah, 2004).
The International day for evaluation of abdominal obesity study evaluated abdominal 
obesity in 63 countries and found that South Asians had the highest prevalence of 
abdominal obesity when compared to North Europeans and other Asians (Balkan et ah, 
2007). Among South Asian Indians there is a difference in the MS in residents from 
urban and rural areas and from various parts of India. Urban residents have an increased 
prevalence of MS. Data suggests that one third of urban residents from large cities have 
MS (Ramachandran et ah, 2003). South Indians are found to have high abdominal 
obesity, hypertriglyceridaemia, low HDL-Chol, increased frequency of hypertension 
and high fasting blood glucose (Ramachandran et ah, 2003) whereas non obese north
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Indians had high prevalence of T2DM, hypertension and hypertriglyceridaemia (Vikram 
et ah, 2003). MS differs among genders; women have one and a half to two times 
increased prevalence of metabolic syndrome compared to men (Wasir IS, 2007). 
Women from south India have higher MS compared to north Indian women (46.5% vs 
36.3%) (Ramachandran et ah, 2003, Reddy KS, 2006).
Sub-clinical inflammation is associated with metabolic syndrome (Ridker et ah, 2003) 
and increased risk ofT2DM and CHD (Indulekha et ah, 2011). High sensitivity CRP (Hs 
CRP) was found to be elevated in 46% of post menopausal South Asian Indian women 
with multiple CV risk factors (Wasir JS, 2007). The increased Hs CRP levels were 
twice that of Caucasians (Forouhi et ah, 2001).
In view of ethnic variations in body composition, new data cut off for waist 
circumference and BMI have been introduced by NCEP ATPIII, WHO and IDF. 
However, their predictive value in identifying type 2 DM and CVD compared to earlier 
cut off has been debated (Misra and Vikram, 2008).
In view of the high background prevalence of MS syndrome in South Asian Indians, it 
would be interesting to explore whether chronic inflammation associated with RA 
increases this prevalence further. Surprisingly there are no published studies on 
metabolic syndrome in South Asian Indian RA patients.
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2.9 Body Mass Index and waist hip measurements
The body mass index of an individual is calculated by dividing an individual’s weight in 
kilograms (kg) by height in meter square (kg/m2). The world health organization has 
classified obesity based on BMI values (WHO, 1995) see Table 2.3
Table 2.3 WHO Classification of Obesity
Classification BMI (kg/m2)
Normal <25
Overweight 25-30
Obese >30
Class I 30-35
Class II 35-40
Class III >40
South Asian Indians exhibit higher risks of CVD at a lower BMI, hence lower cut offs 
were suggested for various ethnic groups. However, there is no consensus of opinion in 
when these should be used and there is debate about interpreting the results (James 
WPT, 2002, WHO, 2004).
The waist to hip ratio is a ratio of waist and hip circumference and is a measurement of 
obesity. Based on these measurements, the body type is described. Increased 
distribution of fat around the waist results in apple shaped body and when the fat 
distribution is more around the hips results in pear shaped body. The “apple shaped” 
body type is associated with adverse health risk. Increased abdominal circumference is a 
part of the metabolic syndrome as discussed already in section 2.8.
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2.10 Cardiovascular risk assessments
Traditional CV risk factors form the basis of CV risk estimation by various methods. 
These methods are used to predict the percentage risk of a CV event in the next ten 
years. Many countries have adopted different scoring systems. Worldwide, the most 
commonly used CV risk estimation method is the Framingham CV risk assessment. 
Other CV risk assessment methods are the Joint British CV risk estimation scores, the 
systemic coronary risk evaluation model (SCORE), Reynolds risk score and the recent 
QRISK prediction scores. Apart from the QRISK prediction score all the other CV 
event prediction algorithms have been developed using data derived from the 
Framingham Heart Study.
The Framingham heart study started in 1948 with 5,209 adults from the town of 
Framingham in Massachusetts, USA. This is a predominantly Caucasian population. 
This study has resulted in long term follow up of individuals. The second generation of 
participants were enrolled in 1971 and is presently following up the third generation of 
participants, which started in 2001. Most of the published literature regarding the 
epidemiology of CHD is derived from this study. 
('http://www.framinghamheartstudv.org/about/milestones.htmn
From the results of this study it was known that CHD is influenced by lifestyle, 
environmental factors and inheritance. The individual CV risk factors are used to 
predict the probability of a CHD event in men and women (Peter W. F. Wilson, 1998).
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This CV risk prediction model is widely used in South Asian Indians (S Kanjilal, 2008). 
The Framingham risk prediction model is based on seven domains given in Table 2.4. 
Table 2.4 Seven domains of Framingham risk score
Constituents of the Framingham risk scores
Age
Total Cholesterol
HDL cholesterol
Blood pressure
Continuous variable
Smoking Dichotomous variable
Diabetes
Left ventricular hypertrophy
In view of increased baseline risk in different ethnic population a modification of cut 
offs were suggested (Scott M. Grundy, 1999).
The British Cardiac Society, British Diabetic Association, British Hyperlipidaemia 
Association together formed the Joint British Society (JBS) for formulating guidelines 
for primary prevention of CHD. The CHD risk is calculated using the cardiac risk 
assessor by a computer programme (Durrington, 2000). The calculator is available 
online on the British heart foundation and British hypertension society website 
(www.hyp.ac.uk.bhs). The cardiac risk assessment is based on age, gender, systolic 
BP, diastolic blood pressure, current smoking, diabetes, total cholesterol, HDL 
cholesterol and electrocardiogram evidence of left ventricular hypertrophy if available..
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Alternatively coronary risk charts may be used. A 10 year risk of CHD event of above 
15% is considered increased risk and CHD preventive measures are to be taken in the 
form of lifestyle modification (primary prevention) or institution of treatment ( 
secondary prevention) (David Wood, 1998).
The Score CHD risk estimation model is based on age, gender, smoking habit, systolic 
blood pressure, either total cholesterol or TC / HDL ratio and predicts the risk of a fatal 
CHD event (Conroy RM, 2003). The current EULAR recommendations for CV risk 
management in RA and other inflammatory arthritis suggests using this model (Peters et 
ah, 2010).
The Reynolds risk score is based on age, gender, smoking, systolic blood pressure, 
Total Cholesterol, HDL Choi, hs CRP and parental history of CVD before the age of 
sixty (Ridker et al., 2007, Ridker et ah, 2008). This score was derived from participants 
who were physicians and health professionals and may not represent the general 
population.
For ethnic minorities especially individuals from individuals from Indian subcontinent it 
is estimated that the CV risk is higher than predicted and a multiplication factor of 1.4- 
1.5 may be used. The Ethrisk calculator for British black and minority ethnic groups 
had been developed based on the Framingham risk calculator (Brindle et ah, 2006).
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The latest addition to the CV risk estimation scores is the QRISK score which was 
based on observational data collected in the UK (Hippisley-Cox et ah, 2010). This risk 
calculation includes socioeconomic status, ethnic origin and presence of RA as potential 
risk modifiers used to estimate CHD risk.
2.11 RA disease activity and CVD
Chronic inflammation in RA is evidenced by raised inflammatory markers namely ESR 
and CRP which are known to predict CVD (Wallberg-Jonsson et ah, 1999).
2.11.1 C reactive protein
C reactive protein (CRP) is an important inflammatory marker secreted by the 
hepatocytes in response to stimulation by cytokines. It was originally isolated in 1930 as 
a protein binding to the C polysaccharide in the cell wall of pneumococci (Tillett and 
Francis, 1930), It is involved in all steps of atherogenesis including initiation, 
progression and destabilization of a atheromatous lesion (Ross, 1999).
In the women’s health study CRP was found to be a strong predictor of future CV event 
in the general population (Ridker, 2002). Del Rincon et al reported that raised levels of 
inflammatory markers such as ESR and CRP in patients with RA and general 
population had an association with raised carotid intima media thickness and carotid 
plaque. This association was signification after adjusting for CV risk factors (Del 
Rincon et ah, 2003). The Rochester study in RA patients has demonstrated that raised
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ESR at baseline is predictive of future CV mortality in an inception cohort followed for 
fifteen years (Maradit-Kremers et al., 2005). CRP values at baseline in patients with 
new onset arthritis were found to be important in predicting death from CVD, thereby 
confirming the role of CRP (Goodson et al., 2005b).
Raised levels of CRP have been observed in obesity and metabolic syndrome as 
discussed in this chapter section 2.8. As the CRP production is from the liver an 
additional role of CRP in dyslipidaemia can be considered.
In active RA pro inflammatory cytokines such as tumour necrosis factor alpha (TNF), 
interleukin 1 (3 and interleukin 6 are released in systemic circulation from the synovial 
tissue. The cytokines are able to affect the vascular endothelium and result in 
endothelial dysfunction and promote premature atherosclerosis by various mechanisms 
(Sattar et al., 2003). The factors causing atherosclerosis in autoimmune rheumatic 
diseases are age, gender, hypertension, diabetes, metabolic syndrome, hyperlipidaemia, 
active disease, use of glucocorticosteroid (GCS) of more than 7.5 mg/day and high 
cumulative dose and biomarkers such as ESR, CRP, pro inflammatory HDL, oxidized 
LDL and hyper homocystinaemia (Bevra H. Hahn, 2007). The chronic inflammation 
may result in progression of atherosclerosis (Maradit-Kremers et al., 2005). Markers of 
inflammation including high levels of CRP are associated with sub clinical 
atherosclerosis in RA which can be determined by arterial wall thickening, stiffness and 
reduced flow mediated dilatation (del Rincon et al., 2005, Nagata-Sakurai M, 2003). 
Systemic inflammation and traditional CV risk factors together play a role in the
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development of atherosclerosis (del Rincon I, 2007). RA patients have a threefold 
increased incidence of carotid plaque when compared to matched controls (Roman et 
al., 2006). Active disease, long disease duration, presence of extra articular 
manifestations are associated with greater carotid intima media thickness (Targonska- 
Stepniak et al., 2011). In addition patients having a positive rheumatoid factor (RF) and 
high disease activity represented by a disease activity score (DAS) 28 of more than 5.1 
was associated with increased mortality (Mikuls et al., 2011).
The therapeutic considerations suggested are to aggressively control disease activity by 
using treatments known to affect atherosclerosis such as methotrexate, 
hydroxychloroquine, treat hypertension, diabetes, obesity, dyslipidaemia and use anti 
platelet agents or anticoagulants when required (Bevra H. Hahn, 2007).
In a study in 19 South Asian Indian RA patients sub clinical atherosclerosis was found 
in one third of the participants and age and tender joint count were independent 
predictors of abnormal carotid intima media thickness (CIMT) (Grover et al., 2006). 
This study was followed by another larger case control study addressing atherosclerosis 
in RA and found CIMT was significantly higher in RA when compared to matched 
controls (Mahajan et al., 2008). Plaques were observed in 21% of the participants. The 
patients in both the studies were young (less than 45 years). However, these two studies 
excluded patients with known traditional risk factors. The second study had patients 
with longer disease duration (12 years). The prevalence of atherosclerosis in this young
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RA cohort in the presence of factors associated with development of atherosclerosis 
especially diabetes is still unknown.
2.12 Medication used in the treatment of RA and the risk of CVD
The medicines used in treatment of RA may positively or negatively affect the CV risks. 
Use of disease modifying anti rheumatoid drugs (DMARDs) may positively affect the 
CV risk by reducing inflammation. The role of corticosteroids and NSAIDS are 
controversial.
2.12.1 Non steroidal anti inflammatory drugs
Non steroidal anti-inflammatory drugs (NSAIDs) are associated with increased CV 
events in the general population (Hippisley-Cox J, 2005, Chan, 2006). The NSAIDs 
used for pain reduction in arthritis are classical NSAIDs that non selectively block 
cyclo- oxygenase (COX) 1 and 2 and selective inhibit COX 2. NSAIDs in general are 
known to be associated with salt and water retention resulting in peripheral oedema and 
weight gain, increased blood pressure and worsening of heart failure (Burnier, 2006, 
Gys'ele S. Bleumink, 2003). Traditional NSAID naproxen was found to decrease the 
risk of CVD by sustained inhibition of platelet aggregation by inhibiting COX 1 
mediated thromboxane (Capone ML, 2004). This effect may be cardioprotective (Daniel 
H. Solomon, 2003). The anti- inflammatory effect of NSAIDs may reduce inflammation 
and be beneficial in atherosclerosis (Ray Wa, 2002). In a study of a cohort of new onset 
arthritis followed for ten years, NSAID use was not found to be associated with excess 
CV mortality (Goodson et ah, 2009).
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2.12.2 Glucocorticosteroids
The role of glucocorticosteroids (GCS) is controversial. Glucocorticosteroid use was 
associated with fluid retention, hypertension, osteoporosis and impaired glucose 
tolerance resulting in diabetes (Andrews and Walker, 1999, Whitworth et al, 2000).
However, use of these drugs to suppress disease activity in RA, may increase physical 
activity levels as well as reducing systemic inflammation. With regard to the 
cardiovascular system, the dose of glucocorticosteroids may be important. In a study by 
Toms et al, in RA patients, low (<7.5mg/day) and medium dose (>7.5 mg/day) 
prednisolone use were not associated with metabolic syndrome, hypertension or lipid 
abnormalities. The authors concluded that this could be due to beneficial effects of 
steroids in suppressing inflammation (Toms et al., 2008). Therefore, whilst it is likely 
that glucocorticoids influence CV risk factors, their effective suppression of disease 
activity in RA may lead to a neutral effect on CVD events in RA. GCS were found to be 
effective in relieving signs and symptoms of RA as monotherapy and in combination of 
DMARDs (Gorter et al., 2010). A review article demonstrated a poor association 
between exposure to low dose GCS and CV risk factors but a trend for increased CV 
events (Adeline Ruyssen-Witranda, 2011).
2.12.3 Disease modifying anti rheumatic drugs 
2.12.3.1 Traditional DMARDs
Disease modifying anti rheumatoid drugs (DMARDs) may reduce disease activity 
thereby reducing CV risk. Studies have reported reduced CVD events in patients using 
DMARDs (Suissa et al., 2006, Naranjo et al., 2008). The most widely studied drug is
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methotrexate. Previously it was thought that this drug may increase CV risk by 
increasing homocystine but concomitant use of folic acid reduced this effect 
(Eikelboom JW, 1999, Slot, 2002, Desouza C, 2002). However in a study assessing 
mortality in patients with RA, use of methotrexate was found to be associated with a 
70% reduction in CV related mortality compared to other DMARDs (Choi et ah, 2002). 
Methotrexate was not found to be associated with increased risk of CVD on long term 
use (C Sal Hot, 2009). A systematic review has reported that methotrexate use is 
associated with reduced CVD events and CVD mortality (Westlake et al, 2010).
Leflunomide use was reported to increase blood pressure and adversely affect the CV 
risk (Solomon et al., 2006, Rozman et al., 2002, Smolen et al., 1999). There are reports 
of leflunomide lowering blood glucose and decreasing body weight (Coblyn JS, 2001, 
Young Hee Rho, 2009),
Hydroxychloroquine use is associated with having benefits on the CV risk in RA by 
improving the lipid profile (M, 1996). It is also known to reduce the risk of developing 
diabetes (Bili et al., 2011) reducing blood pressure (Rho et al., 2009).
Sulphasalazine has not been much studied in the context of its effect on CV risk. There 
is a suggestion that this drug may be associated with a reduction in CVD (van Halm et 
al., 2006). A report has suggested cardioprotective effect by reducing platelet reactivity 
(MacMullan PA, 2008).
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2.12.3.2 Biologic DMARDs
Tumour necrosis factor (TNF) alpha may improve insulin sensitivity (Huvers FC, 
2007). These drugs also reduce CVD but the effect was not found to be as consistent as 
methotrexate (Westlake et ah, 2011). Studies have looked at the effect of these drugs on 
lipid profile, some have reported no effect on lipid profile (Soubrier et ak, 2008) and 
others have found an increase in HDL (Popa et ak, 2005, Spanakis et ak, 2006) and total 
cholesterol but the atherogenic index was the same (Schimmel EK, 2009) while others 
found the effect was found to be for a short term (Hurlimann et ak, 2002, Dixon and 
Symmons, 2007). Lower incidence of first CV event has been reported (Jacobsson, 
2005). Longer exposure to TNF alpha drugs was associated with a lower risk of CV 
events (Naranjo et ak, 2008).
2.13 Statins
Statins are hydroxyl methylglutaryl coenzyme A (HMG co A) reductase inhibitors 
which inhibit cholesterol biosynthesis pathway (Buhaescu and Izzedine, 2007). There is 
evidence that statins have a role beyond their cholesterol lowering property and are 
believed to exhibit “pleotropic effects”(Almuti et ak, 2006, Liao, 2005). Statins 
decrease vascular inflammation, improve endothelial cell function, decrease platelet 
activation and aggregation, decrease vascular smooth muscle cell proliferation and 
migration and also stabilize the atherosclerotic plaque (Sadowitz et ah, 2010). In a 
randomised control study of statin looking at cardiovascular events in individuals with 
normal LDL but high CRP found that patients treated with statins had a 37% lower CRP 
levels (Ridker, 2003). In addition to their use in dyslipidaemia statins are used in
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prevention of CHD, stroke and peripheral arterial disease. Statin use in RA is associated 
with reduction of CV risk factors, disease activity and progression (Nurmohamed and 
Dijkmans, 2009, Gazi et ah, 2007). There are reports of reduction of ESR, CRP and 
other disease activity parameters with the use of statins in patients with RA (McCarey et 
ah, 2004). Statin use is also associated with reduced risk of development of RA in 
patients with hyperlipidaemia(van Halm VP, 2007). The EULAR recommends statin 
use as a preferred treatment option in RA due to their potential anti inflammatory 
effects (Peters et ah, 2010).
2.14 Burden of cardiovascular disease in South Asian Indians
The prevalence of CVD is high in South Asian Indians and occurs almost a decade 
earlier when compared to Caucasians (Salim Yusuf and John Varigos, 2004, Teoh, 
2007). Traditional CV risk factors are more prevalent in this population (Enas et ah, 
1992). The risk of CVD is ten times higher in individuals less than 40 years (Enas et ah, 
1992, Enas, 2000).
A study in UK has demonstrated a 50% increase in CV mortality when south Asian 
migrants were compared to the general host population (McKeigue PM, 1989). There 
are studies in South Asians who have migrated to different countries (Anand et ah, 
2000, Enas et ah, 1997, Misra, 2010, Venkataraman R, 2004, S.S. Liem, 2009).These 
studies have shown a marked increased prevalence of traditional CV risk factors in the 
migrant Indian populations when compared to the country of their residence.
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Indians residing in India have a very high prevalence of traditional CV risk factors. 
Prevalence of metabolic syndrome is high and is seen in 25 - 30 % of adult South Asian 
Indians (Misra A, 2006). In India, there are additional, geographical variations in CV 
risk. Urban Indians have increased risk when compared to rural inhabitants (Mohan et 
al., 2001). South Indians have been reported to have an increased prevalence of CV risk 
factors compared to North Indians (Begom R, 1995). The WHO project on sentinel 
surveillance of Indian industrial populations has demonstrated that in India the highest 
prevalence of obesity and a high waist circumference is observed in Hyderabad, Andhra 
Pradesh. (Reddy et al., 2002).
Due to the increased prevalence of CV risk factors and increased CVD prevalence 
observed, South Asian ethnicity may be considered an independent risk factor for CVD 
(Milan Gupta 2006). Recognition of this strong association with CVD has led to 
incorporation of ethnicity into more recent CV risk prediction tools.
In summary, there is substantial literature demonstrating that RA is associated with 
increased CVD and this is partly due to an increase in CV risk factor prevalence. The 
South Asian population is at increased risk of CVD events and this population has 
greatly increased CV risk factors associated with the metabolic syndrome. What is not 
clear from the current reported literature is whether South Asian Indian subjects who 
develop RA are at further increased risk of CVD.
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Chapter 3 - Aims and Objectives
3.1 Aims
The main aim of this thesis is to measure the prevalence of traditional risk factors for 
CVD in urban Indian patients (Hyderabad, Andhra Pradesh) with rheumatoid arthritis 
(RA) and to compare these risk factors with age and gender matched normal controls 
from a similar geographic location. The effect of treatment by biologic disease 
modifying anti rheumatoid drugs (DMARDs), Etanercept and newer traditional 
DMARD Leflunomide on the traditional CV risk factors are also studied.
3.2 Objectives
3.2.1 Prevalence of traditional CV risk factors
1. To report the prevalence of traditional CV risk factors in consecutive South 
Asian Indian RA patients.
2. To explore the prevalence of CV risk factors in RA patients stratified by gender 
and rheumatoid factor status.
3. To compare the prevalence of traditional CV risk factors in patients with RA and 
age and gender matched controls free from inflammatory arthritis.
4. To evaluate the elevated CV risk factors and composite 10 year risk of coronary 
heart disease (CHD) in RA patients and controls.
5. To examine whether the ten year risk of CHD in patients with RA is associated 
with disease activity score (DAS 28).
6. To ascertain whether this research can form a basis for better identification of 
CV risks in Indian patients with RA.
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Effect of treatment with leflunomide on CV risk factors — Sub group analysis
7. To determine whether lOmg/day leflunomide therapy in patients with active RA 
results in rise in blood pressure and CV risk.
8. To explore if leflunomide use is associated with modification of lipids, body 
mass index and fasting blood glucose.
Effect of treatment with biologic response modifier Etanercept on CV risk
factors - Sub group analysis
9. To determine if treatment with a short course of TNF alpha inhibitor Etanercept 
influences CV risk factors in patients with active RA after etanercept is 
withdrawn.
10. To explore if any long term effect on CV risk factors is observed six months 
after etanercept is withdrawn.
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Overall this research for studying traditional CVD risks factors in RA patients from 
Hyderabad is aimed to address
• The need to undertake research in a population which does not have enough 
published data.
• Day to day available simple cost effective techniques can be applied in patient 
assessments to generate scientific data.
• By using patient-friendly methods an attempt is made to allow research to 
percolate to the understanding of general and lay populations without altering 
the comfort and security level of the participants.
• This work should benefit from the latest research methodologies used in the 
United Kingdom that are applied to patient population in Hyderabad India 
collected under a single organization.
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Chapter 4 - Methods
4.1 Introduction
In this chapter the study populations of patients and controls are described. The 
methodology and data collection for CV risk assessment are described in detail. Data 
collection of each study included in this thesis is discussed. Patient evaluation is 
described in detail. The methods used to measure cardiovascidar risk are described.
4.2 Study location
The RA patients were recruited from rheumatology clinics conducted at the Sri Deepti 
Rheumatology Centre (SDRC) in Hyderabad, Andhra Pradesh (AP), south India.
Patient evaluation was done at SDRC as it is located in central Hyderabad and is well 
connected to surrounding areas. The SDRC is a tertiary care centre which caters to 
patients with rheumatological problems in Hyderabad and surrounding districts (Figure 
4.1) and has one of the largest patient populations in AP. The patients seen are largely 
from middle and upper middle class families. RA accounts for 30-35% of 
rheumatological conditions treated at this centre. Most patients attending this 
rheumatology service are from an urban population. SDRC is an out- patient referral 
centre.
The SDRC is staffed by 2 rheumatologists and 2 general medical interns. There are 
onsite biochemistry and pathology services as well as in-house radiology, phlebotomy,
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physiotherapy and pharmacy. The chief Rheumatologist and director of SDRC is Dr 
Uppuluri Ramakrishna Rao (URKR).
4.3 Timeline
The studies for the thesis were conducted between July 2005 and June 2009. The first 
group of studies: 1) exploring the prevalence of CV risk factors in an RA cohort, 2) 
exploring whether CV risk factors are more prevalent in RA cases compared to 
population controls, and 3) exploring whether CV risk factors are associated with high 
disease activity in RA, recruited study participants between July 2005 and October 
2008. The second group of studies identifying whether use of: 1) leflunomide and 2) 
etanercept influenced the prevalence of CV risk factors, recruited study participants 
between December 2006 and June 2009. The patients were evaluated before and after 
initiating such therapy.
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Figure 4.1 Map of Andhra Pradesh
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Hyderabad is the capital district of A P and has an estimated population of over 7 
million (2008) spread across 6,300 Km square. The city has a cosmopolitan population 
with people of different religions and languages.
79
4.4 Study designs and patient populations
4.4.1 Prevalence of CV risk factors in RA
The prevalence of CV risk factors was an observational cross-sectional study describing 
the prevalence of CV risk factors in a cohort of unselected RA patients attending the 
SDRC for routine rheumatology care.
4.4.2 Comparing CV risk factor prevalence in RA cases with controls
This cross-sectional observational study used a case control design to explore whether 
CV risk factors were more prevalent in RA cases compared to local controls, free from 
inflammatory joint disease, and frequency matched for age and gender to the cases. The 
RA cases were the same patients examined and described as the RA cohort.
4.4.3 Disease activity and CV risk study
This observational cross-sectional study used the RA cohort and stratified them into two 
groups based on their disease activity. The CV risk profile was compared between the 
group of patients with high disease activity (defined as DAS28 >5.1) and those with 
low/moderate disease activity.
4.4.4 The influence of drug treatment on CV risk studies
The drug treatment studies were longitudinal studies, exploring the influence of drug 
treatment on CV risk. Patients who had active RA and were keen to start either 
leflunomide or etanercept were studied. This was an open label study and the patients
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and individuals assessing them were aware of the drug there were taking. Cost of the 
drug treatment was paid by the patient. As this is in accordance with the routine clinical 
practice any bias in patient evaluation was not foreseen. Patients were assessed prior to 
starting leflunomide and were reassessed after leflunomide treatment was established. 
For the etanercept study, patients were assessed prior to starting etanercept. The same 
patients were reassessed after etanercept had been withdrawn. The detailed methods for 
the treatment exposures are discussed in more detail in the relevant chapters.
4.5 Ethical approval
The study proposals and protocols were presented to the institutional ethics committee 
of SDRC by Firdaus Fatima (FF). The ethics committee of SDRC operates as per good 
clinical practice (GCP) guidelines. Ethical approval for all the studies included in this 
thesis was obtained by the institutional ethical committee of SDRC, and an informed 
consent from all the subjects was taken. Literate subjects gave a written consent and the 
individuals who could not read and write gave a witnessed thumb impression. The 
consent procedure was conducted by FF.
4.6 Eligibility criteria
All subjects taking part in the study were above 18 years of age. RA patients fulfilled 
ACR 1987 classification criteria. Subjects who did not report a psychiatric illness and 
were able to give informed consent were included. Subjects with known CVD on 
treatment were excluded. Known subjects with dyslipidaemia on lipid lowering agents
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were not included. All participants were South Asian Indians and no other ethnic groups 
were included in either the cases or control groups.
The inclusion and exclusion criteria are described in Table 4.1, When the subject was 
found to be eligible for inclusion to a study they were provided information about the 
study and informed consent was obtained. After consent was obtained subjects were 
then evaluated by a systematic interview as mentioned in the baseline assessments 
(Section 4.8), by one of the trained physiotherapists.
Table 4.1 Eligibility criteria for enrolment of subjects 
Inclusion criteria
1. All subjects above 18 years
2. Willing to give informed consent
3. Fulfilling ACR 1987 classification criteria (RA cases)
Exclusion criteria
1. Known CYD on treatment
2. Known dyslipidaemia on lipid lowering agents
3. History of stroke, cancer, significant hepatic or renal abnormality
4. Joint deformity causing difficulty in anthropometric measurements
5. Inability to give consent
6. Presence of known inflammatory joint disease (For control subjects)
4.7 Selection of RA patients
Consecutive RA patients from rheumatology out-patient at SDRC were identified The 
ACR criteria (Arnett et ah, 1988) were applied to all cases enrolled in the study. When
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patient fulfilled four out of seven ACR criteria they were included. The significance of 
the CV risk assessment was explained to patients.
4.8 Selection of controls
Control patients who were free from inflammatory arthritis were recruited in the study. 
These were frequency matched for age and gender to the cases. The RA cases were 
encouraged to recommend friends and relatives to take part in the control group for this 
study. This allowed a degree of matching for both social class and urban dwelling of 
participants, as the index case of RA was likely to recommend friends or relatives from 
a similar background to take part in the study. One fourth of the control group 
participants were hospital staff and their relatives. These controls were from middle and 
upper middle class families and were from a similar background to the RA cases. To 
ensure that controls were from a similar background to the cases caution was taken not 
to enrol class four employees and their relatives (sweepers, cleaners, drivers etc). The 
controls were given separate appointments for assessments.
4.9 Baseline assessments of study participants
The inclusion and exclusion criteria were applied to all patients and controls (Table 
4.1). Informed consent was taken by FF. The subjects underwent a detailed assessment 
for the occurrence of traditional CV risk factors. The RA patients were called cases and 
the matched individuals are referred to as controls. While addressing patients and 
controls together they are referred to as subjects.
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The initial history and data collection was done by one of the four physiotherapists who 
have similar training. All the physiotherapists included in patient data collection had 
completed their bachelors in physiotherapy and were taking patient history for the past 
one year. Further training in patient data collection and anthropometric measurements 
was given by FF. After consent the subjects were taken to an examining room and made 
to sit comfortably in a chair. Full details and the scheme of analysis corresponding to 
chronological sequence is outlined see Figure 4.2. The data obtained was recorded in 
paper case record forms (CRF).
Figure 4.2 Flow chart of study procedures
pEthical approval of the study
Patient identified, consent taken
Control identified, consent taken
Baseline evaluation
Rheumatological evaluation
Laboratory investigations
Data entry, CHD risk calculation
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Blood pressure (BP) recording for each patient was done three times in the right upper 
arm in sitting position. The three readings were taken by the same person using same 
mercury sphygmomanometer (Diamond regular (IS3390) Mfg in India). The 
sphygmomanometer was placed at the level of the heart. The BP reading was recorded 
to nearest 2 mm. Three readings were taken i.e. (1) before detailed history (2) after 
history (3) after anthropometric measurements. The timing for BP record was adjusted 
for all patients such that the first recording was after sitting for fifteen minutes, and 
repeated twice after ten minutes intervals. The mean of 3 readings was calculated and 
entered on the paper CRF.
The evaluation process consisted of entering the subjects name, age and gender on the 
CRF. The subject’s initials were also entered. In the subjects who were unable to give 
their exact age then the date of birth was estimated by writing the month and date as 
first January, the year of birth was calculated from the age at which a major life event 
occurred (marriage, birth, death of a family member or a major calamity) and year of 
birth was retrospectively calculated from the year of evaluation. Eg if the subject was 
married at 18 years of age and was married for the past twenty years then the age of the 
subject was entered as 38 years.
A detailed family history including the presence of co morbidities in the family was 
taken. History of CVD was considered when a member of the family (first degree 
relative) was diagnosed to have CVD before the age of 55 years for males and before 
the age of 65 for females (NCEP, 2001).
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The subject’s personal details including history of co morbidities, history of smoking 
and diet (Vegetarian) was taken. The co morbidities, recorded systematically, included 
hypertension (HTN), Diabetes mellitus (DM), CVD and hypothyroidism. The co 
morbidities were classified as being present if the subject reported prior diagnosis by a 
physician or if the subject was taking prescription medicines prescribed for treatment of 
a co morbid condition and the indication was written in the medical records. Review of 
current medication was used to validate current co morbid diagnoses. Subjects with 
known CVD on treatment were excluded. Very few individuals who did not have a 
documented evidence of CVD and were not on any treatment for it but reported an 
anecdotal history of CVD were not excluded.
Smoking history was taken and the subjects were classified as smokers and non 
smokers. Subjects who were ex smokers for more than a year were considered as non 
smokers. Details about vegetarian diet were enquired and if the subject was a vegetarian 
the entry was made as yes and no for non vegetarians respectively.
For RA patients, the duration of disease is determined by the duration of symptoms of 
RA in years. A detailed history of medicines used by patient at the time of evaluation 
was taken. The history comprised the use of medicines for co morbidity and treatment 
of RA. The RA specific drug history included the use of NSAIDs, glucocorticosteroids 
(GCS), and disease modifying drugs including biologic response modifiers.
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4.10 Anthropometric measurements
The anthropometric measurements included weight, height, waist and hip 
measurements. Weight was measured in kilograms using a digital weighing machine 
which was calibrated (Krups Mfg in India). The weight was recorded in minimum 
clothing without footwear, the subject was asked to keep the purse aside and empty 
pockets, when applicable, before climbing on the weighing machine. The subject was 
asked to look straight ahead whilst the weight was recorded. Two reading were taken 
one after another. Average of the two readings was taken and a value close to the 
nearest gram was entered.
Height was measured in centimetres. The subject was asked to remove footwear and 
stand close to a wall in such a way that the head, buttocks and heels were touching the 
wall. Height was measured using a wall mounted height measuring tape (WS045 
Narang medical limited). The height was entered to the nearest centimetre. Using a 
measuring tape waist and hip measurements were taken. The subject was asked to stand 
straight with feet close and the waist measurement was taken at a level midway between 
the lowest rib and the iliac crest. The hip measurement was taken at the widest area of 
the buttocks. The readings were recorded in centimetres and a value corresponding to 
the nearest centimetre was entered. The subject was then referred to URKR / FF for 
physical examination. The schematic representation of the study is given in figure 4.2.
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4.11 Physical and rheumatological evaluation
Detailed physical examination was done either by URKR or FF. Twenty eight joints 
were examined for swelling and tenderness in RA patients. A joint with soft tissue 
swelling which could also be detected by manual palpation was considered as swollen 
joint. Tenderness of the joint was elicited as pain on applying firm pressure on the joint 
in such a way that there was blanching of the examiners nail bed of the thumb and index 
fingers. The joints examined include bilateral shoulders, elbows, wrists, first to fifth 
metacarpophalangeal joints (MCP), thumb interphalangeal and second to fifth proximal 
interphalangeal joints (PIP), right and left knee joints. The 28 joint count was done to 
calculate the disease activity score (DAS 28) which is validated for measuring disease 
activity (Prevoo ML et al 1995).
The patient’s global assessment of disease activity was done by asking the patient to 
mark on a numeric scale of 100 mm (visual analogue scale - VAS). No disease activity 
was marked as ‘O’ and 100 for highest activity possible. The patient record was checked 
for the presence of rheumatoid factor and if the RF was done within six months it was 
not repeated. A chest X- ray was taken in subjects who had not had such imaging within 
the prior three months. Later the subject was sent to the in-house laboratory for blood 
sampling. The scheme of data collection is given in figure 4.3. The paper CRF was 
checked by FF for any missing data. Later the patient details were transferred to a 
Microsoft excel spreadsheet by FF.
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Figure 4.3 Scheme of data collection
Data collection
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Baseline evaluation
Anthropometric
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Rheum evaluation of 
patients
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and CV risk assessment
4.12. Laboratory investigations
4.12.1 Blood samples and test methods
A requisition for investigations was given to the subject. Random blood sample was 
collected in the laboratory. The blood tests requested were full blood count (FBC), 
erythrocyte sedimentation rate (ESR), C reactive protein (CRP), total lipid profile 
including total cholesterol (T-Chol), triglycerides (TG) and high density lipoprotein 
(HDL-Chol) cholesterol, thyroid profile was done in subjects who were not hypothyroid 
but have a clinical suspicion of hypothyroidism and do not have a latest thyroid profile. 
Routine liver and kidney function tests were also performed. A random blood sample 
was taken from the patient. Analysis of the sample collected was done at the in-house 
laboratory on the same day using fresh serum samples. Blood sampling was done by 
one of the phlebotomist and the sample was drawn mostly from the left median cubital 
vein and a unique numbering system was used for all containers in which the sample
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was collected. The same number was used for urine sample containers also. The 
containers were shifted from the sample collection room on the ground floor to the 
laboratory situated on the first floor.
The patient’s blood sample was collected and serum separated by centrifugation using a 
semi automated centrifuge. A whole blood sample was also collected in 
ethylenediaminetetraacetic acid (EDTA). ESR was done by Wintergreen method. T- 
Chol, serum Triglyceride, HDL-Chol was estimated using reagent and standard from 
Bio Systems reagents and instruments Costa Brava Barcelona Spain. LDL-Cholesterol 
(LDL-Chol) was calculated using Friedwalds formula in all subjects (Friedewald, 1972) 
RF and CRP were done by latex agglutination method (Beacon diagnostics India). The 
test serum was mixed with CRP latex reagent and if CRP concentration was greater than 
6 mg/ml a visible agglutination was observed. A CRP concentration of less than 6 does 
not show agglutination on the slide. The concentration of the CRP was calculated by the 
formula CRP (mg/ml) = 6 x D .D was the highest dilution of serum showing 
agglutination and 6 was the sensitivity in mg/ml. Due to cost limitation a dilution 
beyond 96 mg/dl was not done in all subjects. RF was also done by agglutination 
method and the value was calculated by the formula RF IU/ ml=8 x D.
Thyroid profile was done by reagents supplied by Monobind Inc USA. Urine 
examination was done for all subjects. Fasting venous blood was collected the next day 
to assess the fasting blood glucose by using the reagent kit obtained from Beacon 
diagnostics India.
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4.12.2 Radiology
Radiographs were routinely done for all patients to look for involvement of joints due to 
RA. X- ray chest was also routinely done in patients. For subjects included in the study 
a history of latest chest radiograph was enquired and if the subject did not have a recent 
chest radiograph then a requisition was given and the subject was asked to have a chest 
X ray. This was done to rule out any infection, particularly tuberculosis (TB), which 
may give a positive CRP value or elevation in ESR level. South East Asians have high 
occurrence of tuberculosis, 4.97 million TB cases have been identified which is more 
than one third of the global burden and India alone has more than 20% of cases (WHO, 
2011). Average prevalence of all forms of TB in Indians is 5.05 per thousand annually 
(Chakraborty, 2004).
All patients attending SDRC get a baseline hand and feet radiograph as a routine 
procedure and their record was checked for radiological evidence of erosions to classify 
them as per the ACR criteria see table 1.2 chapter 1. Repeat X-ray hand and feet was 
not performed as it would not affect the outcome of the study and also to avoid radiation 
exposure to the participants.
The radiographs are performed at the in-house radiology department and the 
radiographs of all the subjects were examined and recorded by URKR before dispensing 
the X-ray films to the patients.
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4.12.3 Reporting the results of investigations
The results of blood reports were entered in the main register. The patient was asked to 
report the next day after an overnight fast and blood sample was collected for fasting 
blood sugar (FBS). The blood reports of the previous day were reviewed by URKR/FF 
and handed over to the patient. Patients having abnormal lipids and elevated/high 10 
year risk of CHD events were advised lifestyle modification including diet. These 
patients were further advised repeat lipid profile estimation and were counselled 
regarding continuing their medication regularly and keep their disease activity under 
control.
The subject was told that the report of the FBS would be informed by telephone. If the 
value was high the patient was asked to come and collect the report and consult their 
respective physician. The blood reports of the subject were entered in the paper CRF by 
one of the physiotherapists. All the entered patient data was again checked by FF. The 
twenty eight joint disease activity score (DAS 28) was calculated by FF with a DAS 
calculator by entering the values of TJC, SJC5 VAS and ESR.
4.13 Data entry
The patient’s data were transferred from paper CRF to Microsoft® Office Excel 2003 
spread sheet prepared by FF. The patient confidentiality was maintained when 
analyzing the data by giving each subject a unique identification number (ID) described 
in Table 4.2. The example cited in the table is hypothetical and does not reveal the data 
of any patient.
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Table 4.2 Identification codes for subjects
Patient name Mrs D. Lalitha Kumari
Patient initials DLT
Patient ID code 101
Control ID code 1001 (if DLT was a control)
Table 4.3 Entry of variables
Presence of the parameter 1 
Absence of the parameter 0
Eg. If the subject was a female the information was entered in the gender column as 1. 
In case of males the information was entered as 0. For vegetarian subjects the entry was 
1 and 0 for non vegetarian (Table 4.3).
To validate the entered data a check for proper entry and missed data was done after 
every 10 entries by a review of entered data compared to paper CRF. A sample of the 
parameters entered was given in Table 4.4. All data was entered in numerical.
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Table 4.4 Sample of parameters entered
Code, Case,
Personal details
Initials, Age, Gender, old case, Vegetarian, Smoking
Co Morbidities
Family history (n), DM, HTN, CVD, Co morbidity (n), DM, HTN, CVD,
Hypothyroidism
Evaluations
Waist(cm), Hip(cm), Height (cm), Weight (Kg), mean of Systolic BP, Diastolic 
BP
Calculations
W:H ratio, BMI, CVD risk systolic, CVD risk diastolic
Drug history
NSAIDs, Steroids, Methotrexate (Mtx), Leflunomide(Lef), Sulphasalazine (Ssz), 
Hydroxychloroquine (Hcq), Etanercept
Lab data
CRP, FBS, T-Chol, HDL-ChoI, LDL-Chol, Triglycerides, T-Chol:HDL-Chol 
ratio, ESR, RF 
RA related data
RA, disease duration (yrs), TJC, SIS, VAS, DAS 28.
4.14 Calculations
The subjects waist hip ratio (Waist: Hip) were calculated from the anthropometric 
measurements in the paper CRF by dividing the waist measurement value by the hip 
measurement. The body mass index (BMI) was calculated by dividing the weight in 
kilograms by height in meters squared. The formulae for auto calculations of Waist:Hip 
ratio, BMI, and ratio of T-Chol to HDL-Chol were programmed into the Microsoft 
Excel sheet used for data entry.
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DAS 28 was calculated in RA patients by using online DAS 28 calculator by Alfons 
and Michiel (http://www.das-score.nl/dasculators.xls). The DAS 28 value was obtained 
by entering four parameters - TJC, SJC, Patient’s global assessment of disease activity 
and ESR. The DAS28 value ranges were from 0 to 10. A value above 5.1 was 
considered as high disease activity, DAS 28 in the range of 3.2 to 5.1 was moderate 
disease activity and less than 3.2 was low disease activity (Table 4.5).
Table 4.5 EULAR response criteria (J. Fransen, 2005)
Low DAS Moderate DAS High DAS
<3.2 3.2-<5.1 >5.1
The T-Chol : HDL-Chol ratio was obtained by dividing the T-Chol value by the HDL 
value. LDL-Chol value was obtained by using the Friedewald’s formula LDL-Cho! = T- 
Chol - HDL-Chol-TG/5.
4.15 Maintaining the quality of assessments
Measures were taken to ensure that the patient recruitment was done as per the inclusion 
and exclusion criteria. The records of enrolled patients were reviewed randomly by FF 
to see if all the criteria were fulfilled. The subject evaluation was done by trained 
physiotherapists who had a similar training. To maintain uniformity in the standard of 
evaluation the physiotherapists were reassessed periodically by a same subject being 
evaluated by FF and the CRF was compared for discrepancies. The physiotherapists 
were also observed assessing patients from time to time.
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4.16 Coronary heart disease risk assessment
The composite CV risk score for a 10 year risk for coronary heart disease CHD event 
was calculated according to Joint British Society (IBS) calculation using the cardiac 
risk assessor computer program (Durrington, 1997) and the Framingham CHD risk 
score (Wilson, 1998).
The JBS risk score calculation includes age, gender, systolic BP, diastolic BP, smoking, 
total cholesterol, HDL cholesterol, diabetes and ECG evidence of LVH (optional). 
Calculation for a ten year risk of CHD event and stroke is obtained. Risk of stroke is not 
included in this study. A 10 year CHD risk of more than 10% was considered elevated 
and a risk of 15% and above was considered high for the study participants. The 10 year 
risk calculation of a 47 year diabetic female is given in figure 4.4
96
Figure 4.4 CHD risk calculation
CARDIAC RISK ASSESSOR
Risk Factors
Move through RISK FACTOR boxes to enter & amend data. 
Use cursor keys to move through boxes.
Female?(yes=1, no= 0) 
Age()ears)
SBP (mmHg) 
DBP(mmHg) 
Smokes?(yes=1 ,no=0) 
Total -C (mmoM)
HDL - C(mmol/l) 
Diabetes(yes= 1 ,no=0)
47
140
90
220
46
SBP
DBP
CHD risk % Stroke risk %
over 10 years over 10 years
10.9 2.2
11.9 2.1
Print
Known to have 
ECG-LVH? 
(yes=1 ,no=0)
Period of predictedrisk 10 
(years)
The 10 year risk of a CHD event would be 10.9 % for a female with this risk factor 
profile. However, if this was repeated for a male participant this would increase to 
11.3% and to 17.4% if the male participant was a smoker.
The Framingham 10 year coronary heart disease risk prediction (Wilson, 1998) 
calculates CHD risk based on measurement of age, gender, total cholesterol, HDL
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cholesterol, smoking, diabetes and hypertension. The risk estimates for this risk 
prediction tool were derived from the Framingham heart study (Dawber, 1980) For the 
purpose of this study we utilized the “hard” coronary heart disease event prediction, 
which includes all coronary heart disease events but not development of new diagnosis 
of angina. This makes it similar to the JBS CHD risk prediction. A risk score of below 
10% or less is considered low risk, score between 10-20% is intermediate risk and 
above 20% is high risk. The Framingham risk scores have been validated in European, 
African, and Hispanic Americans. (D'Agostino RB Sr, 2001); it has not been validated 
in Asian Indians. However, Framingham risk prediction tools are used worldwide to 
assess CV risk and many other risk prediction tools, including JBS, have been 
developed (Ioanna Tzoulaki, 2009) using data from the Framingham heart study. For 
the purpose of this study a 10 year Framingham risk score of 10% or more was 
considered elevated and a score of 15% or more was considered high for the study 
participants.
4.17 Metabolic Syndrome
Metabolic syndrome is an established risk factor for development of CVD (Peter W.F. 
Wilson, 2005). Metabolic syndrome was assessed using National Cholesterol Education 
Programme Adult Treatment Panel III (NCEP- ATP III) (ATPIII, 2002). A subject was 
classified as meeting the criteria for metabolic syndrome if three out of five criteria 
were fulfilled see Table 4.6
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Table 4.6 Criteria for Metabolic Syndrome
Risk Factor Cut off point
Waist circumference >102cm(>40 inches) in males
> 88cm (>35 inches) in females
Triglycerides >150mg/ dl
Low HDL Male < 40mg / dl, Female < 50mg / dl
Blood pressure >130/85 mm of Hg or an antihypertensive
Fasting blood sugar >110 mg/dl or diabetes
4.18 Elevated CV risk factors
Continuous CY risk factors were divided into categorical variables. These are 
summarised in Table 4.7. The elevated CV risk factor categorical variables were used 
in the analysis of case control study, the high RA disease activity study and the 
treatment effect studies.
The same CV risk assessments and CHD risk prediction methods were used for all 
participants involved in the studies presented in this thesis.
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Table 4.7 CV risk factor variables defining categorical variables denoting 
elevated levels for continuous data
CVD Risk factor Definition Reference
Systolic hypertension Systolic BP >140 mmHg (Bryan Williams
2004)
Diastolic hypertension Diastolic BP > 90 mmHg
High Waist:Hip ratio WaistHip ratio classified as high if 
ratio > 0.95 in Women & if >1 in Men)
(ATPIII, 2002)
Elevated BMI BMI>25 WHO definition of 
overweight/obese compared to normal 
or underweight BMI
(WHO, 1995)
Elevated T-Chol T-Chol >200mg/dl (NCEP, 2001)
Low HDL-chol HDL-Chol <40mg/dl
Elevated T-Chol:HDL-Chol
ratio
TChokHDL ratio >4.5
High triglyceride TG >150mg/dl
Elevated FBS FBS >100mg/dl (NCEP, 2001)
FBS in Diabetic range FBS in DM range >126 mg/dl
Elevated Framingham
CHD risk
Framingham CFID risk >10% n (%) (Peter W. F. Wilson, 
1998)
High Framingham CHD 
risk
Framingham CHD risk >15% n (%)
Elevated CHD risk score 
based on systolic BP
JBS CHD risk >10% n (%) (systolic) (David Wood, 1998)
High CHD risk score based 
on systolic BP
IBS CHD risk >15% n (%) (systolic)
Elevated CHD risk score 
based on diastolic BP
JBS CHD risk >10% n (%) (diastolic)
High CHD risk score based 
on diastolic BP
JBS CHD risk >15% n (%) (diastolic)
Metabolic syndrome Based on NCEP ATPIII definition (ATPIII, 2002)
4.19 Statistical analysis 
4.19.1 Descriptive statistics
In this thesis, non-parametric methods have been used to describe the data that are not 
normally distributed. The distribution of values including central tendency and spread
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of variables are described using median values and the inter-quartile range [IQR]. For 
normally distributed data, means and standard deviations are presented. Number and 
percentage have been used to describe categorical variables.
Comparison of non-parametrically distributed variables between groups was conducted 
using the Wilcoxon ranksum test (also known as the Mann Whitney U statistic) to 
explore whether the distribution of the variable was significantly different in two 
independent populations. For the treatment effect analyses, paired data for each subject 
was available and the Wilcoxon matched pairs Signed-rank test was used as within 
patient matching was available. This statistic explores whether the variable distributions 
between paired observations are the same.
For normally distributed data the students t-test was used and the paired t-test was used 
to compared matched normally distributed data.
Discrete binomial categorical variables were analysed with Chi Squared test. This 
allows simple hypothesis testing for differing proportions in each study group.
For the case control study, the controls were selected to provide a similar frequency of 
gender and age distributions to the cases. It was not practical to perform a matched 
analysis in this study. Therefore logistic regression was used to explore associations 
between categorical variables and cases. This analysis was repeated adjusting for age 
and gender as it was felt that these variables may confound the relationship between CV 
risk factors and RA. The same methods were employed to analyse the disease activity 
study and the treatment effect studies.
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Chapter 5 - Prevalence of traditional cardiovascular risk factors in
rheumatoid arthritis
In this chapter the prevalence of traditional CV risk factors are described and 
composite CHD risk prediction scores are calculated in a cohort of patients with 
rheumatoid arthritis. CV risk factor prevalence is compared between male and female 
RA patients and in rheumatoid factor (RF) stratified subgroups ofpatients.
5.1 Introduction
Mortality is increased in patients with rheumatoid arthritis (RA). RA patients die early 
due to cardiovascular disease (CVD), which is mediated by CV risk factors (Wallberg- 
Jonsson et ah, 1997, Symmons et al., 1998). Traditional CV risk factors and RA disease 
activity markers have been identified as predictors of future CV events (Solomon et al., 
2010). Smoking is strongly associated with increase in the CV risk and is also 
implicated in the development of RA (Goodson, 2002, Heliovaara et ah, 1995, Goodson 
et ah, 2004). Increased CV mortality is observed in patients with RA especially in those 
with a positive rheumatoid factor (RF) (van Schaardenburg D, 1993, Goodson et ah, 
2002, Gonzalez et ah, 2008a). RF is found to have a positive association with diabetes 
and a negative association with total cholesterol (Tomasson et ah, 2010).
There are gender differences in the development of CVD. When compared to men, 
CVD occurs 10—15 years later in women. In premenopausal women the effect of 
estrogens is thought be cardio protective but the risk of CVD rises after menopause.
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This may be in part due to hormonal effects on lipid profiles. Up to puberty the lipid 
profiles are similar in men and women. After puberty, due to the effect of testosterone, 
HDL levels drop in males. After menopause the testosterone levels increase, there is 
increase body weight, decrease in HDL cholesterol and an increase in triglyceride (TG), 
and LDL cholesterol. This worsens the CHD risk (Wark, 2004). It has been documented 
that a 20% reduction in the level of HDL results in 20% increase in CVD rates (Gordon 
DJ, 1989). However, despite this recognised association between gender and lipid 
levels, male gender is accepted as an independent risk factor for the development of 
CYD. There is a paucity of data addressing CV risk specific to gender. However, gender 
is a component of all CV risk assessment tools with male gender adding a weighting to 
the CV risk calculation (Wilson, 1998, society, 2005).
Several studies have demonstrated that Indians residing in India have a high prevalence 
of traditional CV risk factors (Misra et ah, 2004). In addition, Asian Indian migrants 
and their offspring also appear to have increased CV risk compared to the native 
populations of their host countries (Misra and Khurana, 2011, Anand SS, 2000, Enas et 
al., 1997, Venkataraman R, 2004, S.S. Liem, 2009). For any given conventional CV risk 
factor the CHD risk in Indians is higher than Europeans, double that of Americans and 
seven times higher than other Asians (Enas, 2000). Among Indians, the CV risk is 
higher in urban than rural populations; possibly because urbanisation is associated with 
reduced physical activity and increased consumption of fat and calorie rich food, which 
causes abdominal obesity, insulin resistance and dyslipidaemia.
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In India, obesity is more associated with affluent socioeconomic status (perhaps 
reflecting reduced exercise and high calorie intake), whilst poverty is more frequently 
associated with low body weight and malnutrition (Gaiha et ah, 2011). This is in 
marked contrast to western countries, where obesity is linked to poverty. In western 
countries lower socioeconomic groups seem to have less understanding of healthy 
dietary intake and poverty related factors may contribute to limited food choices. These 
appear to result in increased intake of more calorie dense food in their diet (Edwards 
and Clarke, 2009).
South Asian Indians have an increased prevalence of type 2 diabetes, which could be 
due to the effect of the thrifty gene hypothesis, which suggests an interaction between 
genetic predisposition and environment (R Ramaraj, 2008). The Thrifty genes’ enable 
an individual to efficiently collect and process food to deposit fat during periods of 
abundance (Neel, 1962).
In India, there are additional, geographical variations in CV risk. For example, South 
Indians have been reported to have an increased prevalence of CV risk factors compared 
to North Indians (Begom R, 1995). The WHO project on sentinel surveillance of Indian 
industrial populations has demonstrated that in India the highest prevalence of obesity 
and a high waist circumference is observed in Hyderabad, Andhra Pradesh. (Reddy et 
ah, 2002)
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However, there are minimal data describing traditional CV risk factors in South Asian 
Indians with RA. If CV risk factors are highly prevalent in the Indian population, it is 
possible that development of RA in this population will not be associated with 
additional elevation of this risk. This work was undertaken to describe the prevalence 
of traditional CV risk factors in a cohort of South Asian Indian RA patients residing in 
Hyderabad.
5.2 Aims
The primary aim of this study is to report the prevalence of traditional CV risk factors in 
Asian Indian patients with RA.
The secondary aim was to explore the prevalence of traditional CV risk factors in RA 
cases stratified by gender and rheumatoid factor status.
5.3 Patients and methods 
5.3.1 Patients
The RA cohort was recruited from a tertiary care rheumatology centre in Hyderabad, 
South India. The details of the rheumatology centre and its patient population is 
described in chapter 4 section 4.8. Consecutive eligible patients with a diagnosis of RA, 
attending the Sri Deepti Rheumatology centre were invited to participate. The eligibility 
criteria for the study are described in detail in chapter 4 table 4.1.
The study was approved by the institutional ethics committee of Sri Deepti 
Rheumatology Centre and all subjects gave written informed consent to participate.
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5.3.2 Data collection
To maintain uniformity, a standard pro forma, was used to collect information from the 
study participants. Demographic details including age and gender were recorded. The 
details of selection of the cohort and assessments are described in detail in chapter 4 
section 4.12.
5.3.3 RA disease characteristics
Rheumatoid arthritis related details including disease duration, rheumatoid factor status, 
and detailed history of current medications including NSAIDS, steroids, DMARDs and 
biological response modifiers were taken in the RA cohort. The patients were examined 
for 28 tender and swollen joints. Patient global assessment of disease activity using the 
visual analogue scale (YAS) was recorded and the disease activity score (DAS) was 
calculated with the DAS 28 calculator (Alfons and Michiel online DAS calculator). In 
total, seven RA disease markers studied were RF, disease duration, tender joint count, 
swollen joint count, ESR, CRP, global VAS and DAS was calculated. 
nittp://www,das-score.nl/dasculators.xlsT
5.3.4 CV risk assessments
Participants underwent a detailed analysis including measurements of height, waist and 
hip. Patients were weighed, clothed with footwear removed (Krups Mfg in India) and 
weight was recorded in kilograms (Kgs). Height was measured using a fixed 
stadiometer and was recorded in metres. Body mass index was calculated. Waist and hip
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circumferences were measured using a hand held tape measure as described in chapter 4 
section 4.10 .A high waist hip ratio was defined as more than 0.95 in females and more 
than 1.00 in males according to NCEP ATP (III, 2002). Blood pressure was measured 
after sitting at rest for 15 minutes (Diamond regular (IS3390) Mfg in India) see chapter 
4 section 4.9. The mean of 3 readings was calculated and entered on the paper CRF.
Traditional CV risk factors recorded included modifiable and non modifiable risk 
factors. In total eight risk factors including lipid profile were studied. Participants were 
asked about family history of HTN, Diabetes and CVD. A family history of CVD was 
defined as a first degree relative with atherosclerotic CVD, that developed, before the 
age of 55 years in males, and before 65 years in females (NCEP, 2001)
A detailed past medical history was recorded for each patient. A coexisting disease not 
related to RA was defined as a co morbid condition. History of co morbid hypertension, 
diabetes mellitus, hypothyroidism, and CVD were taken. Co morbidity was considered 
if the subject had a diagnosis of another condition or was on medication for a particular 
problem.
History of smoking was taken and the subjects were classified as smokers and non- 
smokers. Ex smokers for more than a year were considered as non smokers. History of a 
vegetarian diet was recorded.
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Laboratory evaluation included non-fasting lipid profile, ESR, RF, CRP, and fasting 
blood glucose. A chest X- ray was taken in subjects who had not had such imaging 
within the prior three months.
Coronary risk assessment was done and metabolic syndrome criteria were applied as 
described in chapter 4 section 4.15 and 4.16
5.3.5 Analysis
The data was analysed by simple descriptive statistics. Categorical variables were 
described by number (n) and percentage (%). Continuous data was described as median 
and inter quartile range [IQR] for non parametric data. Risk factors such as HTN, DM, 
BMI, W:H ratio were presented as both continuous variables and categorical variables. 
The categorical variables were defined according to cut offs for elevated values as 
suggested by the British Hypertension society and high cut off of NCEP ATP III 
respectively (JAMA 2001). The composite 10 year risk score of a CHD event calculated 
by Framingham and IBS were treated as continuous variables and categorical variables 
were generated based on elevated and high CHD risk levels (see table 4.7 chapter 4)
Chi squared test was used to compare the prevalence of categorical variables and 
Wilcoxon’s Ranksum test was used for comparing non parametrically distributed 
continuous data. The RA disease variables in the cohort were stratified by gender and 
RF status and were analysed.
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5.4 Results
5.4.1 RA disease variables
The RA disease related characteristics in the cohort of 800 RA patients are shown in 
table 5.1. Patients had median disease duration of 4 years. The majority of the cohort 
was RF positive 629 (78.6%). High ESR and CRP were found in most of the 
participants with the median being 63 [IQR 42, 84] for ESR and 48 [IQR 24, 84] for 
CRP. Patients had a high disease activity - the Median DAS 28 in the RA cohort was 
5.7 [4.5, 6.9]. High disease activity (DAS 28 > 5.2) was observed in 59.8% of 
individuals (n =478).
Table 5.1 RA disease characteristics
Baseline Parameters Description Patients n = 800
RF positive n (%) 629 (78.6)
Duration of disease (yrs) med [IQR] 4 [1.6,10]
CRP (mg/dl) med [IQR] 48 [24,48]
ESR med [IQR] 63 [42,84]
TJC med [IQR] 9 [4,17]
SJC med [IQR] 4 [2,8]
VAS med [IQR] 60 [50,90]
RF - rheumatoid factor, DAS - disease activity score based on 28 joint counts, ESR - 
erythrocyte sedimentation rate, TJC - tender joint count, SJC - swollen joint count, global health 
VAS - visual analogue scale, and IQR — inter quartile range.
The medication used by patients for their RA treatment is presented in table 5.2. All the 
patients using steroids were on a dose of 7.5 mg or less prednisolone per day.
Steroids were used by 41.8% and NSAIDs by 68.9% RA patients. A combination of 
NSAIDS and steroids was used by 37,8 % of patients. Methotrexate was used by most 
of the participants (91.6%). Other biologic or non biologic DMARDS were used in
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combination with methotrexate. The most frequently used combination DMARDs were 
methotrexate and hydroxychloroquine (n= 145); methotrexate and leflunomide (n-130); 
methotrexate and sulphasalazine (n=56) and methotrexate and etanercept (n=33). 8.4% 
of individuals who were not on methotrexate either had a mild disease, were intolerant 
of methotrexate, or were planning progeny (n=l 6).
Table 5.2 Medicines used by RA patients
Medications used n = 800 percentage
NS AIDS 551 68.9
Steroids 334 41.8
Methotrexate 733 91.6
Leflunomide 130 16.3
Hydroxychloroquine 148 18.5
Sulfasalazine 59 7.4
Etanercept 33 4.1
Steroids +NSAEDS 302 37.8
NSATDS - non steroidal anti inflammatory drugs
5.4.2 General descriptive data in RA cohort
The RA cohort comprised 800 consecutive adult patients fulfilling 4 out of 7 of the 
1987 ACR classification criteria (Arnett et ah, 1988). The mean age of the RA patients 
was 46.4 years, 668 were females (83.5%), and 142 were males (26.5%) see Table 5.3. 
The female : male ratio was 5:1. None of the females and only twelve males reported 
smoking histories. This cohort had a high family history of HTN (n=236 (29.5%)), DM 
(n=252 (31.5%)) and CVD (n=101 (12.6%)).
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Table 5.3 Descriptive baseline data in the cohort
Cases n = 800
Parameters description
Age in yrs med [IQR] 46.5 [38, 55]
Female n(%) 668 (83.5)
Male n (%) 132 (16.5)
Vegetarian n(%) 213 (26.6)
Smoking n(%) 12 (1.5)
Family History CVD n(%) 101 (12.6)
Family History DM n(%) 252 (31.5)
Family History HTN n(%) 236 (29.5)
Co morbid DM n (%) 138 (17.3)
Co morbid HTN n(%) 236 (29.5)
Co morbid CVD n (%) 5 (0.6)
Hypothyroid n(%) 82 (10.5)
Waist: Hip ratio med [IQR] 0.92 [0.86,0.98]
High Waist: Hip ratio * 218 (27.5)
BMI Kg/m2 med [IQR] 26.1 [23.1,29.7]
High BMI (BMI >25) n (%) 481 (60.1)
Systolic mmHg med med [IQR] 130 [120, 140]
Diastolic mmHg med med [IQR] 80 [80, 90]
CVD- Cardiovascular Disease, HTN- Hypertension, DM- Diabetes Mellitus, BMI- Body Mass Index, 
IQR- Inter Quartile Range *Waist:Hip ratio classified as high if> 0.95 in Women & if, >1 in Men)
The RA cohort had a high prevalence of CV related co morbidities especially with 
29.5% reporting HTN and 17.3% having a diagnosis of type 2 DM. Anecdotal evidence 
of co morbid CV was recorded in five patients and they were not on any treatment of 
the same. The presence of these co morbidities was important as they are part of the CV 
risk assessment. Multiple co morbidities were reported in 100 (12.5%) of the cohort. 
Hypothyroidism was reported by 82 participants. Hypertension, Diabetes and 
Hypothyroidism were present together in 10 RA patients.
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High waist hip ratios were observed in 27.5% of the participants. The median BMI was 
26.1 Kg/m2 and 481 (60%) were classified as being overweight or obese as per the 
WHO classification (WHO 2000).
5.4.3 Fasting blood glucose and lipid parameters in RA cohort
The median fasting blood glucose in the RA cohort was 87 mg/dl Table 5.4. When the 
patients were categorized as having fasting blood glucose of more than 100 mg /dl 
(NCEP, 2001) it was found that 27.5 % of participants had high blood glucose. Using a 
cut off of 126mg/dl, the level taken for diagnosis of diabetes mellitus (DM) according to 
NCEP ATPIII (NCEP, 2001) it was noted that 7.1% had fasting blood glucose in the 
diabetic range. Whilst most of these patients were known to have DM, 20% were not 
known to have a diagnosis of co morbid DM. These patients were informed of this 
abnormality and were encouraged to adopt dietary change, lose weight and increase 
exercise levels. Repeat blood glucose measurements were organised for these patients to 
allow diagnosis of DM fo be made.
Table 5.4 Fasting blood glucose in cases
Parameters Description RA cases n=800
FBS med [IQR] 87 [76,102]
Fasting blood glucose >100mg/dl n(%) 220 27.5
FBS in DM range >126 mg/dl n(%) 57 7.1
FBS- Fasting Blood Sugar, DM- Diabetes mellitus
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The median lipid profile was within the normal range see Table 5.5. A quarter of the 
patients (25.4%) had T-Chol more than 200 mg/dl. High TG >150 mg/dl was seen in 
39.9% of cases, 5.9% had low HDL-Chol <40mg/dl and 13.3% had a T-Chol: HDL- 
Choi ratio more than 4.5.
Table 5.5 Baseline lipid parameters and elevated parameters in cohort
Baseline Values Description Patients n = 800
T- Choi med [IQR] 175 [154, 201]
T-Chol >200mg/dl n(%) 203 25.4
HDL- Choi med [IQR] 48 [45,51]
HDL- Choi <40mg/dl n(%) 47 5.9
LDL- Choi med [IQR] 99 [79.5, 120.5]
TG med [IQR] 132.5 [98, 184]
TG >150mg/dl n(%) 319 39.9
T-Chol: HDL-Chol ratio med [IQR] 3.7 [3.3, 4.2]
T-Chol :HDL- Choi ratio >4.5 n(%) 106 13.3
T-Chol — Total Cholesterol, HDL-Chol- High Density Lipoprotein Cholesterol, LDL-Chol- Low Density 
Lipoprotein Cholesterol, TG — Triglycerides
5.4.4 Framingham and JBS calculated CVD risk scores in the RA cohort
Table 5.6 shows the composite 10 year risk of CVD calculated using JBS and 
Framingham risk score calculator. The median Framingham risk score was 4.0% risk of 
a CHD event in a 10 year period. However, over a quarter of the cohort (212 (26.5%) 
patients) had an elevated CHD risk score (defined as >=10%) and 11% had high CHD 
risk with Framingham risk scores above 15%.
The CHD risk scores were lower when calculated using JBS. The median risk score of 
a CHD event according to JBS was 3.2% based on systolic blood pressure and 3.6%
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when based on diastolic BP. A much smaller proportion of the cohort was identified as 
having elevated CHD risk (12.6%) or high CHD risk (5.6%) when CHD risk was 
assessed using JBS. When the JBS scores were divided into tertiles it is clear that the 
data is skewed to the left with most patients having very modest CHD risk scores. The 
range of JBS CHD risk scores for patients is shown in figure 5.1.
Table 5.6 Calculated CHD risk scores in the cohort
Patients n = 800
Calculated CHD risk
Based on Framingham 10 yr CHD risk % med [IQR] 4 1,8
10 year CHD risk >10% n (%) 212 26.5
10 year CHD risk >15% n (%) 90 11.3
*Based on JBS 10 yr CHD risk % med [IQR] (systolic) 3.2 [0.9,6.6]
10 yr CHD risk % med [IQR] (diastolic) 3.6 [0.9, 7.3]
10 year CHD risk >10% n (%)(systolic) 101 (12.6)
10 year CHD risk >15% n (%)(systolic) 45 (5.6)
Tertiles of 10 year CHD % risk (Systolic BP)
*Based on JBS <1.5% 257 (32.1)
1.5- <5% 266 (33.3)
>5% 277 (34.6)
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Figure 5.1 Graph of frequency of JBS CHD risk scores in cases
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5.4.5 Metabolic syndrome in RA cohort
Criteria for metabolic syndrome were applied to all RA patients see Table 5.6. Nearly 
half of the cohort (46% of RA patients) had three out of five criteria and qualified as 
having metabolic syndrome see Table 5.7. Only 7.4% of the cohort did not have any of 
the criteria for calculating metabolic syndrome according to the ATPI11 classification 
(NCEP, 2001).
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Table 5.7 Meets criteria for ATPIII metabolic syndrome in cases
Patients n = 800
n %
ATP III score 0 59 7.4
1 156 19.5
2 217 27.1
3 235 29.4
4 119 14.9
5 14 1.8
ATPIII Meets Criteria for MS 368 46.0
5.5 Descriptive data in the RA cohort stratified by gender
5.5.1 RA disease variables stratified by gender
Females in the RA cohort had a trend for longer disease duration and were more 
frequently positive for RF. The swollen joint count, tender joint count, global VAS was 
numerically higher in females. The disease activity parameters like ESR and CRP were 
similar. No difference was observed in the DAS 28 in male and female RA patients see 
Table 5.8.
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Table 5.8 RA disease variables stratified by gender
Baseline Parameters Females n = 668 Males n = 132 P value
RF positive n (%) 528 79.1 101 76.5 NS
Duration of disease(years) 4 [2,10] 3 [1,8] NS
DAS 28
Mean (SD)
5.7 (1.6) 5.6 (1.6) NS
C reactive protein(mg/dl) 42.0 (21.8) 41.8 (21.9) NS
ESR Med [IQR] 63 [43,84] 64 [40,84] NS
TJC Mean (SD) 11.3 (8) 10.7 (7.7) NS
SJC Mean (SD) 5.9 (5.4) 5.6 (4.9) NS
VAS Mean (SD) 65.2 27.7 64.3 (29.0) NS
RF-Rheumatoid Factor, DAS- Disease activity score, ESR- Erythrocyte Sedimentation Rate, TJC- Tender 
Joint Count, SJC- Swollen Joint Count, Global Health VAS- Visual Analogue Scale, and SD- Standard 
Deviation.
5.5.2 General descriptive data
The eight hundred patients in RA cohort were stratified by gender and analyzed. The
females in the cohort were 668 and 132 were males. Females in the cohort were
younger and were more often vegetarian this difference was not statistically significant.
There were very few smokers in the cohort (n=12 (9.09%)). None of the females
smoked. Family history of CVD was similar in the two groups (12.1%). Co morbidities
such as DM and HTN were more frequently seen in males (15.7% vs 25.0% and 28.6%
vs 34.1%) this difference did not display a statistical difference. Hypothyroidism was
common in females (11.1% vs 3.03%). This difference was statistically significant
(p<0.01). The difference in median waist: hip ratio was significant (pO.Ol). Though
high waist: hip ratio of more than 0.95 was more frequently observed in females 27.8%
it was not statistically significant. Females also exhibited a high BMI in the overweight
/ obese range (>25) 63.1% vs 45.5% which was statistically significant (p<0.001). The
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median systolic and diastolic pressure was similar in the groups but when a cut off of 
>140 mm of Hg systolic and > 90 mm diastolic BP was used there was a difference 
between male and female RA cohort (p<0.03, <0.01) see Table 5.9.
Table 5.9 Descriptive data in RA cohort stratified by gender
Parameter Females n=668 (83.5%) Males n=132 (16.5%) p value
Demographics
Age in yrs, med [IQR] 46 [38, 54.5] 49 [40,56] NS
Vegetarian n (%) 185 (27.7) 28 (21.2) NS
History of CVD risk factors
Smoking n (%) 00 (00) 12 (9.09) -
F history CVD n (%) 81 (12.1) 16 (12.1) NS
Co morbid DM n (%) 105 (15.7) 33 (25.0) NS
Co morbid HTN n(%) 191 (28.6) 45 (34.1) NS
Co morbid CVDn(%) 4 (0.6) 1 (0.76) NS
Hypothyroid 78 (11.7) 4 (3.03) p<0.01
Anthropometric measurements
waist: hip med[IQR] 0.91 [0.86, 0.98] 0.97 [0.91, 0.99] pO.001
High W:H ratio n (%) 186 (27.8) 32 (24.2) NS
BMI med [IQR] 26.4 [23.4,30.0] 24.7 [22.2,27.4] pO.001
BMI> 25 kg/m2 n (%) 421 (63.1) 60 (45.5) p<0.001
BP mm Hg
Systolic med[IQR] 130 [120,140] 130 [120,140] NS
High Systolic >140 173 25.9 46 34.9 p=0.03
Diastolic med[IQR] 80 [80,90] 80 [80,86] NS
High Diastolic >90 251 37.6 64 48.5 p=0.01
CVD- Cardiovascular Disease, HTN- Hypertension, DM- Diabetes Mellitus, BMI- Body Mass Index, 
IQR- Inter Quartile Range, F history- Family history, W:H ratio- Waist: Hip ratio 
*Waist:Hip ratio classified as high if > 0.95 in Women & if, >1 in Men)
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5.5.3 Fasting blood glucose and lipid parameters in RA cohort stratified by gender
Though the fasting blood glucose was higher in males who also exhibited a trend fol­
lower lipid parameters. The high FBS and low HDL-Chol was significant statistically 
(p<0.05) see Table 5.10
Table 5.10 Fasting blood glucose and lipid parameters in RA stratified by gender
Parameter Females n = 668 (83.5%) Males n = 132 (16.5%) p value
FBS med [IQR] 86 [76,101] 92 [77.5,104.5] NS
High FBS 174 26.1 46 34.8 p<0.05
FBS in DM range 43 6.4 14 10.6 NS
T- Choi med [IQR] 175.5 [155,202] 171 [150,195.5] NS
High T-Cho 174 26 29 22.0 NS
HD1- Choi med [IQR] 48 [45,51] 47 [44,50] NS
Low HDL-Chol 34 5.1 13 9.9 p<0.05
LDL-Chol med [IQR] 99 [43,50] 97 [80.5,121] NS
High LDL-Chol 31 4.6 9 6.8 NS
TG med [IQR] 133 [98,185] 132 [95,179] NS
High TG 272 40.7 47 35.6 NS
T -Choi: HDL-Chol 3.7 [3.3,4.2] 3.6 [3.3,4.2] NS
High T-Chol:HDL ratio 6 0.9 2 1.5 NS
5.5.4 Framingham and JBS calculated CHD risk scores in the RA cohort stratified 
as per gender
The composite 10 year risk score of CHD event was calculated as per Framingham and 
JBS calculator see Table 5.11. The median risk score was higher in males (7% vs 4%). 
Males exhibited a higher elevated score (>10%) which was almost twice that of 
females. When the group was further categorized as having a high score (>15%) males 
had a four times higher risk score when compared to females (30.3% vs 7.5%). There
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was a statistical significance in the gender stratified RA cohort in median, elevated and 
high categories of the Framingham CHD risk scores see Table 5.11
Table 5.11 Calculated CHD risk scores in the RA cohort
Parameters Females n= 668 
(83.5%)
Males n=132 
(16.5%)
p value
Based on 
Framingham
10 yr CHD risk % med [IQR] 4 [0, 8] 7 3, 12 pO.OOI
10 year CHD risk >10% n (%) 155 23.2 57 43.2 p<0.05
10 year CHD risk >15% n (%) 50 7.5 40 30.3 pO.OOI
*Based on
JBS
10 yr % CHD risk med [IQR] 
(systolic)
2.8 [0.7,5.95] 5.7 [3.2,10.3
]
pO.OOI
10 yr % CHD risk med [IQR] 
(diastolic)
3 [0.6, 6.6] 6.3 [3.3,
11.8]
pO.OOI
10 year CHD risk >10% n (%) 
(systolic)
65 (9.7) 36 (27.3) pO.OOI
10 year CHD risk >15% n (%) 
(systolic)
24 (3.6) 21 (16.0) pO.OOI
Tertiles of 10 year CHD % risk (Systolic BP))
*Based on
JBS
<1.5% 240 (35.9) 17 (12.9) pO.OOI
1.5- <5% 226 (33.8) 40 | (30.3) pO.OOI
>5% 202 (30.2) 75 1 (56.8) pO.OOI
The median systolic and diastolic risk score of a CHD event according to JBS was 
higher in males. A higher elevated (>10%) risk was found in males (27.3% vs 9.7%). 
High score of >15% was found to be more than four times higher in males. Males more 
frequently had a high score in the highest tertile (>5%) tertile of CHD risk and females 
more frequently had a CHD risk score in the <1.5, 1.5- <5 range. The CHD risk score in 
median, elevated, high and all the tertiles was statistically significant see Table 5.11.
5.5.6 Metabolic syndrome in RA cohort stratified by gender
The gender stratified ATPIII metabolic syndrome criteria in the RA cohort revealed a 
significant difference between male and female RA cohort. More than half of the 
female RA population (50.9%) meet the criteria for metabolic syndrome. There was a
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statistical difference in the females (5.9%) and males (14.4 %) who did not have any 
criteria of metabolic syndrome see Table 5.12.
Table 5.12 Meets criteria for ATPIII metabolic syndrome
Patients n = 800 p value
Females Males
n % n %
ATP III
score
0 40 5.9 19 14.4 p<0.05
1 108 16.2 48 26.4 p<0.05
2 180 27.0 37 28.0 NS
3 214 32.0 21 15.9 pO.001
4 112 16.8 7 5.3 pO.001
5 14 2.1 0 0 -
ATPIII Meets Criteria for M S 340 50.9 28 21.2 pO.001
5.6 Descriptive data in the RA cohort stratified by gender 
stratified by RF status
5.6.1 RA disease variables stratified by RF status
The RA cohort was stratified as per rheumatoid factor status. RF was found to be 
positive in 629 cases and 171 were negative for RF see Table 5.13. The RF positive 
group was older (47 vs 45 yrs) and were more often females (n= 528 (83.9 %)). The RF 
positive group had longer disease duration (5 yrs vs 3 yrs) see Table 5.13. A trend for 
numerically higher tender, swollen joints and global VAS and ESR was observed in the 
RF positive group but this was not statistically significant.
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Table 5.13 RA disease variables as per RF
Parameters Description RF + n = 629 RF- n = 171 p value
RA details
Disease duration years med[IQR] 5 [2, 10] 3 [1,6] pO.OOl
TJC mean(SD) 11.4 8.0 10.4 7.7 NS
SJC mean(SD) 5.9 5.3 5.6 5.2 NS
YAS mm mean(SD) 65.4 27.7 63.5 28.3 NS
DAS 28 5.7 1.6 5.6 1.7 NS
ESR mm/hr med [IQR] 65 [43,
85]
57 [40, 80] p<0.05
CRT mg/dl mean(SD) 42.8 21.9 39.0 30.0 pO.OOl
The RF positive group displayed a trend for increased use of NSAIDs (70.0% vs 64.9%) 
and steroids (43.3% vs 41.3%) see Table 5.14. Methotrexate use was significantly 
higher in the RF positive group (93.3% vs 85.4%). There was a 2 fold increase in use of 
leflunomide by RF positive patients when compared to the RF negative group. 
Etanercept was more frequently used in the RF positive group (4.8% vs 1.8%). 
Sulphasalazine (9.4% vs 6.4%) and hydroxychloroquine (23.4% vs 17.2%) were more 
frequently used in the RF negative group.
Table 5.14 Medicines used by the RA cohort stratified as per RF
Parameters Description RF + n — 629 RF - n = 171 p value
NSAIDS n Yes (%) 440 (70.0) 111 (64.9) NS
Steroids n Yes (%) 260 (41.3) 74 (43.3) NS
Methotrexate Yes (%) 587 (93.3) 146 (85.4) pO.OOl
Leflunomide Yes (%) 114 (18.1) 16 (9.4) NS
Etanercept Yes (%) 30 (4.8) 3 (1.8) NS
Sulphasalazine Yes (%) 43 (6.4) 16 (9.4) NS
HCQ Yes (%) 108 (17.2) 40 (23.4) NS
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5.6.2 General descriptive data in the RA cohort stratified as per RF status
RF positive patients were more frequently vegetarian see Table 5.15. Though the 
number of smokers in the cohort was very few it was found that smoking was very 
strongly associated with RF positive status (p<0.05). Interestingly family history of 
CVD was more frequent in the RF negative group. The RF positive group displayed 
increased prevalence of co morbid conditions such as DM (8.4% vs 2.9%), HTN 
(31.2%, 23.4%) and hypothyroidism (10.1% vs 8.2%). High blood pressure of >140 and 
>90 mm of Hg was similar in the two groups but RF negative patients demonstrated a 
trend for higher diastolic BP.
The median BMI was slightly higher in RF negative group who also frequently 
exhibited BMI of > 25 which is in the overweight / obese range (67.3% vs 58.2%). The 
categorical BMI of < 25 was more often seen in RF positive group (41.2% vs 32.2%) 
where as the RF negative group had an increased prevalence of high BMI 25-< 30 
(42.7% vs 36.7%) and > 35 BMI (24.6% vs 21.6%) respectively. Waist: hip ratio was 
similar in the two groups. High waist hip ratio of >0.8 in females and >1 in males was 
seen in 28.6% of RF positive and 22.2% in the RF negative group.
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Table 5.15 Descriptive data in RA cohort stratified by RF status
Parameters Description RF + n = 62978.6%) RF- n = 171 (21.4%) p value
Demographics
Age Years Med [IQR] 47 [38, 55] 45 [37, 55] NS
Female n (%) 528 (83.9) 140 (81.9) NS
Vegetarian n (%) 177 (28.1) 36 (21.1) NS
CV risk factors
Smoking n (%) 11 (1.75) 1 (0.58) p<0.05
F history CVD n (%) 70 (11.3) 27 (15.8) NS
DM n (%) 116 (18.4) 22 (12.9) NS
HTN n (%) 196 (31.2) 40 (23.4) NS
CVD n (%) 3 (0.5) 2 (1.2) NS
Hypothyroid n (%) 68 (10.1) 14 (8.2) NS
Blood pressure
BP Systolic mmHg Med[IQR] 130 [120,140] 130 [120, 140] NS
BP Diastolic mmHg Med[IQR] 80 [80, 90] 80 [80, 90] NS
High BP
Systolic
>140 n 172 27.3 47 27.5 NS
Diastolic >90 n 252 40.1 63 36.8 NS
Measurements
BMI Kg/m2 Med[IQR] 25.9 [22.8, 29.6] 26.6 [24.1,30.0] NS
High BMI >25 (%) 336 (58.2) 115 (67.3) NS
Cat BMI <25 (%) 262 (41.2) 56 (32.2) NS
25 -< 30 (%) 231 (36.7) 73 (42.7) NS
>35 (%) 136 (21.60) 42 (24.6) NS
W : H ratio Med [IQR] 0.92 [0.86, 0.98] 0.91 [0.86, 0.96] NS
High W:H >0.95 F
> 1 M
(%) 180 (28.6) 38 (22.2) NS
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5.6.3 Fasting blood glucose and lipid parameters in RA stratified by RF status
Median fasting blood glucose and fasting blood glucose of more than 126 mg/ dl which 
is in the diabetic range was similar in the RF positive and RF negative group.
Total cholesterol was found to be significantly higher in the RF negative group who 
also exhibited an increased number of patients having a high T-Chol > 200 mg/dl see 
Table 5.16. Low HDL cholesterol (7.6% vs 5.4%) and significantly high triglyceride 
(48.0% vs 37.7%) (PO.05) were more frequently observed in the RF negative group. 
There was trend for higher LDL cholesterol in the RF negative group. The T-Chol: 
HDL-Chol was similar in the two groups.
Table 5.16 Fasting blood glucose and lipid parameters stratified by RF status
Parameters Description RF + n = 629 RF - n = 171 p value
FBS mg/dl Med [IQR] 86 [77,102] 87 [76, 102] NS
High FBS>126 mg/dl n(%) 173 (27.5) 47 (27.5) NS
T-Chol mg/dl med [IQR] 173 [153, 198] 182 [158,210] p<0.05
High T-Chol >200 n(%) 145 (23.1) 58 (33.9) p<0.05
HDL -Choi mg/dl med [IQR] 48 [45,51] 49 [45, 52] NS
Low HDL-Chol <40 n(%) 34 (5.4) 13 (7.6) NS
LDL-Chol mg/dl med [IQR] 97 [79, 119] 102 [82,127] NS
High LDL C n(%) 31 4.9 9 5.2 NS
T-Chol: HDL med [IQR] 3,7 [3.3, 4.1] 3.8 [3.3, 4.3] p=0,002
High TChohHDL n (%) 5 0.79 3 1.75 NS
TG mg/dl med [IQR] 130 [97, 178] 147 [102, 207] p=0.007
High TG >150 n(%) 237 (37.7) 82 (48.0) p<0.05
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5.6.4 Framingham and JBS calculated CHD risk scores in the RA cohort stratified 
as per RF status
The composite 10 year CYD risk score for the probability of a CV event was calculated 
as per Framingham and JBS calculator see Table 5.17. Though there was no statistically 
significant difference in the CHD risk scores the JBS calculation revealed that the 
median score was higher in the RF positive group who also exhibited a trend for having 
elevated (>10%) (13.2% vs 10.5%) and high (>15%) (5.6% vs 4.7%) score of JBS. The 
number of patients in tertiles of CV risk as per JBS (<1.5, 1.5- <5% and >5%) was more 
in RF positive group where as the RF negative group had more patients in the <1.5% 
(32.6%).
Table 5.17 Calculated CHD risk scores in the RA cohort stratified as per RF status
Parameters Description RF + n = 629 RF - n = 171 p value
CV risk Systolic med [IQR] 3.4 [1,6.7] 2.8 [0.7, 6] NS
CV risk Diastolic med [IQR] 3.7 [1,7.5] 3 [0.7, 6.5] NS
Tert CVD <1.5 n(%) 195 (31.0) 62 (36.3) NS
1.5-<5 n(%) 210 (33.4) 56 (32.6) NS
>5 n(%) 224 (35.6) 53 (30.1) NS
JBS CHD >10% n(%) 83 (13.2) 18 (10.5) NS
JBS CHD>15% n(%) 37 (5.6) 08 (4.7) NS
Fratn CHD risk
score
med [IQR] 4 [1, 10] 4 [0, 8]
Fram CHD >10% n(%) 172 27.3 40 23.4 NS
Fratn CHD >15% n(%) 75 11.9 15 8.8 NS
MS n(%) 286 45.5 82 48.0 NS
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5.7 Discussion
This cohort of young South Asian Indian RA patients has demonstrated a very high 
prevalence of traditional CV risk factors despite their age, predominantly female 
population and negligible smoking history. The most common co morbidity observed 
was hypertension, followed by DM (30%, 17%). It was interesting to note that nearly 
half the patients met criteria for metabolic syndrome, which may reflect clustering of 
multiple CVD risk factors in these RA patients. A quarter of the individuals had an 
elevated (>10%) CHD risk score, when this was calculated using Framingham CHD 
risk score. A much smaller proportion was identified as having elevated CHD risk when 
the JBS risk calculator was used.
Gender stratified analysis revealed that male gender has a strong association with CV 
risk factors like hypertension, diabetes and smoking. This is in accordance with 
published literature. The QUEST RA study demonstrated increased prevalence of CV 
risk factors in males who also had increased CV events. The authors confirmed the 
association of traditional CV risk factors to CV morbidity (Naranjo et al., 2008). 
However, this study did not calculate the CHD risk score. The males in our cohort had 
significantly higher prevalence of elevated (>10%) CHD risk which was double that of 
females. This difference was more marked when high CHD risk (>=15%) was 
compared by gender in the RA cohort. Males had a 4 fold increased prevalence of high 
CHD risk when compared to females. Whilst this may be explained by the increased 
weighting in the risk calculation given to men it is interesting that the difference is more 
marked at the high CHD risk cut off. Very few previous studies have looked at the risk
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score specific to gender. The high CHD risk in males is an important finding as our 
cohort was younger than the study population of most of the published data and another 
important feature is that there are negligible smokers in the population.
More than half of the females in this cohort had met the criteria for metabolic 
syndrome. Whilst the published data reports a high prevalence of metabolic syndrome 
in the South Asian Indian population this seems a remarkably high prevalence in the RA 
cohort. The reasons for this high prevalence are not clear but may reflect the relatively 
affluent socioeconomic background of this patient population or possibly the urban 
setting of this study. We have already acknowledged that obesity is associated with both 
these factors and it may be that high prevalence of obesity in the patients studied is 
responsible for this high metabolic syndrome prevalence. There is a need to compare 
the prevalence of metabolic syndrome in a similar non RA control group to explore 
whether this risk factor is associated with RA. This is in accordance with published data 
that metabolic syndrome is high in the South Asian Indian population (Misra and 
Vikram, 2004). However, it is remarkable that this RA patient group had such a high 
prevalence of metabolic synd.
No difference was found in the RA disease activity between males and females.
Increased co morbidities and a trend for higher 10 year probability of CHD event was 
observed in the RF positive patients. Though the cohort had very few smokers it was 
found that all but one of the twelve smokers belonged to the RF positive group. This
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might reflect the association between smoking and the development of RF in RA 
(Criswell et ah, 2002). However the number of smokers was very small in this cohort. It 
is unlikely that the increased 10 year CHD risk is due to the effect of smoking alone. 
The occurrence of association between CVD mortality and RF positive status has been 
explored (Goodson et al., 2008). These authors have suggested that RF positive status 
is associated with more severe disease and higher inflammatory disease burden 
contributes to the excess CVD mortality observed through inflammation accelerating 
atherosclerosis.
Higher waist hip ratio was found in the RF positive group. The RF positive cohort had a 
trend for low BMI of <25 as the disease activity was high the possibility of rheumatoid 
cachexia cannot be ruled out. Therefore it seems that RF positive patients have more of 
a centripetal distribution of body fat. This suggests that these patients may have more 
rheumatoid cachexia and more abdominal fat. We were not able to measure percentage 
body fat or distribution of body fat in this study. It would be interesting to measure this 
in future studies. Rheumatoid cachexia is associated with inflammation and abdominal 
body fat distribution is associated with increased CHD risk and metabolic syndrome.
The RF positive group displayed increased CHD risk scores when compared to RF 
negative group. Though RA disease activity was similar in the two groups, the RF 
positive group displayed increased use of NSAIDS, steroids, methotrexate, leflunomide 
and etanercept whereas sulphasalazine and hydroxychloroquine were frequently used by 
the RF negative group. Rather surprisingly the RF negative patients had a high family
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history of CVD, a trend for higher diastolic BP, higher BMI and higher T-Chol, TG and 
low HDL-Chol. This interesting finding needs to be studied further.
The strengths of this study are the large number of patients studied. To my knowledge 
this is the largest cohort of Indian RA patients in whom traditional CV risk factors were 
studied and their composite CV risk calculated. The large number increases the 
statistical power of the study, affords better potential for the results to be generalised to 
the wider Indian RA population, allows research questions to be better tested and more 
reliability for the means obtained. The fact that Hyderabad is a cosmopolitan city, 
catering to individuals from disparate societies and beliefs, further increases the scope 
for generisability of the results. Controls free from inflammatory arthritis were matched 
for age, gender, ethnic and social background (See chapter 4 section 4.7). Finally, this 
study has generated a large database of RA patients and matched controls, which can be 
helpful in further studies.
Our findings are consistent with earlier published literature. Studies have demonstrated 
that RA is associated with dyslipidaemia, diabetes mellitus and metabolic syndrome 
(Han et ah, 2006). An increased prevalence of co morbidities in RA has also been 
observed before (Gabriel et ah, 1999a, Wasko, 2004). In a study looking at CV risk 
factors in rheumatic conditions it was found that increased prevalence of CV risk factors 
are common in rheumatic diseases (M. Antivalle, 2007, Panoulas et ah, 2007) and found 
hypertension to be highly prevalent in RA and diastolic hypertension was also observed 
(McEntegart, 2001).
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A weakness of this study has been the fact that I was unable to get data from the 
participants who refused to participate in the study. In addition, as patients in this cohort 
were recruited from a tertiary care centre, there is a possibility that I recruited more 
severe cases than would be found in the community. As I enrolled participants from 
regular outpatient clinic there is also a possibility that patients with well-controlled RA 
may not have turned up at the clinic, or those patients may not have agreed to 
participate as they were happy with their disease control and did not want further 
evaluation. This may potentially explain the high DAS 28 scores of the study 
participants. Other potentially confounding factors are that our patients were not fully 
fasted before giving the blood sample. I also was unable to capture the duration of 
medicines used in the RA group - but, as the median disease duration of the group was 
4 years it is unlikely that participants were on medications for long. Most commonly 
used NSAIDs are celecoxib, etodolac and diclofenac. The type of NSAID used by RA 
patients was not recorded and this may have affected the results. However, I was not 
looking at CV events in the study population and it is established that the CV risk 
factors may be affected by the use of NSAIDs. Goodson et al have demonstrated that 
NSAID users have displayed reduced CV mortality in an inception cohort of RA 
patients who were followed for ten years. The mean duration of NSAID use was four 
years (Goodson et al., 2009). As the median disease duration of RA cohort was 4 years I 
would not expect the NSAID users to have a longer exposure and perhaps it may not 
have had an impact on the CV risk factors. When the study was started 1987 ACR 
criteria were used for classification of RA patients (Arnett et al., 1988)and all 
participants included in RA cohort fulfilled the criteria. It may have been possible that
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few patients with early arthritis and possibly less active disease who could be included 
using the 2010 criteria (Aletaha, 2010) may have been missed when 1987 criteria were 
applied. Finally, extra articular manifestations of disease were not recorded.
CV risk prediction early in the disease is important. Our study participants had active 
disease and disease duration of 4 years and this study suggests the need CV risk 
estimation early in the disease to address CV risk prevention. The importance of CV 
risk prediction early in the disease was described by Kremers et al (Kremers et ah, 
2008) in a study of 553 RA patients and 574 controls. The authors found that 85 % of 
newly diagnosed RA patients had 1 in 5 chance of developing CV events compared to 
40% in controls. In each age group this finding was similar to controls that were 5-10 
years older. The authors have suggested prediction of CV risk in RA patients within 10 
years of diagnosis as patients suffer from significant pain and stress and CV prevention 
may be delayed. Another study has emphasized the CV risk prediction early in the 
disease. The study looking at CV events in early RA followed up for five years have 
found that occurrence of CV events was explained by traditional CV risk factors and 
was potentiated by high disease activity (Innala et ah, 2011).
The observation that the patients had such a high prevalence of metabolic syndrome of 
46% is important, since the general Indian population already has a high prevalence of 
metabolic syndrome and diabetes (Misra et ah, 2010) and inflammation is considered to 
be a link between obesity, metabolic syndrome and CVD (Gremese and Ferraccioli, 
2011).
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Very few studies have previously been conducted in Indian RA patients looking at 
traditional CV risk factors and calculating their CV risk score. Grover et al (Grover et 
ah, 2006) studied 57 Indian RA patients and found that one third of these had 
subclinical atherosclerosis, which occurred at a relatively young age (41.5 years). 
Another case controlled study by Mahajan et al (Mahajan et ah, 2008) studied 100 RA 
patients and 100 controls (mean age 43 years) and found that 33% of RA and 28% of 
controls exhibited dyslipidaemia and that premature atherosclerosis and carotid plaques 
were common in the patients with RA.
This study highlights the need for an aggressive approach towards identifying and 
treating CV risk in RA patients of South Asian Indian origin who already have an 
increased risk of CVD. In view of the observation that these RA patients displayed a 
high prevalence of traditional CV risk factors and metabolic syndrome, it would be 
rather interesting to compare these findings in a case controlled study in this population.
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Chapter 6 - Prevalence of CV risk factors in cases and controls
The prevalence of traditional CV risk factors in patients with rheumatoid arthritis is 
compared with controls free fiAom inflammatory arthritis in this chapter. Individual risk 
factors are described in detail.
6.1 Introduction
Rheumatoid arthritis patients have increased incidence of cardiovascular disease which 
is two times higher when compared to general population (Maradit-Kremers H, 2005). 
The reasons for this increased CVD event rate associated with RA are likely to be 
multifactorial and may be related to effects of either treatments or chronic systemic 
inflammation accelerating atherosclerosis. In general population traditional CV risk 
factors have been demonstrated to be strong predictors of future CV events (Wilson, 
1998). However, the role of traditional CV risk factors is controversial in development 
of CVD events in association with RA. A study by del Rincon et al found that whilst 
RA patients had excess CVD events compared to controls this excess was not totally 
explained by a higher prevalence of CV risk factors, (del Rincon et al., 2001). A further 
study by this group reported that, in RA, the variance in carotid atherosclerosis, was 
explained by both traditional CV risk factors and measures of inflammation (del Rincon 
et al., 2005).Whilst it is likely that in RA disease related factors, such as inflammation, 
may accelerate atherosclerosis, there is evidence that RA is associated with elevated CV 
risk factors. A meta analysis suggested that when compared to controls increased 
prevalence of diabetes, smoking and low HDL cholesterol are found in RA (Boyer et 
al., 2011). Smoking has been identified as a CV risk factor associated with RA (Saag et
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al., 1997, Wolfe, 2000a) and several studies have reported a higher prevalence of 
smoking in RA cohorts compared to the general population (Maradit-Kremers et al., 
2005, McEntegart, 2001, Hutchinson D, 2001, Boyer et al, 2011). However, results 
from the Nurses health study has not demonstrated any difference in the prevalence of 
traditional CV risk factor profile in women with and without RA (Solomon et al., 2004).
Dyslipidaemia appears to be more commonly associated with RA but patterns of lipid 
abnormalities appear to differ between studies (Steiner G, 2009). Active untreated RA 
appears to influence lipid profile. Whilst several studies have demonstrated lowering of 
HDL levels in active RA (Park et al., 1999, Kitas, 1997), the effect of disease activity 
on total cholesterol appears to vary between studies. Some studies have reported disease 
activity is associated with an increase in total cholesterol (Georgiadis AN, 2006) while 
others demonstrate that total cholesterol is reduced in active RA (Situnayake and 
(Kitas, 1997). However, further studies in RA have not identified any associations 
between disease activity and total cholesterol levels (Choi and Seeger, 2005, 
Dursunoglu D, 2005). There is also evidence that levels of triglycerides are influenced 
by RA disease activity. In a US longitudinal study it was observed that triglyceride 
levels fall in the years prior to diagnosis of RA (Elena Myasoedova and Patrick D Fitz- 
Gibbon, 2011). Others have suggested that serum triglyceride may reduce in 
inflammatory autoimmune disease states (lannello S, 2003). However, others have 
suggested that triglyceride levels rise in chronic inflammatory states (Sattar et al., 2003)
135
In addition it seems RA may be associated with abnormal glucose metabolism. Chronic 
systemic inflammation in RA has been linked to an increased prevalence of insulin 
resistance (IR) and type 2 Diabetes mellitus (T2DM) (Dessein et al.5 2002, Sidiropoulos 
et ah, 2008). However, there is little published data reporting prevalence of type II DM 
in the context of RA. As type 2 DM and metabolic syndrome are strongly associated 
with increased CV events this is an important area to study.
Many of the studies of CV risk associated with RA have been conducted in European or 
American populations of patients. There are to date very few published studies 
exploring whether CV risk may be increased in South Asian Indian RA patients 
compared to controls.
South Asian Indians have an increased risk of CVD events which tend to occur at a 
younger age than that observed in western populations (Enas et ah, 1992). This has been 
estimated to be 5-10 years earlier when compared to Caucasians (Yusuf S, 2004, Teoh, 
2007). Indians residing in India have a very high prevalence of traditional CV risk 
factors. Metabolic syndrome is seen in 25 - 30 % of adult South Asian Indians (Misra 
A, 2006).
If the prevalence of CV risk factors in the Indian population is very high it is possible 
that development of RA may increase this risk of CVD even further. Understanding this 
would be important as the Indian RA patient could be targeted for aggressive CV risk 
factor modification treatment. However the converse of this could be that in a
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population with a very high background prevalence of CV risk factors, development of 
RA may not further increase the prevalence of elevated CV risk factors.
Case control studies addressing this problem may provide information whether CV risk 
in Indians is further magnified in the presence of RA. This study was undertaken to 
compare CV risk factors in RA cases and local population controls free from 
inflammatory joint disease.
6.2 Aim
The primary aim of this study was to compare the prevalence of elevated traditional CV 
risk factors in patients with RA to that observed in age and gender matched controls, 
free from inflammatory arthritis.
6.3 Materials and methods
6.3.1 Patients and controls
This cross-sectional study included consecutive RA patients fulfilling ACR 1987 
criteria (Arnett et al., 1988). These RA cases comprised the RA cohort described in 
chapter 4 section 4.6 and details of inclusion and exclusion criteria and evaluation for 
these RA patients are described in the methods chapter.
Control patients who were free from inflammatory arthritis were identified and recruited 
to the study. The controls were frequency matched for age and gender to the cases. RA
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cases were encouraged to recommend friends and relatives to take part in the control 
group for this study. This allowed a degree of matching for both social class and urban 
dwelling of participants, as the index case of RA was likely to recommend friends or 
relatives from a similar background to take part in the study. One fourth of the control 
group participants were hospital staff and their relatives see chapter 4 section 4.8. The 
control patients were given separate appointments for assessments. All participants were 
South Asian Indians and no other ethnic groups were included in either the cases or 
control groups. Details of assessments are described in chapter 4 section 4.9.
6.3.2 Analysis
The distribution of CV risk factors in cases and controls were described. Simple 
hypothesis testing using the Chi squared test was used to explore whether elevated 
levels of CV risk factors were more prevalent in cases than controls.
Logistic regression was used to identify whether elevated risk factors were associated 
with being a case of RA.
6.3.3 Data collection
The RA cases and controls underwent a detailed questionnaire using a standard pro 
forma, physical examination, and laboratory analysis were performed as described in 
the methods chapter.
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6.3.4 Cardiovascular risk assessment
Traditional CV risk factors were recorded in cases and controls and the 10 year risk of 
developing a CVD was calculated using Framingham (Wilson, 1998) and IBS risk score 
(Durrington, 1997) for predicting 10 year risk of a CHD event.. Anthropometric 
measurements were taken. Details of the evaluations are described in methods chapter 4 
section 4.10.
6.4 Results
6.4.1 CVD risk factors in cases and controls
6.4.1.1 General descriptive data
Eight hundred consecutive RA patients fulfilling 1987 ACR criteria and 800 controls 
free from inflammatory arthritis were recruited. The mean age of RA patients was 46.5 
years, 668 (83.5%) were females and 132 (16.5%) were males. In the control group 
mean age was 47 years and 666 (83.3%) were females. Prevalence of females in the RA 
group was slightly higher than in the control group. This difference was not statistically 
significant. Vegetarianism was reported more frequently by participants in the control 
group i.e. 224 vs 213. General demographics are summarized in Table 6.1. The 
prevalence of reporting a family history of DM and CVD was similar in the two groups. 
A family history of hypertension was more frequently reported by the participants with 
RA than in the control group 29.5% vs 21.8%. Smoking was rarely reported by study 
participants. Only 12 RA patients (1.5%) and five controls (0.6%) recording a history of 
current or ever smoking.
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Table 6.1 Descriptive data of demographics and co morbidities and blood pressure
Parameters Description Cases n=800 Controls n=800
Demographics
Age in yrs med [IQR] 46.5 [38, 55] 47 [37, 55]
Female n (%) 668 (83.5) 666 (83.3)
Male n (%) 132 (16.5) 134 (16.7)
Vegetarian n (%) 213 (26.6) 224 (28.0)
Smoking n(%) 12 (1.5) 5 (0.6)
Family history
F. history CVD n(%) 101 (12.6) 97 (12.1)
F. history DM n(%) 252 (31.5) 242 (30.3)
F. history HTN n (%) 236 (29.5) 174 (21.8)
Co morbidities
Co morbid DM n(%) 138 (17.3) 57 (7.1)
Co morbid HTN n(%) 236 (29.5) 174 (21.7)
Co morbid CVD n (%) 5 (0.6) 0 0
Hypothyroid n(%) 82 (10.5) 29 (3.6)
Blood pressure
Systolic mmHg med [IQR] 130 [120, 140] 130 [12140]
Diastolic mmHg med [IQR] 80 [80, 90] 80 [80, 90]
Anthropometric measurements
Waist: Hip ratio med [IQR] 0.92 [0.86,0.98] 0.91 [0.87, 0.96]
High Waist : Hip 
ratio *
n(%) 218 (27.5) 183 (22.9)
BMI med [IQR] 26.1 [23.1,29.7] 26.4 [23.6, 29.4]
BMI >25 n(%) 481 (60.1) 514 (64.3)
Fasting Sugar and lipids
FBS med [IQR] 87 [76,102] 84 [77, 91]
T-Chol med [IQR] 175 [154,201] 168 [153.5,187]
HDL-Chol med [IQR] 48 [45,51] 47 [44,50]
LDL-Chol med [IQR] 99 [79.5,120.5] 98 [85,114]
TG med [IQR] 132.5 [98,184] 114 [90,146]
T-Chol: HDL ratio med [IQR] 3.7 [3.3,4.2] 3.6 [3.2,4]
F. history- Family history, CVD- Cardiovascular Disease, HTN- Hypertension, DM- Diabetes Mellitus, 
IQR- Inter quartile range, BMI- Body Mass Index, ,*Waist: Hip ratio classified as high if > 0.95 in 
Women & if, >1 in Men, T-Chol- total cholesterol, HDL-Chol- high density lipoprotein cholesterol, LDL- 
Chol- low density lipoprotein cholesterol, TG- triglyceride
6.4.2 Co morbidities in cases and controls
Co morbidities were more frequently reported by RA patients. Nearly 30% of the RA 
cases reported co-morbid hypertension compared to 174 (21.8%) of controls. Median 
systolic and diastolic blood pressure values were the same in cases and controls. Very 
few patients or controls had systolic BP below 120 mm Hg which is unusual in a
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younger aged predominantly female group. The BP data was not normally distributed 
and was skewed to the left in the RA cases. 219 RA patients displayed a systolic BP 
above 140 mm of Hg compared to 201 controls. Diastolic BP above 90 was observed in 
39.4% of the RA cohort compared to 34.9% of the controls (see Table 6.4).
Prevalence of co morbid diabetes was particularly high in the RA cases and was 
reported by (17.3%) of this group. Co morbid DM was fairly prevalent in the control 
group affecting 57 (7.1%) of control participants. RA patients exhibited a high 
prevalence of hypothyroidism. It was found to be three times higher in RA 10.5% vs 
3.6% in controls. In addition when the numbers of reported co morbidities were 
examined, 12.5% of the RA cases and 5.5% of controls reported 2 or more co 
morbidities.
6.4.2.1 Anthropometric measurements
The median waist hip ratio was similar in the two groups. However, when subjects were 
classified as having a high ratio (defined as > 0.95 in women & >1 in men), 27% of RA 
patients compared to 23% of controls had elevated waist hip ratios.
Body mass index was found to be similar in the two groups. It is to be noted that both 
RA cases and controls had a median BMI in the obese / overweight range (>25 kg/m2).
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6.4.2.2 Lipid ProHle and fasting blood glucose
Though the median values of blood sugar and lipids were within normal range in both 
cases and controls the median FBS, T-Chol, HDL-Chol, TG and T-Chol: HDL-Chol 
ratios were all slightly higher in RA cases.
6.4.2.3 Composite CHD Risk scores
CHD risk scores were calculated for all 800 patients and 800 controls. Median CV risk 
score as per JBS and Framingham were similar between cases and controls. Using 
Framingham the 10 year risk of a CHD event was 4%. The CHD risk scores calculated 
using JBS and based on systolic BP were slightly lower at 3.2% in cases and 2.9% in 
controls. The JBS CHD risk scores were divided into tertiles (<1.5%, 1.5-<5%, >5%) 
and slightly more controls had CHD scores in the lowest tertile (see Table 6.2).
Table 6.2 Calculated CHD risk scores in cases and controls
j Patients n = 800 | Controls n = 800
Calculated CHD risk
Based on
Framingham
10 yr CHD risk % med [IQR] 4 1,8 4 0, 7.5
*Based on
JBS
10 yr CHD risk % med [IQR] 
(systolic)
3.2 [0.9,6.6] 2.9 [0.6, 5.8]
Tertiles of 10 year CHD % risk (Systolic BP)
*Based on
JBS
<1.5% 257 (32.1) 298 (37.3)
1.5-<5% 266 (33.3) 248 (31.0)
>5% 277 (34.6) 254 (31.8)
Calculated 10 year % risk of Coronary Heart Disease (CHD) event using JBS (Joint British societies) 
CHD risk calculator
142
6.4.2.4 Metabolic Syndrome
NCEP ATP III (national cholesterol education programme adult treatment panel III) 
metabolic syndrome (MS) criteria were applied to all cases and controls see Table 6.3. 
Forty six percent cases met criteria for metabolic syndrome vs 33.4 % in the control 
group. Only 7.4% of RA cases and 8.1% of controls did not have any criteria for MS. 
Table 6.3 Meets criteria for ATPIII metabolic syndrome in cases and controls
Patients n = 800 Controls n = 800
n % n %
ATP III score 0 59 7.4 65 8.1
1 156 19.5 201 25.1
2 217 27.1 267 33.4
3 235 29.4 208 26.0
4 119 14.9 54 6.8
5 14 1.8 5 0.6
ATPIII Meets Criteria for MS 368 46.0 267 33.4
6.4.2.5 Elevated CVD risk factors in cases and controls
The CV risk factors were divided into categorical variables and associations between 
elevated risk factors and RA cases are presented in Table 6.4. These have demonstrated 
that a significant association between elevated CHD risk scores and RA exists. In 
addition co morbid DM was significantly elevated in RA cases (p <0.001). A trend for 
association was observed between elevated diastolic BP (>90 mm of Hg) and RA 
(p=0.06) but no associations were seen with elevated systolic BP defined as (>140 mm 
of Hg).
After categorization of BMI into two groups, the prevalence of overweight and obesity 
(BMI >25) was found to be higher in controls (64.3%) vs cases (60.1%) see Table 6.4.
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No significant differences were seen with elevated waist hip ratios between cases and 
controls.
Table 6.4 Prevalence of elevated CVD risk factors in RA cases and controls
CVD Risk factor RA Cases 
n=800
Controls
n=800
Chi2 p value
n % n %
Comorbid Type II DM (Prior 
diagnosis)
138 17.3 57 7.1 38.2 p<0.001
Smoking (Current smoker) 12 1.5 5 0.6 2.9 p=0.08
Family history CVD 101 12.6 97 12.1 0.09 p=0.76
Systolic BP >140 mmHg 219 27.4 201 25.1 1.05 p=0.36
Diastolic BP > 90 mmHg 315 39.4 279 34.9 3.47 p-0.06
High WaistiHip ratio 451 56.4 443 55.4 0.16 p=0.69
BMI>25 481 60.1 514 64.3 2.9 p=0.09
T-Chol >200mg/dl 203 25.4 84 10.5 1142 p<0.001
HDL- Choi <40mg/dl 47 5,9 31 3.9 3.5 p=0.06
T -ChokHDL- Choi ratio >4.5 106 13.3 44 5.5 28.3 pO.OOl
TG >150mg/dl 319 39.9 176 22.0 59 pO.OOl
FBS >100mg/dl 220 27.5 91 11.4 66 pO.OOl
FBS in DM range >126 mg/dl 57 7.1 3 0.4 50 pO.OOl
Framingham CHD risk >10% 
n (%)
212 26.5 174 21.8 pO.OOl
Framingham CHD risk >15% 
n (%)
90 11.3 60 7.5 pO.OOl
* JBS CHD >10% n (%) (systolic) 125 15.6 69 8.6 18 pO.OOl
* JBS CHD >15% n (%) (systolic) 101 12.6 61 7.6 11 pO.OOl
** JBS CHD >10% n (%) 
(diastolic)
59 7.4 18 2.3 22 pO.OOl
** JBS CHD >15% n (%) 
(diastolic)
45 5.6 13 1.6 18 pO.OOl
Waist:Hip ratio classified as high if > 0.95 in Women & if, >1 in Men), *CHD risk (systolic) elevated CHD risk score based on systolic DP 
**CHD risk (diastolic ) elevated CHD risk score based on diastolic BP
Differences in the lipid profiles of RA cases and controls were observed. A quarter of 
the RA patients had high total cholesterol and this proportion was significantly lower 
than in the control group (10.5%) (p<0.001). Though the numbers of cases with low 
HDL were slightly more prevalent in the RA group this difference did not reach 
statistical significance (p=0.06). High triglycerides in RA cohort were almost two times
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more prevalent than in controls 39.9 % vs 22% and Chi squared testing revealed a 
significant association between RA and elevated triglyceride levels (p<0.001). The 
ratio of total cholesterol and HDL cholesterol was found to be two and a half times 
higher in RA cases compared to controls 13.3% vs 5.5%, again reaching statistical 
significance (p<0.001).
The subjects were classified according to elevated blood glucose levels. Two hundred 
and twenty RA patients (27.5%) and 91 (11.4%) controls had fasting blood glucose 
above 100 mg/dl (p<0.001). A significant difference was also seen when fasting blood 
glucose in diabetic range of above 126 mg/dl was taken into consideration with 57 RA 
patients compared to 3 controls had a blood sugar in the diabetic range (p<0.001).
Though the median CHD risk scores were similar in the two groups, elevated levels of 
CHD risk (>10%) calculated using Framingham and JBS were significantly more 
prevalent in RA compared to controls. This was also true for high CHD risk (>15%).
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6.5 Univariate and age and gender adjusted logistic regression - exploring 
associations between RA and individual CVD risk factors age and gender 
adjusted logistic regression in cases and controls
Results of the univariate and age adjusted logistic regression are shown in Table 6.5 and 
Figure 6.1. Nearly all of the traditional CV risk factors were significantly associated 
with being an RA case. Increased prevalence of elevated BMI, elevated systolic BP and 
family history of CHD were not strongly associated. There was nearly a 3 fold increase 
in odds of Type 2 diabetes in cases of RA compared to controls. When the elevated 
fasting blood glucose values were compared, elevated fasting blood sugar (>100mg/dl) 
was strongly associated with RA. However, fasting blood sugar in diabetic range 
(>126mg/dl) was very strongly associated with RA (ORadj 20.6 (95% Cl 6.4, 66.2) in 
the age and gender adjusted analysis. Despite high prevalence of metabolic syndrome in 
the control population, metabolic syndrome remained strongly associated with RA (1.8 
(ORadj 1*45, 2.23)) in this case control study. A weak association between elevated 
waist hip ratios was observed, with RA patients having a 20% increased odds of 
increased waist to hip measurements compared to controls. However, increased BMI 
was not significantly different between cases and controls.
Whilst smoking was more common in cases of RA, the age and gender adjusted 
analysis did not reach statistical significance (OR 2.6 (95%CI 0.9, 7.5)).
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High diastolic BP (>90 mm of Hg) had a trend for association with being a case of RA 
and high systolic BP (>140 mm of Hg) did not show any association with RA. Rather 
interestingly when a high cut off of diastolic BP of more than 95 mm of Hg was used 
there was a strong association with being a case of RA (OR 3.41(95% Cl 2.21, 5.24)).
A strong association between high total cholesterol (>200 mg/dl) and RA was seen. A 
three fold increased odds of high cholesterol was seen in RA cases (OR 2.9 (95%CI 2.2, 
3.9)). The association between low HDL cholesterol and RA was significant but not as 
marked. However, the prevalence of elevated triglycerides in RA was increased by a 
factor of 2 (> 15 Omg/dl).
When the composite CHD risk scores were explored, RA was strongly associated with 
both elevated and high CHD risk scores when calculated with Framingham and IBS. 
However, the strongest associations were seen with high CHD risk calculated with IBS 
based on diastolic BP where RA patients had a 4 fold increase, in age and gender 
adjusted analyses see Table 6.5.
Figure 6.1 demonstrates pictorially the age and gender adjusted associations between 
individual CV risk factors, CHD risk scores and RA.
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Table 6.5 Results of univariate and age and gender adjusted logistic regression- 
exploring associations between RA and individual CVD risk factors
RA cases 
n = 800
Controls 
n = 800
Univariate adjusted age & 
gender
CVD Risk factor OR 95% Cl OR 95% Cl
Co morbid Type II DM 138 57 2.72 1.96, 3.76 2.85 2.05,
3.99
Co morbid Hypertension 236 174 1.5 1.20, 1.89 1.56 1.23,
1.99
Smoking 12 5 2.42 0.84, 6.90 2.58 0.88,
7.54
Family history CVD 425 438 0.94 0.76, 1.14 0.94 0.76,
1.13
Systolic BP >140 219 201 1.12 0.89, 1.40 1.13 0.89,
1.44
Diastolic BP > 90 315 279 1.21 0.99, 1.49 1.22 0.99,
1.51
Diastolic BP >=95 91 29 3.41 2.21,
5.24
3.46 2.25,
5.34
High Waist:Hip ratio* 218 183 1.26 1.01, 1.58 1.26 1.01,
1.59
BMI>25 481 514 0.84 0.69, 1.02 0.82 0.67,
1.02
T-Chol >200mg/dl 203 84 2.90 2.19, 3.82 2.96 2.23,
3.91
HDL-Chol <40mg/dl 47 31 1.54 0.97, 2.46 1.56 0.98,
2.48
TG >150mg/dl 319 176 2.35 1.89, 2.93 2.38 1.91,
2.97
FBS >100mg/dl 220 91 2.96 2.26, 3.86 3.07 2.34,
4.03
FBS in DM range >126 
mg/dl
57 3 20.4 6.35, 65.4 20.6
2
6.42,
66.19
Framingham CHD
risk>10%
212 174 1.30 1.03, 1.63 1.44 1.10,
1.92
Framingham CHD risk 
>15%
90 60 1.56 1.12, 2.20 1.72 1.18,
2.50
*10 year CHD risk >10% 
n (%) (systolic)
101 61 1.75 1.25, 2.44 1.96 1.36,
2.83
*10 year CHD risk >15% 
n (%) (systolic)
45 13 3.61 1.93, 6.74 4.01 2.10,
7.67
**10 year CHD risk >10% 
n (%) (diastolic)
125 69 1.96 1.44,2.68 2.34 1.65,
3.33
**10 year CHD risk >15% 
n (%) (diastolic)
59 18 3.46 2.02, 5.92 3.91 2.23,
6.84
Meets criteria for MS 368 267 1.70 1.4, 2.1 1.8 1.45,
2.23
High waist hip ratio =Waist hip ratio >1 in males and >0.95 in females
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6.6 Discussion
This study has demonstrated that RA patients have a much higher prevalence of 
elevated CY risk factors when compared to controls. This is particularly interesting 
given the high background prevalence of CV risk factors in the Indian control 
population. Therefore it seems that having RA is associated with a significant rise in 
traditional CV risk factors. This contributed to the higher 10 year CHD risk scores 
observed in RA patients.
Compared to controls, RA patients had fourfold increased odds of having elevated CHD 
risk. This finding is important as Indians exhibit increased risk of CVD events at a 
lower BMI when compared to Caucasians (Misra and Khurana, 2011).
In view of increased prevalence of CV risk factors there is an urgent need for mortality 
studies in South Asian Indian RA patients. When the individual CV risk factors were 
analysed separately it is clear that dyslipidaemia, co morbid DM and elevated fasting 
blood glucose as well as diastolic hypertension were the risk factors most strongly 
associated with RA. In addition an elevated waist to hip ratio was associated with RA 
but not increasing BMI. These risk factors all contribute to the metabolic syndrome. 
Metabolic syndrome was significantly associated with RA. This is interesting given the 
very high background prevalence of metabolic syndrome in this region of India. The 
prevalence of metabolic syndrome was high affecting 46% of cases and 33% of 
controls. This prevalence rate appears very high and other studies of metabolic 
syndrome in general population of South Asian Indians have reported similar high rates
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(Misra A, 2006, Misra and Vikram, 2008, Deepa et al., 2009). A recently reported study 
from urban and rural districts of West Bengal has reported rates of metabolic syndrome 
using the ATPHI definition as high as 58% in urban dwelling females (Das, 2011). The 
fact that having RA was associated with a further 80% increased risk of metabolic 
syndrome over and above that observed in age, gender and urban dwelling controls is of 
concern as this group of RA patients appear to be at greatly increased risk of 
developing type II diabetes as well as being at risk of future CV events.
Rheumatoid cachexia has been identified in patients with active disease. There is 
abnormal body composition in the form of loss of lean muscle mass and increase in fat 
mass. These changes may be seen with normal or low BMI. Chronic inflammation in 
active RA is associated with increase in circulating pro inflammatory cytokines 
especially tumour necrosis factor alpha which further increases joint inflammation and 
fatigue causing a reduction in physical activity. The reduced physical activity may be 
associated in loss of muscle mass. Rheumatoid cachexia is associated with increased 
visceral fat and increased waist circumference. Rheumatoid cachexia has been observed 
in 38% of patients with active disease (Engvall et al., 2008). In a review article a 
possible link of rheumatoid cachexia to increase in CY risk factors, metabolic syndrome 
and thereby increased risk of CVD has been discussed (Summers et al., 2010).
Dyslipidaemia, with a higher ratio of total cholesterol to HDL cholesterol, was also 
significantly associated with RA, further contributing to the elevated CHD risk score 
observed in RA cases compared to controls. In addition, the RA cases had a 
significantly higher prevalence of elevated triglyceride levels. Whilst dyslipidaemia has
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been described in association with RA the pattern of dyslipidaemia that has been 
observed in this case control study is interesting. Compared to healthy controls we 
would expect that the RA cohort would have a higher systemic inflammatory burden. 
Inflammation influences the lipid profile in different way. High levels of inflammation 
are associated with lowering of HDL cholesterol and active RA has been associated 
with both low total cholesterol and HDL cholesterol resulting in an unfavourable 
atherogenic index (White D et al 2006). However in this case control study RA was 
associated with a significantly higher prevalence of elevated total cholesterol when 
compared to controls and only modest reduction in HDL. Therefore whilst a strong 
association between RA and dyslipidaemia defined by the total cholesterol to HDL 
cholesterol ratio this was largely due to elevation in total cholesterol associated with 
RA. Possible reasons for this might include the effects of glucocorticosteroid treatment 
on the lipid profile in RA patients. However, suppression of inflammation by RA 
treatments is known to improve the lipid profile (Park YB et al 2002). QUEST RA 
study has demonstrated that 14% of RA patients had dyslipidaemia (Naranjo et al., 
2008). Literature on triglyceride is limited but there appears to be an inverse association 
between inflammatory auto immune disease and triglycerides (lannello S, 2003) which 
was not what was observed in this case control study. Possible explanations for this 
apparent paradoxical rise in triglycerides in RA patients is not clear. This might reflect 
the effects of RA disease on exercise capacity. We know that hypertriglycerideamia is 
associated with high fat dietary intake but apart from the slight increase in number of 
cases that reported vegetarian diets it was not possible to explore dietary differences in 
any detail between cases and controls. Other factors associated with increased
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triglyceride levels include hypothyroidism. The prevalence of hyothyroidism was much 
higher in RA cases and this could have contributed to the increased prevalence of raised 
triglycerides. However as most patients were on thyroxine treatment at the time of 
assessment it is unlikely that this would have increased triglyceride levels to such a 
degree.
Increased prevalence of elevated triglyceride levels could be related to obesity. Though 
BMI was similar in the two groups, RA patients had a higher prevalence of high waist: 
hip ratios. This suggests that RA may be associated with different body composition. 
Unfortunately measuring body composition was not a part of this study. However, high 
waist measurements but similar BMI do suggest accumulation of abdominal girth. This 
usually represents increased fat and may fit with the known association of loss of lean 
muscle associated with inflammation and RA. This is the picture observed in insulin 
resistance and this may be the reason for increased DM as part of inflammation 
associated metabolic syndrome.
It is estimated that India has approximately 32 million diabetics which is projected to 
increase to 70 million by year 2025 (King et ah, 1998). The prevalence of co morbid 
DM is alarmingly high in our RA population and this study gives an important message 
for assessing the CV risk factors in RA because according to a survey published in a 
leading national daily - The Hindu business line (21 Oct 2005) Hyderabad is emerging 
as the diabetic capital of India. As the study population belongs to this region, even 
normal controls may display an increased risk of diabetes. Not many studies have
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addressed the prevalence of diabetes in patients with rheumatoid arthritis. An 
association between systemic inflammation and diabetes (Pradhan AD, 2001) and 
impaired glucose handling in patients with RA has been reported (Svenson KL, 1988). 
A study in different races in Singapore has demonstrated that mortality due to type 2 
DM was higher in Asian Indians when compared to Chinese and Malay population (Ma 
et ah, 2003). The increased prevalence of type 2 diabetes in our population could be due 
to high prevalence of metabolic syndrome which is known to increase the prevalence of 
type 2 DM. As RA was active in the cases we also presume them to be less physically 
active. Possibility of clustering of autoimmune disease was considered but all the 
participants reporting diabetes had type 2 DM hence autoimmune clustering is not 
thought to be the reason.
Co morbid hypertension was higher in RA when compared to controls. Increased 
prevalence of HTN was observed earlier in RA (Panoulas et ah, 2007). However this 
study did not compare the prevalence of hypertension with normal control population. 
In our cohort elevated diastolic blood pressure was found to be associated with RA and 
a statistically significant association was seen with the 95 mm Hg cut off for diastolic 
hypertension. This is in accordance with a previous study which had demonstrated high 
prevalence of diastolic blood pressure in RA patients (McEntegart, 2001). However, the 
Nurses health study did not observe such an association (Solomon et ah, 2004). 
Participants in this study were older; also there is no information of disease duration, 
disease activity and drugs used for the control of RA all of which are known to have an 
impact on CV risk factors. The effect of gender on CV risk cannot be ruled out.
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Hypertension may be related to treatment and in this study more than 60% of patients 
were treated with NSAIDs. Thirty seven percent of them were on combination of 
steroids and NSAIDs. A well recognised side effect of NSAIDs is moderate elevation in 
BP (Armstrong and Malone, 2003). However, as much of this is due to renal effects and 
salt retention this usually influences systolic BP more than diastolic BP and therefore is 
unlikely to be responsible for the elevated diastolic BP seen in the RA cases in this 
study. Another explanation might be pain induced BP rise but rise of BP due to anxiety 
is usually in systolic blood pressure and we cannot explain the diastolic rise in blood 
pressure in our RA cohort. Another cause of hypertension could be renal impairment. 
Though this study did not include testing renal parameters but as a routine clinical 
practice all patients on treatment undergo regular renal and liver function testing once in 
three months.
The effects of drugs in causing hypertension cannot be ruled out. Patients in the RA 
cohort using glucocorticoids were on physiological dose (<7.5mg/day). Low dose 
corticosteroids have a week association with CV risk factors in a dose related manner 
(Adeline Ruyssen-Witranda, 2011). Low dose steroids may have a cardio protective 
effect by their anti inflammatory and anti proliferative effect on the vessel wall 
(Bartoloni et ah, 2011). Sixteen percent of RA patients in this study were on 
leflunomide which is known to elevate blood pressure. There are no reports regarding a 
selective diastolic rise in blood pressure seen with this drug. The exact reason for this 
diastolic hypertension is not clear. Further studies are needed addressing hypertension 
in RA.
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Hypothyroidism is associated with increased risk of CYD in the general population 
(Walsh JP5 2005). Co morbid hypothyroidism in this study was significantly higher in 
cases when compared to controls. Our finding is in accordance with published literature 
that prevalence of hypothyroidism in more in RA patients (H G Raterman, 2008). The 
increased prevalence of hypothyroidism in RA may be due to autoimmune clustering 
and may be referred to as “disease pyramid theory”. A study has demonstrated that RA 
may accelerate progression of subclinical hypothyroidism into clinical hypothyroidism 
(Chan et al.; 2001).
Recent literature states that presence of RA is an additional risk factor for CVD like DM 
(Peters et ah, 2009). Hence, this South Asian Indian RA population is at a further 
magnified risk of CVD in view of the prevalent co morbidities.
Prevalence of vegetarianism being more in females may be because Indian females 
follow religious and social customs more than the male population. There was no 
significant difference between cases and controls regarding the use of vegetarian diet. 
This is in accordance with recently published literature that there is no association 
between RA risk and the consumption of non vegetarian diet (Benito-Garcia et ah, 
2007). This is cross sectional data and diet may be modified after RA has developed.
Smoking was reported very infrequently in this study. This may reflect the fact that the 
populations consisted of a large proportion of female middle class participants and in 
this demographic smoking in females is considered a taboo in many Indian families.
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Most of the studies in RA addressing CV risk are conducted in European or American 
populations and report a much higher prevalence of smoking. The QUEST RA study 
conducted at 48 sites in 15 countries across Europe and USA including 4,363 patients 
reported current smoking in 26% male and 15% females (Naranjo et ah, 2008). 
However, despite the very low prevalence of current smoking in this study we still 
detected a higher prevalence of smokers in the RA cohort.
There appears to be an inverse relationship between RA and lipids. Active RA is 
associated with low total cholesterol and HDL cholesterol resulting in an unfavourable 
atherogenic index (White et al., 2006). Suppression of inflammation by RA treatments 
is known to improve lipid profile (Park et al., 2002). The QUEST RA study has 
demonstrated that 14% of RA patients had dyslipidaemia (Naranjo et al., 2008). 
Literature on triglyceride is limited but there appears to be an inverse association 
between disease activity and triglycerides.
Dyslipidaemia in South Asians Indians is about 20 - 30 % in various studies. Two 
studies from Andhra Pradesh have reported a prevalence of hypercholesterolemia of 
18.5% and 31% (Reddy KK et al 2002, Reddy NK et al 2002). Compared to Caucasians 
South Asian Indians tend to have high triglyceride and low HDL (Anand et al., 2000). 
When compared to prevalent dyslipidaemia in the background normal population, RA 
patients in this study have demonstrated more than three times increased odds of having 
elevated total cholesterol, more than two times increased odds of having elevated 
triglycerides and one and a half times the odd of having low HDL cholesterol. The
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dyslipidaemia observed could be due to active RA. Compared to controls the RA cohort 
had fourfold increased odds of having elevated CHD risk score.
Patients in the RA cohort had active disease and were on treatment with NSAIDs, 
steroids and DMARDs. Our cohort represents the setting of a specialist tertiary care 
centre where patients with active disease consult rheumatologist for disease control. Our 
cohort does not represent patients who have very mild disease which is controlled by 
non specialists or by other systems of medicine such as Ayurveda, Homeopathy, Unani, 
Naturopathy and Herbal medicines, which are used by patients in developing countries.
This is the largest case control study in South Asian Indian patients. We have generated 
a database which will be helpful in comparing the RA cases and controls and plan to 
look at different aspects in future studies.
The weakness of our study is that we were unable to accurately assess fasting lipid 
samples although blood glucose was measured after an overnight fast. We were also 
unable to record the use of over the counter medicines especially NSAIDs. However, 
when the control population was included care was taken in asking and examining for 
the presence of joint pains. Hence we presume that the patients were not on high dose 
NSAIDs.
India is in the middle of a CAD epidemic. Asian Indians have demonstrated CAD rates 
which are 50 to 400 times higher than individuals of other ethnic origins and at least
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four times that of Caucasians (Enas, 2001). Asian Indians are at an increased risk of 
developing CAD and diabetes which occurs at least 10 years earlier when compared to 
other populations. The world health organization has predicted CVD to be a major 
cause of morbidity and mortality in the world and South East Asians are expected to be 
the most effected among all ethnic populations (Lancet Series on Health in Southeast 
Asia,25 Jan2011). WHOJanuary2011
f'http://www.who.int/nmh/publications/9789241597418/en/index.html).
Most of the published studies are in Caucasian RA patients. There may be a genetic 
influence on the CV risk factors as South Asian Indians are a genetically challenged 
ethnic group. Compared to RA studies performed in US and European populations this 
South Asian Indian study has demonstrated that RA seems to be strongly associated 
with an increased prevalence of traditional CVD risk factors and appears to be 
particularly associated with type 2 DM . We propose screening and treating modifiable 
CVD risk factors in RA patients is even more important in South Asian Indian patients.
It appears that compared to the background population they have a 2-3 fold increase in 
prevalence of elevated CHD risk. As the prevalence of CVD is high in the background 
population this increased CV risk associated with RA is likely to lead to increased CV 
events in these patients. The median age of this cohort was relatively young and 
therefore these patients may benefit greatly from risk factor reduction in an attempt to 
reduce CVD events in the future. There is an urgent need for preventive strategies in 
South Asian Indian RA patients in the form of physician awareness, patient education, 
lifestyle modification, aggressive control of RA and institution of reduction of 
dyslipidaemia in the form of statins. Co morbid hypertension and diabetes should be
159
addressed and the treating rheumatologist should routinely check patient’s blood 
pressure at every clinic visit and blood glucose should be monitored frequently. The 
Cochrane review of preventive strategies has found that preventive strategies are helpful 
in persons with pre existing disease such as hypertension and diabetes in the form of 
better adherence to therapy (Ebrahim et ah, 2011). Since our RA cases had a high 
prevalence of co morbid conditions there is a possibility of preventive strategies to be 
effective. Evaluation of lipid profile and CV risk assessment should become a routine 
practice in all patients annually. In patients with low risk the evaluation can be done less 
frequently, once in two to three years (Peters et ah, 2010). As there are no 
recommendations for South Asian Indian RA patients the recommendations set by the 
EULAR standing committee for clinical affairs may be followed until local 
recommendations are available for Indian patients.
Our study highlights the importance of an aggressive approach towards identifying and 
treating CV risk in RA patients of South Asian Indian origin who already have an 
increased risk of CVD
Whilst this cross sectional study has identified that RA is associated with increased CV 
risk in a South Asian Indian population, little is known about CVD event rates in Indian 
RA cohorts. It will be interesting to follow these patients up to explore whether rates of 
events are increased compared to the background rate. However, interventions to 
reduce CV risk factors that were identified as part of this study may influence future CV 
event rates.
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Chapter 7 - Association of traditional cardiovascular risk factors with 
rheumatoid disease activity.
The traditional cardiovascular disease risk factors in patients with rheumatoid arthritis 
are studied in relation to disease activity and associations between CV risk and level of 
disease activity are explored,
7.1 Introduction
The cause for increased CVD associated with RA is unknown, but is likely to be due to 
a number of factors including raised traditional cardiovascular (CV) risk factors, 
inflammation, effects of medication, and reduced capacity to exercise (Boyer et ah, 
2011, Wallberg-Jonsson et ah, 1999, Atzeni, 2010). We have already demonstrated that 
traditional cardiovascular risk factors are elevated in RA patients compared to controls 
(see results chapter 5).
When considering CV risk in RA, some authors advocate using traditional CV risk 
factor scores such as Framingham (Wilson, 1998), SCORE (Conroy RM, 2003) or JBS 
(Durrington, 1997), but then applying a RA associated weighting to adjust the final CV 
risk value by applying a 1.5 multiplication factor which should be used when disease 
duration is more than 10 years, RF or anti CCP is positive, presence of extra-articular 
manifestations. The patient should meet two out of the three criteria (Peters et ah, 
2010). QRISK is the new CV risk calculator (Julia Hippisley-Cox, 2007). However, as 
levels of CV risk factors may be modified by the active disease process in RA this
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approach might be too simplistic and may lead to inaccurate estimation of CV risk in 
RA.
CV risk factors may be modified in states of high inflammation. There is substantial 
evidence for an association between inflammation and dyslipidaemia. Several studies 
have suggested that high inflammatory states in RA are associated with lowering of 
total cholesterol (Situnake (Kitas, 1997, Munro R, 1997, Park et ah, 2002, Nurmohamed 
and Dijkmans, 2009, Boyer et ah, 2011) , In a more detailed review Sattar describes 
how the lipid profile is typically influenced in association with inflammation (Sattar et 
al., 2003). The characteristic changes of inflammation include lowering of total 
cholesterol (T Choi), high density lipoprotein (HDL) and triglyceride (TG) levels. In 
particular levels of HDL cholesterol are disproportionately lowered. So whilst the total 
cholesterol is reduced in association with inflammation, the marked lowering of HDL in 
relation to total cholesterol leads to an unfavourable atherogenic index.
However, in the general population, chronic low grade inflammation has also been 
identified as a predictor of future CVD events. Ridker et al found that in apparently 
healthy men the value of CRP can predict myocardial infarction and stroke (Ridker et 
al., 1997). Systemic inflammation is said to play a role in all the stages, including 
initiation, formation and rupture of atherosclerotic plaques by various mechanisms 
(Pasceri, 1999). Markers of inflammation are strongly associated with RA in the form 
of sub clinical atherosclerosis which can be determined by arterial wall thickening, 
arterial wall stiffness and reduced flow mediated dilatation (del Rincon et al., 2005,
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Nagata-Sakurai M, 2003) A study by del Rincon et al looking at the contribution of CV 
risk factors and RA disease to the development of atherosclerosis observed that 
atherosclerosis correlated with RA disease duration. CV risk factors and RA disease 
activity contribute to the development of atherosclerosis and may modify each other 
(del Rincon et ah, 2005). Another study by the same group confirmed the association of 
systemic inflammation and CV risk factors with atherosclerosis (del Rincon I, 2007). 
There is also a hypothesis that inflammation may make atherosclerotic plaque unstable 
and more prone to rupture resulting in myocardial infarction.
In addition, high levels of disease activity in RA may influence the CV system through 
other mechanisms. When RA is active, physical activity is likely to decline. Reduced 
cardiovascular fitness may therefore be a contributing factor to the increased CV events 
seen in RA cohorts as well as contributing to weight gain.
Another important factor to consider is the effect of concomitant medications on the 
cardiovascular system. When RA disease is active, patients may take more medicines 
that alter their CV risk factors and influence the vasculature. Use of glucocorticoids 
may exacerbate fluid retention, hypertension and impair glucose tolerance, causing DM. 
(Andrews and Walker, 1999, Whitworth et al., 2000). However, use of these drugs to 
suppress disease activity in RA, may increase activity levels as well as reducing 
systemic inflammation. With regard to the cardiovascular system the dose of 
glucocorticoids may be important. In a study by Toms et al, in RA patients, low 
(<7.5mg/day) and medium dose (>7.5 mg/day) prednisolone use was not associated
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with metabolic syndrome, hypertension or lipid abnormalities. The authors concluded 
that this could be due to beneficial effects of steroids in suppressing inflammation 
(Toms et ah, 2008). Therefore, whilst it is likely that glucocorticoids influence CV risk 
factors their effective suppression of disease activity in RA may lead to a neutral effect 
on CVD events in RA.
Use of NSAIDs may also influence CV risk factors by causing hypertension and fluid 
retention. These drugs tend to be used more during active disease, for additional 
symptom relief. In addition, some NSAIDs may have a prothrombotic effect and there 
is some evidence that they may exacerbate heart failure (Gys'ele S. Bleumink, 2003). 
Observational studies have demonstrated that both selective COX2 inhibitors as well as 
non COX2 selective NSAID use is associated with increased prevalence of CV events 
in the general population (Hippisley-Cox J, 2005, Chan, 2006).
In RA, CV events may be increased as a result of the effect of inflammation on CV risk 
factors, vascular endothelium or a mixture of both. Therefore it is important to 
understand the effect of high disease activity in RA on CV risk factors.
South Asian Indians have a high prevalence of traditional CV risk factors (Misra and 
Vikram, 2004). We have demonstrated in the case control study reported in results 
chapter 6 section 6.4 that RA patients have marked elevation of CVD risk factors 
associated with metabolic syndrome compared to controls from the same population. 
Studies have demonstrated that the South Asian Indian population has an increased
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incidence of metabolic syndrome, dyslipidaemia and premature atherosclerosis. The 
WHO (2002) has reported that by 2020 CYD will be a major cause of death and 
disability in south Asians and nearly half of the deaths will be in young and middle aged 
South Asian population (WHO report 2002). The high prevalence of metabolic 
syndrome in Asian Indians with RA is of particular interest as metabolic syndrome is 
associated with a high inflammatory burden. It is possible that chronic inflammation 
may promote central obesity and metabolic syndrome further contributing to 
acceleration of CV risk in RA patients with high disease activity.
Therefore it is clear that the associations between inflammation, CV risk and the 
development of CVD events is complicated.
7.2 Aim
This cross sectional study was conducted to explore whether elevated disease activity is 
associated with elevated CV risk factors in a South Asian Indian population of RA 
patients.
The primary aim was to explore whether the 10 year risk of CVD by Framingham risk 
score and Joint British Societies risk score of CVD was associated with high disease 
activity, measured using a DAS 28 score.
The secondary aim was to explore which individual CVD risk factors are associated 
with elevated disease activity.
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7.3 Materials and methods
The eight hundred consecutive adult RA patients fulfilling 1987 ACR criteria (Arnett et 
ah, 1988) and willing to participate in this study were recruited as described in Chapter 
4 section 4.7 and used in this analysis.
Joint evaluation was performed by URKR or FF. Disease activity score(DAS28)was 
calculated using a 28 tender joint count, a 28 swollen joint count, pain visual analogue 
scale and ESR (Prevoo et ah, 1995). The EULAR has set up guidelines for categorising 
disease activity in RA as low, moderate or high, based on DAS28 score (Alfons and 
Michiel online DAS calculator). The cut offs for these categories are shown in Table 7. 
1. For this study, the patients were classified into two groups depending on their DAS 
28, Patients with a DAS 28 of less than or equal to 5.1 formed the moderate/ low 
disease activity group and patients with a DAS 28 more than 5.1 were classified as 
being in the high disease activity group.
Table 7.1 EULAR response criteria (J. Fransen, 2005)
Low DAS Moderate DAS High DAS
<3.2 3.2-<5.1 >5.1
CV risk prediction scores to predict ten year risk of CHD events were calculated using 
the 10 year Framingham coronary heart disease risk score and Joint British Societies 
(JBS) CFID risk assessor as described in chapter 4 section 4.16. Patients were 
categorised as having elevated CHD risk if their 10 year Framingham CHD risk score or
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JBS score was greater than 10%, and high risk if the Framingham or JBS risk score was 
greater or equal to 15%.
The ATPIII criteria of metabolic syndrome were applied to all patients and the 
individuals meeting the criteria were identified. For criteria of metabolic syndrome see 
methods chapter 4 section 4.17.
Elevated T-Chol was defined as T-Chol >200 mg/dl, Low HDL-Chol was defined as 
FIDL < 40 mg/dl, high TG was defined as TG >150 mg/dl, high LDL-Chol was defined 
as LDL >160 mg/dl (III, 2002). High BMI was classified as a BMI >25 which 
corresponds to overweight as per WHO guidelines (WHO, 1995).
7.4 Analysis
The data was analysed using simple descriptive statistics. Categorical variables were 
described as number (n) and percentage (%). Continuous data was described as median 
and inter quartile range [IQR]. The composite 10 year risk of a CHD event was 
calculated by Framingham and JBS risk scores was treated as continuous and 
categorical variables.
The associations between high DAS 28 and CV risk factors were studied with univariate 
and age and gender adjusted logistic regression.
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7.5 Results
The data from the cohort of 800 consecutive RA patients was examined. Their 
characteristics are presented in Table 5.2 and 5.4 in chapter 5- Prevalence of traditional 
CV risk factors in RA,
Figure 7.1 shows the distribution of DAS scores within the two groups. DAS 28 scores 
for this cohort were high, with 59% having a DAS 28 in excess of 5.1. These were 
classified as having high disease activity (high DAS).
There were 322 patients in the low/moderate disease activity group vs 478 in the high 
DAS group. The stratified baseline characteristics are presented in Table 7.2. The 
median age of individuals in the high DAS group was 47 years and 46 years in the 
low/moderate DAS group. The high DAS group had more females, they were older and 
there were fewer vegetarians. There were more smokers in the high DAS group 
compared to the low/moderate DAS group (9 vs 3). Co morbid diabetes, hypertension 
and hypothyroidism were also more frequently observed in the high DAS group. 
Laboratory parameters such as FBS, T-Chol, HDL-Chol and LDL cholesterol (LDL- 
Chol) were similar in the two groups. However, the low/ moderate DAS group had 
marginally higher TG levels compared to the high DAS group (142 vs 129).
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Figure 7.1 Bar chart indicating range of DAS 28 scores
DAS28 frequency plot
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The median CHD risk scores were low in both DAS stratified groups but were 
marginally higher in those with higher DAS. The prevalence of metabolic syndrome 
(MS) was high in both DAS groups. This was observed in 47% of the low/moderate 
DAS group and 45 % of the High DAS group.
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Table 7.2 Exploring associations between disease activity and cardiovascular risk 
factors.
Parameter DAS28 <=5.1 
n= 322
DAS28>5.1 
n= 478
Gender, female, n (%) n(%) 263 (81.7) 405 (84.7)
Age in yrs, med [IQR] med [IQR] 46[38,55] 47 [39,55]
RA duration med [IQR] med [IQR] 4 [2,10] 4 [1,9]
Vegetarian n (%) n (%) 91 (28.3) 122 (25.5)
RF positive n (%) n(%) 242 (75.2) 387 (80.1)
Smoking n (%) n(%) 3 (0.9) 9(1.9)
No FH CVD n (%) n (%) 160 (49.7) 265 (55.4)
Co morbid diabetes n(%) 52(16.5) 86 (18.0)
Co morbid hypertension n (%) 93 (28.8) 143 (29.9)
Co morbid CVD n(%) 48 (14.9) 49 (10.3)
Co morbid hypothyroid n(%) 30 (9.3) 52 (10.9)
BP Systolic med [IQR] 130 [120,140] 130[120,140]
BP Diastolic med [IQR] 80 [80,90] 80 [80,90]
Waist cm med [IQR] 94 [86,101] 93 [85,100]
Hip cm med [IQR] 102 [96,109] 100 [93,108]
Waist/Hip ratio med [IQR] 0.92 [0.86,0.97] 0.92 [0.86,0.98]
BMI mg/dL med [IQR] 26.3 [23.4,29.9] 25.6 [23.0,29.6]
FBS mg/dL med [IQR] 84 [76,102] 88 [78,102]
T-Chol mg/dL med [IQR] 3.7 [3.3,4.2] 3.7 [3.3,4.21
HDL-Chol mg/dL med [IQR] 48 [45,51] 48 [44,51]
LDL-Chol mg/dL med [IQR] 98 [78,120] 99 [81,121]
TG mg/dL med [IQR] 142 [103,187] 129 [95,182]
T-Chol / PIDL-Chol 
ratio
med [IQR] 3.7 [3.3,4.2] 3.7 [3.3,4.2]
CHD risk scores
Framingham 10 yr risk 
%
med [IQR] 4 [0,8] 4 [2,10]
JBS CHD 10 yr risk % 
(systolic)
med [IQR] 3.1 [0.7,6.6] 3.4 [1.1,6.6]
JBS CHD 10 yr risk % 
(diastolic)
med [IQR] 3.2 [0.6,7.2] 3.8 [1.1, 7.3]
Meets criteria for MS n (%) 151 (46.9) 217 (45.4)
7.5.1 RA disease activity
RA disease duration was similar in the two groups Table 7.3. The high disease activity 
group had more rheumatoid factor positive patients (80.1% vs 75,2%). As is expected 
the high DAS group had higher disease activity parameters including 28 joint counts, 
global VAS and ESR. The median DAS in low/moderate DAS group was 4.3 vs 6.6 in
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high DAS group. Only 45 patients in the low/moderate DAS group were in low disease 
activity (<3.2) Figure 7.1.
Table 7.3 RA disease variables stratified by disease activity
Parameter Description Low/moderate disease activity High disease activity
DAS 28<5.1 DAS 28 >5.1
RA duration
(yrs)
med [IQR] 04 [2,10] 04 [T9]
RF positive 11 (%) 242 (75) 387 (80.1)
SJC med [IQR] 02 [0,3] 07 [4,14]
TJC med [IQR] 04 [0,3] 14 [9,22]
Global VAS med [IQR] 40 [25,50] 83 [60,100]
ESR mni/hr med [IQR] 41 [35,55] 75 [59,100]
DAS 28 med [IQR] 4.3 [3.6,4.7] 6.6 [5.8,7.5]
7.5.2 Medication used to treat inflammation
Steroid usage in the high DAS group was more than two times that of the low/moderate 
DAS group, with 54% reporting use compared to 23%. In the high DAS group 94.4% 
were current NSAID users. NSAID use was much lower in the low/moderate DAS 
group where only 31% reported current use. The biologic response modifier etanercept 
was only used by 2.5% of the low/moderate DAS group vs 5.2% in the high DAS 
group. The usage of NSAIDS and steroids together was three and a half times higher in 
the high DAS group. Methotrexate use was high with over 90% using methotrexate in 
both DAS groups. Both DAS groups had much lower use of other non biologic 
DMARDS like sulphasalazine, hydroxychloroquine and leflunomide.
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Table 7.4 Medications used by patients in the two groups
Medication Low/moderate DAS group 
DAS28 <5.1
High DAS group 
DAS28 >5.1
Steroid use n (%) 73 22.7 261 54.6
Methotrexate n (%) 292 90.7 441 92.3
Sulphasalazine n (%) 28 8.7 31 6.5
Leflunomide n (%) 59 18.3 71 14.9
Hydroxychloroquine n (%) 71 22.1 77 16.1
Etanercept n (%) 8 2.5 25 5.2
NSALDs n (%) 100 31.1 451 94.4
Steroids & NSAIDs n (%) 45 14.0 257 53.8
7.5.3 Association between DAS 28 and CV risk factors
The associations between CV risk and high disease activity are presented in Table 7.5. 
No statistically significant associations were observed between high disease activity and 
the elevated or high composite CHD risk scores (Framingham and JBS). High 
Framingham CHD risk score and high DAS had a trend for an inverse association (OR 
adj 0.76 (95%CI 0.46, 1.23)), but this did not reach statistical significance. There 
appeared to be a trend for a lower prevalence for metabolic syndrome in patients with 
high DAS 28 (OR adj 0.86 (95% Cl 0.69, 1.17)), but again this did not reach statistical 
significance.
When the individual CV risk factors were analysed, the only risk factors observed to 
have significant association with disease activity was Triglyceride (TG). However, this 
was an inverse association, with high DAS being associated with lower TG levels. This 
association remained significant after adjusting for age and gender (OR adj 0.70 
(95%CI 0.52, 0.94)). No significant associations were observed between disease activity 
and other lipid components (figure7.2).
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Table 7.5 Associations between DAS 28 and CVD risk factors
Univariate adjusted age & gender
CVD Risk factor DAS 28 
<5.1 n=322
HighDAS28
>5.1n=478
OR 95% Cl OR 95% Cl
n(%) I n(%)
Co morbid DM 52(16.2) 86(18.0) 1.34 0.78,1.66 1.13 0.76,1.67
Co morbid HTN 93 (28.9) 143(29.9) 1.05 0.77,1.43 1.02 0.73,1.42
Smoking 3 (0.9) 9(1.9) 2.00 0.55, 7.60 2.61 0.67,10.1
FH CVD 160(49.7) 265(55.4) 1.26 0.95,1.67 1.25 0.94,1.67
Systolic BP >140 93 (28.9) 12(26.4) 0.88 0.64,1.21 0.85 0.60,1.18
Diastolic BP 
>90
119(37.0) 196(41.0) 0.98 0.63,1.52 0.97 0.62,1.52
High Waist:Hip 
ratio
81(25.12) 137(28.7) 1.20 0.87, 1.64 1.17 0.85,1.62
BMI>25 (%) 200(62.1) 280(58.8) 0.87 0.65, 1.16 0.82 0.61,1.11
T Choi >200mg/dl 86(26.7) 117(24.5) 0.89 0.64, 1.22 0.86 0.62,1.20
HDL Choi 
<40mg/dl
13(4.0) 34(7.1) 1.82 0.95,3.51 1.87 0.97,3.62
TG >150mg/dl 143(44.4) 176(36.8) 0.72 0.55, 0.97 0.70 0.52,0.94
LDL chol > 160 
mg/dl
16(5.0) 24(5.0) 1.01 0.53, 1.93 1.00 0.52.1.92
High T ChokHDL 
ratio
3(0.9 5(1.1) 1.12 0.26, 4.74 1.13 0.27, 4.77
FBS>100mg/dl 85(26.4) 135(28.2) 1.10 0.80, 1.51 1.09 0.78,1.51
FBS in DM range 
>126 mg/dl
20(6.2) 37(7.7) 1.26 0.72, 2.23 1.26 0.72, 2.23
Framingham risk 
>=10%
84(26.1) 128(26.8) 1.03 0.75, 1.42 1.00 0.67, 1.48
Framingham risk 
>=15%
41(12.7) 49(10.3) 0.78 0.50,1.22 0.76 0.46, 1.23
JBS risk >10% 
(systolic BP)
38(11.8) 63(13.2) 1.13 0.74, 1.74 1.15 0.71, 1.86
JBS CHD >10% 
(diastolic BP)
50(15.5) 75(15.7) 1.01 0.69, 1.49 0.99 0.63,1.56
JBS CHD >15% 
(systolic BP)
18(5.6) 27(5.7) 1.01 0.55, 1.87 1.02 0.53, 1.96
JBS CHD >15% 
(diastolic BP)
25
(7.8)
34
(7.1)
0.91 0.53, 1.56 0.88 0.49, 1.56
Meets criteria for 
MS
151(46.9) 217(45.4) 0.94 0.71, 1.25 0.86 0.64, 1.17
There appeared to be an inverse association between blood pressure (especially systolic 
BP) and high disease activity, though this difference was not statistically significant. 
Low/moderate DAS patients displayed a tendency for having an elevated BMI in the 
overweight and obese category (BMI> 25).
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Figure 7.2 CVD risk factor association with DAS score >5.1 adjusted for age
and gender.
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7.6 Discussion
1 his cross-sectional study has not observed any association between the composite CV 
risk scores and high DAS in this cohort of patients with RA. However, when the 
traditional CV risk factors were analysed separately, a significant association between 
high disease activity and low TG levels was observed. The other lipid measurements 
were not significantly associated with disease activity though there was a trend for 
lower HDL in the high disease activity group. Other risk factors were similar across the 
two DAS28 groups.
The finding that the composite CV risk score, using both Framingham and JBS were 
similar in the two groups was surprising, as our prior hypothesis was that CV risk would 
be reduced in higher inflammation and high disease activity states as inflammation is 
associated with reduction in total cholesterol and HDL cholesterol (Sattar et ah, 2003).
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In this study we did not observe any association between HDL or Total cholesterol with 
high DAS. However, this lack of association might reflect the moderately high disease 
activity in the low/moderate DAS comparator group. The median DAS28 in the 
comparator group was 4.3. Only 14% were in low disease activity, and of these only 5 
patients were in DAS28 remission. Therefore, it may be that CV risk modification in 
association with disease activity actually occurs at moderate levels of disease activity. A 
study in stable coronary artery disease (CAD) patients has demonstrated that very low 
level inflammation was associated with dyslipidaemia (Marz W and Bracker, 2004). In 
the CAD study, the median CRP, measured using high sensitivity assays, was reported 
as being 3mg/L with an interquartile range between 2 and 8 mg/L. This represents a 
very low level of inflammation and is very different to that observed in the RA cohort 
where the lowest ESR was above 30mm/Hr. Unfortunately, the number of RA patients 
with low DAS28 scores was too small to perform subgroup analyses to test whether low 
DAS28 was associated with CV risk or dyslipidaemia.
The only significant association observed in this study was between high triglyceride 
and lower levels of disease activity. As the composite CV risk score is not calculated 
using triglycerides it is not surprising that the CHD risk scores were observed to be so 
similar in the two DAS groups.
The finding regarding triglycerides and disease activity is interesting as it is 
counterintuitive. In the presence of active inflammation there is an increase in
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circulating pro inflammatory cytokines especially TNF alpha which increases hepatic 
lipogenesis causing hypertriglyceridaemia (Feingold et a!., 1989).
We would therefore have expected triglycerides to be higher in inflammation and this 
has been described in studies of patients without RA but with known CAD (Marz W 
and Bracker, 2004) . The reason for increased triglyceride levels in the low/ moderate 
disease activity group is not known. It is reported that glucocorticosteroid use increases 
triglycerides. However, the high DAS group reported more prednisolone use than the 
low/moderate DAS group so it is unlikely that the difference in triglyceride levels was 
due to different prednisolone use in this study. The effect of RA disease activity on 
triglycerides needs to be studied further.
One potential explanation for this anomalous result may be the fact that participants for 
this study were not fully fasted for accurate assessment of triglyceride levels.
Current recommendations suggest a 9-12 hour fast for fasted lipid assessment. 
http://www.nhlbi,nih.gov/guidelines/cholesterol/atglance.pdf. It was not possible for 
many patients to adhere to this in this study and we were unable to request further fasted 
samples because of time and financial constraints. Therefore the disease activity 
associated difference in triglyceride levels may simply reflect reduced appetite observed 
in patients with very active RA. The raised TG levels further emphasize the importance 
of lifestyle modification in Indians who are more prone to increased CV risk. The HDL 
and total cholesterol levels do not require a fasted sample and these values were not 
seen to differ with disease activity. This was unexpected, as many studies have reported
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inflammation and disease activity associated dyslipidaemia. A study by Hadda et al 
(Hadda V., 2007) in 90 RA patients with active disease (mean DAS28 was 4.9) and 
mean disease duration of 5.5 years, observed that 38.5% of participants had 
dyslipidaemia. At baseline low HDL was observed in 34.3%, 4.2% had low total 
cholesterol and high triglycerides were seen in 4.2%. This study excluded patients with 
diabetes. The same patients had their lipid profile measured after starting traditional 
DMARD therapies (methotrexate or sulphasalazine) steroids and NSAIDs. When the 
patients were evaluated after 8-12 weeks it was observed that there was a small but 
statistically significant improvement in HDL cholesterol (p<0.008). They observed only 
modest improvement in DAS 28 score with the mean score after treatment being 4.4. It 
is interesting to note that in my study, the difference in DAS28 scores between the two 
DAS groups was of a similar magnitude to the improvement in DAS scores observed in 
Hadda’s study, but I did not observe any significant association between DAS and 
HDL-Chol. Another small study from Jaipur (n=25) reported lower lipid levels and 
negative correlation of lipids with disease activity (Ghosh et al., 2009). However in my 
study the number of RA patients was much larger, but the difference in disease activity 
was modest between the two DAS groups and very few of our comparator group were 
in a low disease activity state.
One of the strengths of my study is the large number of patients studied. This allowed 
me to explore associations between DAS group and the whole CV risk profile as well as 
look at the CHD risk assessments. To my knowledge this is the largest number of RA 
patients in India who had their CV risk assessment done.
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The RA cohort was quite heterogeneous in that we studied patients with wide variation 
in disease duration (Bjornadal L, 2002 ). As the risk of CHD events rise appears to rise 
with increasing RA disease duration even after adjustment for age disease duration. We 
did not explore whether increased duration of RA influenced CV risk. If this was the 
case in my cohort we could have adjusted the associations between disease activity and 
CV risk factors for disease duration at time of assessment.
Another weakness of my study was the examination of a large number of CV risk 
factors with DAS group. This multiple hypothesis testing approach may have led to a 
type 1 error, where significance is falsely assigned to an association due to a chance 
event. The only significant association that was detected was that between elevated 
triglycerides and lower DAS. Whilst it is possible that this was a chance finding the 
strength of association was strong and the level of significance for this association was 
high (p <0.01). This association should be tested in other Asian Indian RA cohorts to 
explore whether a true association exists between DAS and triglycerides.
Another weakness is that whilst I set out to explore whether CV risk was influenced by 
high disease activity the comparator lower disease activity group had a median DAS of 
4.3 and only 45 patients had low DAS (<3.2) as per EULAR guidelines. As there were 
so few patients in low disease activity it is possible that comparing CV risk in moderate 
disease activity with high disease activity would make it more difficult to detect any
178
difference in levels of CV risk. It would be interesting to study patients with active 
disease and compare them with patients in remission or low disease activity.
Other studies have commented that inflammation, even at low levels, influences lipid 
profiles (Sattar et al., 2003). However, if as in my group, all patients studied had 
moderate or high disease activity it is likely that the inflammatory burden would be 
great enough, even in the lower DAS group, to influences lipid profiles. In a review 
article Sattar et al (Sattar et al., 2003) described the lipid pattern associated with RA as 
having low TC, HDL C and high TG. There was an inverse association between 
increasing inflammatory markers such as ESR and CRP with HDL cholesterol. I have 
not observed this pattern of lipids associated with disease activity in my cross-sectional 
study. However, others studying Indian RA patients have demonstrated that reduction 
in inflammation after treatment initiation is associated with a rise in HDL-Chol 
concentration (Hadda V., 2007, Ghosh et al., 2009). Whilst this is possible confounded 
by DMARD treatment effects it does highlight the importance of optimising control of 
disease activity in RA. It could be that with better suppression of disease activity that 
CV risk modification will improve, leading to improved CV outcomes for the RA 
patient.
This work has highlighted a need for new studies, comparing low, moderate and high 
DAS groups. To my knowledge the high triglycerides association with low/moderate 
DAS is a novel finding, which has not been documented in literature. Further studies 
with fasting lipids are needed to address this finding. It would be worthwhile to study 
triglyceride levels in prospective studies.
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Chapter 8 - Effect of leflunomide on cardiovascular risk in rheumatoid 
arthritis
In this chapter the effect of leflunomide on CV risk factors in patients with active RA is 
studied. The prevalence of CV risk factors and composite CHD risk score for the 
prediction for a CHD event in the next 10 years are calculated before and after starting 
leflunomide.
8.1 Introduction
Medication used to treat rheumatoid arthritis (RA) may potentially influence the 
development of associated cardiovascular disease (CYD) in a number of ways. Drugs 
commonly used in treatment of RA are non steroidal anti inflammatory drugs 
(NDAIDS), glucocorticosteroids, traditional disease modifying anti rheumatic drugs 
(DMARDS) and biologic response modifying drugs. NSAIDS are known to be 
associated with increase in blood pressure (Armstrong and Malone, 2003). Data 
regarding the use of steroids is controversial; some reports suggest that steroids may 
adversely affect CVD by increasing body weight, adversely affecting lipid profile, 
insulin resistance and inducing diabetes (Bartoloni et al., 2011). A literature review has 
demonstrated a weak association of low dose steroids and CV risk factors but a trend 
for increase in CV events (Adeline Ruyssen-Witranda, 2011). However the association 
between steroids and CV events was mostly dose dependent with a higher risk of CV 
events associated with doses in excess of 10 mg per day The EULAR working group 
recommendations on management of systemic glucocorticosteroid therapy in rheumatic
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diseases advises using low dose steroids (7-10 mg/day) for a short duration and 
tapering off gradually (Gorter et al.} 2010). Use of methotrexate has been associated 
with a 70% reduction in CV related mortality compared to other DMARDs (Choi et al., 
2002). Hydroxychloroquine is associated with an improvement in glucose and insulin 
sensitivity in patients with lupus and RA and reduces the risk of developing diabetes in 
association with RA (Androniki Bili 2011). In addition, hydroxychloroquine use has 
been shown to reduce deleterious effects of glucocorticoids on the lipid profile (Wallace 
DJ, 1994, Penn SK, 2010). The effects of sulphasalazine on the lipid profile are unclear, 
with some studies reporting beneficial effects on cardiovascular risk that may be 
attributed to reduction in inflammation (van Halm et al, 2006) and others the reverse. 
Sulphasalazine may exert cardioprotective effects by decreasing platelet reactivity 
(MacMullan P.A., 2008).
Some observational studies have demonstrated reduced CVD events in RA patients 
treated with disease modifying anti-rheumatic drugs (DMARDs) (Suissa S 2006, Choi 
HK 2002,). However, Solomon et al reported an increased risk of CV events in RA 
patients who received leflunomide (Solomon DH 2006). It was reported that 
leflunomide may adversely affect the CV risk by increasing blood pressure (Rozman et 
al, 2002). Little is known about the effect of this DMARD on cardiovascular risk in 
RA. Hypertension is a recognised side effect of leflunomide. It seems that leflunomide 
may cause worsening of existing hypertension as well as development of new cases 
hypertension (Rozman et al, 2002) . A significant rise in BP was reported in up to 
10.6% of patients receiving 25 mg leflunomide in a US phase II study of this drug
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(Mladenovic V 1995) and newly detected hypertension was observed in nearly 4% of 
RA patients in a European study (Smolen JS 1999). The mechanisms underlying the 
rise in BP mediated by leflunomide are not clear. Some studies demonstrated a modest 
rise in resting heart rate 4-6 weeks after starting this drug, suggesting that the rise in BP 
may reflect a drug-induced increase in sympathomimetic drive (Rozman B 2002)
The effects of leflunomide on lipids are controversial. Leflunomide was associated with 
decreased disease activity and a significant increase in total cholesterol and HDL 
cholesterol. No significant change in the atherogenic index was observed (B. 
Targohska-St^pniak, 2008), However, another small study reported a progressive 
deleterious effect of leflunomide on lipid profile (Prokopowitsch AS, 2002); there is 
also a report of life threatening hypertriglyceridaemia (F. Laborde, 2004), Further 
studies are needed to explore the effects of this drug on the lipid profile.
Studies on the safety profile of leflunomide have suggested that gastro intestinal 
disturbance in the form of increased bowel movement, dyspepsia, abdominal pain and 
weight loss are seen in patients using this drug (Strand V, 1999, Alcorn et ah, 2009). 
Other side effects described include allergic skin rash, alopecia, hypertension and 
increased liver enzymes (Strand V, 1999, Rozman et ah, 2002)(Strand V 1999, Rozman 
B et al 2002, (E.N. van Roon, 2004). The prevalence of side effects of this drug may be 
comparable to other DMARDs, but they persist longer, as more than 98% of the drug is 
bound to plasma protein and has a longer half life than other DMARDs. A recent review 
article comparing the efficacy and safety of leflunomide and methotrexate as
182
monotherapy or in combination with biologies has suggested close monitoring of LFT 
when patients are on this drug. It is possible that leflunomide may increase 
cardiovascular risk through effects on raising blood pressure (BP). However reduction 
in inflammatory disease burden may counteract this and reduce cardiovascular risk.
There have been few studies exploring the effect of leflunomide in Asian Indian RA 
patients. Leflunomide use was associated with an incidence rate of new hypertension 
of 0.9% in an established RA cohort based in Hyderabad (Rao URK, 2004). In 
comparison, a multicentre study assessing safety and efficacy of leflunomide in Indian 
patients reported that, whilst 25% of participants had adverse drug reactions, there was 
no mention of hypertension as an adverse event (Agarwal SK, 2002). This may be 
especially notable since a loading dose of leflunomide 100 mg per day for three days 
was used is these studies. Therefore it is possible that the increased dose in the initial 
days may be responsible for the new onset hypertension and 25% adverse effects.
Various studies have demonstrated that loading doses of leflunomide did not show extra 
clinical benefit, but rather a higher rate of adverse reactions (Maddison, 2005, Kremer 
et al., 2004). Leflunomide use has also been reported to lower blood glucose, which was 
attributed to a reduction in body weight (Young Hee Rlio, 2009). There are no 
significant data on other traditional CV risk factors and the use of leflunomide.
Leflunomide is a pro-drug that is metabolised in the liver to its active metabolite 
(teriflunomide) by cytochrome P450. It reduces cell proliferation in activated
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lymphocytes, such as those found in patients with RA, by inhibiting dihydroortate 
dehydrogenase (an enzyme involved in pyrimidine synthesis). Leflunomide is said to 
improve vascular function by reducing sub endothelial migration of peripheral blood 
mononuclear cells, inhibiting nuclear factor kappa B signal pathway associated with pro 
inflammatory and pro atherosclerotic phenomenon in the endothelial cells (Feng H, 
2005) and impairment of antigen presenting dendritic cells (Piercarlo Minoretti, 2007). 
This drug is an effective DMARD in RA with an anti-inflammatory effect and the 
ability to reduce progression of rheumatoid disease comparable to methotrexate. Whilst 
clinical effects of leflunomide can commence within a couple of weeks, it may take 
some months before maximal benefit is achieved(Bozena Targohska-St^pniak, 2008).
Leflunomide is widely used in the treatment of RA as it has proved to be an effective 
DMARD therapy. However, the drug is costly when compared to other traditional 
DMARDs. Therefore in India, where patients are responsible for the cost of their drug 
therapy, it is often reserved for those whose disease is not well controlled by 
methotrexate, and is usually used in combination with other DMARDS. The monthly 
cost of leflunomide at the lOmg/day dose is £20/month, rising to £40/month with the 
20mg/day dose. This higher dose of leflunomide is too expensive for many RA patients 
seen in the rheumatology clinic in Hyderabad. Therefore, a routine practice at our clinic 
is to use lOmg of leflunomide /day in combination with methotrexate therapy or with 
other DMARDS in the small number of patients who cannot tolerate methotrexate. As 
studies have suggested that higher dose leflunomide may influence CV risk, and in
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particular cause a rise in BP, I was keen to identify whether similar effects would be 
observed at lower dose in a South Asian Indian cohort of RA patients.
8.2 Aim
The primary aim of this study was to explore whether the introduction of lOmg/day of 
leflunomide to treat active RA leads to a significant increase in blood pressure and 
cardiovascular risk.
Secondary aims were to explore whether leflunomide use was associated with 
modification of lipids, body mass index or fasting blood glucose.
8.3 Methods
Adult RA patients fulfilling ACR criteria (Chapter 1) with inadequate response to 
existing DMARDS, able to afford the drug and willing to participate between July 2007 
and June 2008 were included. All patients had significant disease activity (DAS 28 > 
3.2) despite adequate dose of other DMARDs. The study was approved by Sri Deepti 
Rheumatology Centre ethics committee and all patients gave their written consent to 
participate. Patients with known CVD, on lipid lowering drugs and those with 
deformities causing difficulty in anthropometric measurement were excluded.
A full history and examination, as detailed in Chapter 4, were carried out. The 
assessments were repeated after instituting leflunomide treatment.
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8.4 CVD risk assessments
Blood pressure was measured using a Diamond regular (IS3390) sphygmomanometer at 
baseline, after sitting for fifteen minutes, and repeated twice after ten minutes intervals. 
The mean of 3 readings was calculated. Fasting blood glucose and a lipid screen 
including total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides were 
measured. LDL cholesterol was calculated using Friedwald’s formula. Patient height 
and weight were recorded and BMI was calculated. In addition waistdiip ratio was 
calculated from waist and hip measurements. Patient smoking history was recorded. A 
28 joint count, global assessment of disease and ESR were used to calculate DAS28. 
Health assessment questionnaire was administered. These evaluations were repeated 
after four month of leflunomide therapy.
The 10 year percentage risk of a coronary heart disease (CHD) event was calculated 
using the Joint British Societies CHD risk calculator (Durrington 1997). This calculates 
a 10 year CHD risk based on systolic and diastolic BP separately. A ten year CHD risk 
of 10% or more was defined as elevated CHD risk. These measures were then repeated 
4 months after leflunomide lOmg daily was started. Twenty milligram (mg) per day was 
not used as it was costlier and may increase the possibility of toxicity.
8.5 Drug therapy
Current medication including regular NSAID, DMARDs and glucocorticosteroid use 
were noted. Participants on prednisolone used < 7.5 mg per day. Patients were initiated 
on leflunomide lOmg per day without loading doses. Any change in requirement for
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NSAIDs or glucocorticoids was recorded. In all situations leflunomide was added in 
combination to other DMARDs in order to step up DMARD therapy. Nine patients 
were on etanercept which was withdrawn as leflunomide was started. On improvement 
in joint pain the patients were allowed to reduce or stop the dose of glucocorticosteroid 
and NSAIDs.
8.6 Analysis
The study was powered based on an anticipated 10% increase in BP with leflunomide 
treatment. Using this estimation of effect size, power of 0.9 and alpha of 0.05 a sample 
size of 40 patients was required.
Baseline pre leflunomide measures of BP and CV risk factors were compared with 
values recorded after 4 months of leflunomide treatment. Significance testing using 
paired T-test for normally distributed variables and Wilcoxon’s signrank test for non- 
parametric data. Chi squared test was used to compare categorical variables pre and post 
leflunomide treatment.
8.7 Results
A cohort of 40 RA patients was identified. The patient and disease characteristics are 
summarised in Table 8.1. The mean age of the cohort was 48.5 years and 93 % were 
female. Patients had established RA with median disease duration of 5.5 years. This 
cohort of patients did not include any smokers. All were established on DMARDs and 
the baseline treatment is summarised in table 8.2.
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Methotrexate (mtx) was used by 95% of the cohort. Patients were advised to continue 
with their DMARD therapy during the period of this study. The only change to 
rheumatic drug therapy was withdrawal of etanercept around eight weeks after adding 
leflunomide. All patients had active RA at the time of starting leflunomide. The median 
DAS 28 score was 7.1, reflecting high RA disease activity. At the baseline assessment 
all but one patient was using regular NSAIDs for symptom control and 77% were also 
using oral glucocorticoids. All patients were on methotrexate 10-15 mg/week, the 
median dose being 12.5mg/week. Prednisolone was used in a physiological dose of less 
than 7.5 mg/day.
Table 8.1 Baseline disease characteristics of the cohort
Variables Description RA Cohort n=40
Age (yrs) mean (SD) 48.5 10.3
Gender Female n (%) 11 (%) 37 92.5
Vegetarian n (%) n(%) 17 42.2
Duration of RA (years) med [IQR] 5.5 3, 11.5
Rheumatoid factor positive n (%) n (%) 39 97.3
DAS 28 med [IQR] 7.1 5.7, 7.6
ESR med [IQR] 85 58, 115
CRP med [IQR] 48 48, 48
Global health VAS med [IQR] 75 50, 100
Swollen joint count med [IQR] 6 3, 10
T ender j oint count med [IQR] 13 6, 18
HAQ score med [IQR] 1.75 1.50,2.24
BMI Kgs/m2 ~ ” mean (SD) 25.8 0.7
History of DM n(%) 9 22
History of hypertension 11 (%) 11 27.5
Abbreviations:- (medj - Median, (SO) - Standard deviation, [IQRJ - Inter quartile range.
Table 8.2 Baseline anti-rheumatic therapy
Medication n %
Methotrexate 38 95.0
Sulphasalazine 1 2.3
Hydroxychloroquine 3 7.7
Glucocorticoids 30 76.9
NSAIDs 39 97.5
Etanercept 9 22.5
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8.7.1 Response to leflunomide treatment
Table 8.3 demonstrates the observed change in disease variables for the cohort. There 
was evidence of significant improvements in disease activity with evidence of reduction 
in swollen and tender joint counts (p<0.001). The inflammatory markers reduced with 
treatment and the DAS 28 dropped from a median of 7.1 to 4.9 after 4 months of 
leflunomide treatment(p<0.001). The median HAQ score also dropped significantly 
from 1.75 to 0.92 demonstrating a marked reduction in level of disability (p<0.001). Of 
interest, the proportion of patients requiring: 1) NSAID treatment reduced from 98% to 
78%, and 2) steroid treatment dropped from 77% to 43% (p=0.003).
Table 8.3 Change in disease variables with leflunomide treatment
Variables Description Pre-
leflunomide
treatment
Post-leflunomide
treatment
statistical 
test used
p value
ESR med [1QR] 85 58,115 43 32.5, 66.5 Wilcoxon’s
signrank
p<0.001
CRP med [IQR] 48 48, 48 24 24,48 Wilcoxon’s
signrank
pO.001
Global 
health VAS
med [IQR] 75 50, 100 30 20, 50 Wilcoxon’s
signrank
pO.OOl
Swollen 
joint count
med [IQR] 6 3, 10 2 1,3 Wilcoxon’s
signrank
pO.OOl
Tender joint
count
med [IQR] 13 6,18 5 2,7 Wilcoxon’s
signrank
pO.OOl
DAS 28 med [IQR] 7.1 5.7, 7.6 4.9 4.1, 5.4 Wilcoxon’s
signrank
pO.OOl
HAQ score med [IQR] 1.75 1.50,
2.24
0.92 0.69, 1.29 Wilcoxon’s
signrank
pO.OOl
NSAID use n <%) 39 97.5 31 77.5 chi squared p=0.007
Steroid use n (%) 30 76.9 17 42.5 chi squared p=0.003
The cardiovascular risk assessments are shown in table 8.4. At baseline, prior to starting 
leflunomide, 33% of patients had elevated systolic BP. Of this group, only 5 were 
known to have hypertension and no modification of antihypertensive therapy was 
instituted.
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Table 8.4 Comparing CVD risk factors pre and post leflunomide treatment.
Variables Description Pre-
leflunomide
treatment
Post-
leflunomide
treatment
statistical 
test used
pvalue
Systolic BP
(mmHg)
mean (SD) 128.0 2.4 127.0 2.0 paired t-test p=0.79
High systolic BP 
(>140 mmHg)
11 (%) 13 33 9 23 paired t-test p=0.31
Diastolic BP
(mmHg)
mean (SD) 84.1 1.2 84.5 1.2 paired t test p=0.79
High diastolic BP 
(>90 mmHg)
n (%) 20 50 18 45 chi squared p=0.65
Pulse pressure 
systolic-diastolic
mean (SD) 43.3 2.0 42.5 1.6 paired t test p=0.65
BMI Kgs/m2 mean(SD) 25.8 0.7 25.8 0.6 paired t-test P=0.75
Waist:Hip ratio mean (SD) 0.89 0.01 0.89 0.01 paired t-test
00oIIC
l
FBS mean (SD) 93.2 2.7 91.0 2.1 paired t-test p=0.40
Total Cholesterol mean (SD) 180 4.48 178 5.0 paired t test p=0.68
HDL Cholesterol mean (SD) 46.5 0.9 48.2 1.00,
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paired t-test p=0.08
Low HDL n(%) 5 12.5 1 2.5 chi squared p=0.09
Triglyceride mean (SD) 128.4 9.8 120.7 8.0 paired t-test p=0.47
T- ChokHDL
Choi ratio
mean (SD) 3.9 0.64 3.7 0.53 paired t-test p-0.04
Composite CHD risk scores
CHD risk score ' 
(systolic BP)
mean (SD) 5.3 0.8 4.8 0.8 paired t-test p=0.47
High CHD risk 
score1’1’ (systolic 
BP)
11 (%) 8 20 7 17.5 chi squared p=0.77
CPID risk score * 
(diastolic BP)
mean (SD) 5.9 0.9 5.4 0.8 paired t-test p=0.08
High CHD risk 
score** (diastolic 
BP)
n (%) 10 25 6 15 chi squared p=0.26
SD standard deviation, 95% Cl Confidence interval, DAS28: 28 joint Disease activity score, 
ESR: Erythrocyte Sedimentation Rate. 
t (% risk of CHD event over 10 years, based on systolic BP)
(>10% risk of cvd event over 10 years based on systolic BP)
* (% risk of CHD event over 10 years, based on diastolic BP)
(>10% risk of cvd event over 10 years based on diastolic BP)
No significant differences were noted in either systolic or diastolic BP before and after
starting leflunomide. It was noted that the mean BP remained the same on leflunomide
therapy. However, the proportion with elevated systolic BP (systolic BP >140 mm of
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Hg) fell from 13 (33%) to 9 (23%) after leflunomide was started. As leflunomide 
therapy is often avoided in the presence of hypertension, this is an interesting 
observation.
At baseline it was observed that 13 (32.5%) of patients had elevated systolic BP. When 
the group was stratified by baseline systolic BP, those with baseline systolic BP less 
than 140 mmHg (normotensive patients), had a statistically significant mean increase in 
systolic BP of 4mmHg (SD 9.3 mmHg) (paired t test p=0.02); whilst those with 
elevated systolic BP (systolic BP >140) at baseline had a statistically significant 
reduction in systolic BP of 9.2mmHg (SD 12.6) after starting leflunomide therapy 
(paired t test =0.01). No anti-hypertensive medication was added during the period of 
this study.
In both the systolic hypertension subgroup and the normotensive subgroup, leflunomide 
use was associated with a 23% reduction in NSAIDS use. The prevalence of steroid use 
was also reduced by 40% in both the systolic and normotensive subgroups. No 
significant difference in reduction in DAS28 scores were observed when the 
normotensive and systolic hypertensive subgroups were compared.
There was a non-significant trend for improvement in nearly all the individual 
components of the CHD risk score. However, the composite CHD risk score did not 
significantly change after leflunomide was started. Whilst total cholesterol level and 
triglyceride level were lower after starting leflunomide, this was not a significant
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difference. There was a trend for HDL cholesterol level to increase and total
cholesterol: HDL C ratio was observed to reduce with lefhmomide treatment (p=0.04). 
A significant reduction in T- Choi: HDL ratio was also observed, with a drop from 3.9 
to 3.7. However, the size of this reduction was very small and is unlikely to be of 
clinical significance.
8.8 Discussion
This small study of the effect of leflunomide on cardiovascular risk has not 
demonstrated any significant increase in either systolic or diastolic BP with this 
treatment. If anything, the blood pressure was observed to fall after leflunomide was 
added and the magnitude of BP reduction was largest in those patients with elevated BP 
at the baseline assessment. The encouraging results of a fall in systolic BP of 9.2 mm of 
Hg in patients with elevated blood pressure are important. As blood pressure is one of 
the components of CV risk assessment, even a small reduction in blood pressure (10-12 
mm of Hg) substantially reduces CV risk.
The reason for the paradoxical reduction in BP is likely to be explained by the reduction 
in RA disease activity and a reduced requirement for NSAIDs and glucocorticoids after 
leflunomide was started. It was interesting to note that the fall in BP was only observed 
in the subgroup with hypertension at baseline and there was a very modest rise in the 
systolic BP observed in the baseline normotensive patients with leflunomide treatment..
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When the prevalence of NSAID and glucocorticosteroid use was explored, no 
difference was observed in the reduced requirements for these drugs in either subgroup. 
This suggests that the change in BP is not simply due to a change in requirement for 
NSAIDs and glucocorticoids. However, we were unable to record the reduction in dose 
of steroids in the patients who continued steroid treatment. This study was not 
adequately powered to explore this in more detail.
Another possible explanation for a fall in BP might be due to the reduction in anxiety in 
RA patients as they become accustomed to the study assessments, or possibly as a 
consequence of reduced pain associated with reduced disease activity. However, as 
response to leflunomide did not differ between those who, at baseline, were 
normotensive and those with elevated systolic BP, this would not explain the 
paradoxical changes in BP observed in these two subgroups.
The modest mean rise in systolic BP of 4 mmHg observed in the baseline normotensive 
patients is of a magnitude similar to that seen in previous clinical trials of leflunomide. 
An earlier phase three study observed a mean increase in systolic BP of 2.2 mm of Hg 
and a diastolic BP of 1.9 mm of Hg (Strand V, 1999). Hypertension was reported in 
3.7% of patients in another phase two study (Smolen et al., 1999).
Another interesting observation was the slight but significant reduction in the total 
cholesterol to HDL-Chol ratio. This was largely driven by an increase in the 
concentration of HDL and is likely to reflect the improvement in the inflammatory
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disease burden rather than any effect of leflunomide on lipid metabolism. However, 
leflimomide is metabolized to the active drug by cytochrome P450 1A2 in the liver. Up 
regulation of this enzyme may have a beneficial effect on the lipid profile. Studies have 
demonstrated that drug induced elevation of liver cytochrome P450 is associated with 
higher levels of apolipoprotein AI (apo AI) and HDL cholesterol (HDL-C) as well as 
reduced LDL cholesterol (LDL-C) levels in plasma. Therefore, it is possible through the 
liver metabolism of leflunomide, that there may be a beneficial effect on lipid profile 
through induction of cytochrome P450. My finding is in contrast to a previous study in 
thirty established RA patients observed before and three months after starting the drug 
which observed that, though there was an insignificant trend for an increase in TC and 
triglyceride, the atherogenic index (T-Chol:HDL-Chol ) remained constant and 
leflunomide failed to demonstrate an effect lipid profile in RA patients (van Halm 
2003). Patients in that study were older than our study participants, had a longer 
duration of disease (9.8years) and a lower proportion of females than my cohort and 
were already on multiple DMARDs, leflunomide was the fourth DMARD added. The 
observed effects may not be directly attributed to leflunomide alone because 
background medications for RA were multiple. The disease activity of RA and the use 
of steroids and NSAIDs have not been recorded. However this study did not explore the 
effects of leflunomide on blood pressure nor its effect on other CV risk factors. We 
have observed an improvement in the atherogenic index.
Earlier studies have shown that dyslipidaemia is associated with systemic inflammation 
in RA (Park TB 2002). What was interesting in this study was the fact that the HDL 
increased, despite reduction in the proportion of patients using glucocorticosteroid
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medications. Previous studies have demonstrated that use of glucocorticoids tends to 
cause a rise in HDL levels, but it is not clear whether this is due to the effects of 
inflammation reduction or due to an effect of the glucocorticoids (Boers M 2002), 
which alter carbohydrate and lipid metabolism (Hansel B 2010). The increase in HDL 
cholesterol may possibly be due to the direct hepatic effects of leflunomide. However 
this needs further investigation.
A limitation of this study was that it was observational and no placebo treatment group 
was examined. Both patients and researchers conducting the assessments were aware of 
treatments prescribed. It is possible that this lack of blinding to treatment may have 
influenced the study results. However it is unlikely that this would have changed the 
individual CV risk factors especially the lipid profiles. It would have been useful to 
conduct this study using a double blind cross over trial design. This would have 
overcome problems with bias. However, as the current study relied on participants 
being responsible for the cost of their drug treatment it was not ethical or practical to 
conduct the study using placebo treatment period
A recent study from the Asia Pacific region (New Zealand) in 90 patients on 
leflunomide looking at the long term survival characteristics and side effect profile of 
the drug reported gastrointestinal side effects to be the most common. The patients were 
followed for 6.5 years and rather interestingly the investigators did not observe any CV 
side effects of leflunomide. The investigators could not consistently record the starting 
dose of the drug, the patients were older than in my cohort and there was no information
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about disease activity (Jagoda, 2011). Another study in Pakistani patients comparing the 
effect of leflunomide monotherapy and in combination with methotrexate for 24 weeks 
did not mention CV side effects of the drug. The age of those patients was similar to our 
cohort and all patients had active disease. However, there was no consistency in either 
the use of loading dose or maintenance dose of the drug (10-20 mg /day was used) 
(Nighat M. Ahmad, 2011). An observational study in Indians observed only 5 out of 
230 patients developed hypertension with leflunomide use (Arvind Chopra 2008). 
Whereas Rao et al (Rao URK, 2004) observed 0.9% of 548 patients on leflunomide for 
six months had high blood pressure during follow up. These two studies used a loading 
dose of leflunomide. With the results from Asia Pacific populations it would be 
interesting to know if there is a true difference in safety of leflunomide in different 
geographical and ethnic backgrounds. It would be interesting to note the CV effects of 
leflunomide in Asia Pacific countries.
Leflunomide had been in general use for more than a decade, yet there is not much 
published about its effect on CV risk. My findings are interesting and need to be 
addressed in further studies that are powered to investigate the effect of leflunomide on 
individual CV risk factors. It would be intriguing to explore the direct effect of this 
drug, over a longer period of follow up, in larger number of patients with a stable dose 
of steroids and NSAIDs.
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The primary aim of this study was to explore if leflunomide increases blood pressure. I 
have found that the drug does not increase blood pressure - on the contrary, there 
appears to be a fall in blood pressure. In addition, I did not find evidence for increased 
cardiovascular risk with use of leflunomide in active RA. The possibility that 
leflunomide may lead to improvements in RA-associated dyslipidaemia is an attractive 
hypothesis, but warrants further study in a larger group of patients, allowing for 
adjustment for confounding effects of reduced inflammation and glucocorticosteroid 
use.
Finally, the fact that this was an observational prospective study and conducted in a 
routine clinical setting, carries a greater applicability for these results to be relevant to 
the general RA population, compared to randomised clinical trials. This may be of 
special value for South Asian Indian RA patients, who have increased CV risk factors 
and limited choice of the use of DMARDs, especially biological response modifiers, 
due to their prohibitive cost.
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Chapter 9 - The influence of etanercept treatment on cardiovascular 
risk in active rheumatoid arthritis
This chapter explores whether a short course of treatment with the anti-tumour necrosis 
factor alpha (anti-TNF) drug, etanercept, is associated with a change in the CV risk 
profile ofpatients with active RA. The patients ’ CV risk profiles were evaluated at 
baseline, and at 3 and 6 months after the anti TNF drug was withdrawn.
9.1 Introduction
Rheumatoid arthritis is associated with increased mortality and morbidity which may be 
attributed to RA specific factors such as disease activity related dyslipidaemia, vascular 
inflammation, medicines used to treat RA or increased levels of circulating pro 
inflammatory cytokines like tumour necrosis factor alpha. There are reports that use of 
anti TNF treatment reduces the CVD event rate in RA patients who respond to 
treatment (Dixon and Symmons, 2007). Therefore, this suggests that anti-TNF 
treatment may influence CV risk in RA. However, in the study by Dixon et al, CVD 
event rates were only reduced in the subgroup of RA patients who demonstrated 
moderate to good EULAR response to anti-TNF therapy, and were not reduced in those 
who were non responders. If CVD events were only reduced in responders this suggests 
that the reduction in CVD events may reflect reduction in inflammation rather than a 
beneficial effect of the anti TNF drug on CV risk factors.
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Many studies have explored the effect of anti TNF treatments on markers of vascular 
function in RA. Endothelial function is found to improve with anti TNF treatment 
(Hurlimann et al., 2002). However, this beneficial effect was found to be transient in 
another study with endothelial function returning to pre treatment levels after one month 
of therapy. However, in this same study the authors have supported long term use of the 
drugs to reduce CV complications based on a reduced rate of atherosclerosis mediated 
by endothelial function (Gonzalez-Juanatey et al., 2004).
Long term (2yrs) treatment with etanercept has demonstrated a reduction of carotid 
IMT in RA patients (Ferrante et al., 2009). A meta-analysis of the effect of anti TNF 
alpha therapy has demonstrated that there is reduced risk of all CV events in 
observational cohorts (Baraabe et al., 2011). However, Suissa et al failed to observe any 
reduction in CVD event rates in anti-TNF treated RA patients compared to patients 
treated with traditional DMARD therapies (Suissa et al., 2006).
The effect of anti TNF treatment on lipid profiles in RA is controversial. Some studies 
have not observed any effect of the treatment on the lipid profile. (Soubrier et al., 2008). 
However, several studies have reported an increase in total cholesterol. In a study by 
Seriolo et al (Seriolo et al., 2006) anti TNF treatment was given to 34 active RA 
patients and the lipid profile was measured at baseline and 16 and 24 weeks and it was 
found that treatment was associated with an increase in T-Chol and HDL cholesterol but 
the atherogenic index remained the same. The same findings were also confirmed in a 
review article (Schimmel EK, 2009). Anti TNF treatments have found to increase HDL
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cholesterol (Popa et al., 2005, Spanakis et ah, 2006). We know from other studies that 
inflammation influences the lipid profile in RA. Several studies have demonstrated a 
rise in total cholesterol with suppression of systemic inflammation (Boyer et al., 2011, 
Kitas, 1997)(Situnake). As the studies exploring the influence of anti TNF on lipid 
profiles were conducted in different RA populations with varying levels of disease 
activity, it is difficult to know whether the lipid modification reflects a direct effect of 
the drug or the effects of reduced inflammation.
In addition, metabolic syndrome and insulin resistance may be modified by anti-TNF 
therapy (Popa et al., 2007). In type 2 diabetic patients use of anti TNF therapy has been 
reported to reduce the level of insulin resistance (Rosenvinge A, 2007). A Spanish study 
on 27 RA patients has reported improvement in insulin resistance 2 hours after 
infliximab infusion (Gonzalez-Gay et al., 2006).
Previous studies have mentioned the effect on CV risk factors while the patients were 
continuing anti TNF treatments. No study in the literature addresses whether the effect 
is sustained after the withdrawal of the drug. The effects of anti TNF treatment on lipids 
are controversial and the information in South Asian Indian patients treated with anti 
TNF treatments with respect to traditional CV risk is scanty.
In the UK currently 5 TNF treatments are available 1) infliximab a chimeric monoclonal 
antibody given as an intravenous infusion in a dose of 3-5 mg / kg body weight, 2) 
Etanercept a recombinant fusion protein given as a 25 mg subcutaneous injection twice
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a week, 3) Adalimumab a fully humanized antibody given as 40 mg subcutaneous 
injection every other week 4) Certolizumab pegol is given as a 400 mg subcutaneous 
injection on week 2 and 4 followed by 200 mg every other week , and the most recently 
licensed 5) Golimumab is a synthetic protein given as a 50 mg per month subcutaneous 
injection. However in India only Infliximab and Etanercept are available.
In contrast to western countries, RA patients in India are mostly self funded and are 
responsible for the cost of their treatment. As biologic response modifiers are costly, 
patients cannot afford to use them for indefinite periods. Hence, biologic response 
modifiers are used for a short duration usually about three to four months to try and 
induce remission / or improve disease activity which is later maintained by non biologic 
traditional DMARDS. Indian patients use this expensive treatment to try and optimize 
their disease control infrequently and often this investment is made prior to an important 
family or social event. Examples of these situations that we often observe in the 
rheumatology practice at the Sri Deepti Rheumatology Centre include planned travel to 
attend their children’s wedding or to go abroad to help their children especially during 
pregnancy and delivery. Before such occasions patients request use of anti-TNF in order 
to optimize better disease control. In this situation if the patient or their family can 
afford it arrangements are made to initiate a short course of biologic response modifiers. 
The cost of this course of anti TNF treatment is around 2,600 GBP. Though this is not a 
licensed use of the drug, nor it is evidence based, this is the usual clinical practice. 
There are instances where patients use etanercept single dose as and when required at 
times similar to a steroid injection. This use was not included in this study. As our clinic
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is in an outpatient setting the most commonly used biologic drug is etanercept due to 
the ease of administration.
9.2 Aim
The aim of this study was to explore whether 4 months use of etanercept influences CV 
risk factors in patients with active rheumatoid arthritis after etanercept is withdrawn. 
Secondary aims were to explore whether any long-term effect on CV risk is observed 6 
months after etanercept is withdrawn.
9.3 Methods
This prospective observational study was conducted in patients who were exposed to a 
short course of anti TNF therapy, with etanercept, as part of their ongoing rheumatology 
treatment.
Patients were invited to take part in the study if they had active RA (defined as a 
DAS28>5.1), despite treatment with methotrexate or methotrexate in combination with 
other DMARDs like leflunomide, sulphasalazine or hydroxychloroquine. As patients 
were responsible for the costs of all medication, this subgroup of patients was not 
representative of the rest of the RA cohort described in chapter 4. They represented a 
more affluent subgroup of patients, as the high cost of 4 months of etanercept was 
beyond the socioeconomic capabilities of most of the patient group studied in chapter 5. 
DMARDs and prednisolone were at a stable dose for three months prior to starting 
etanercept. The treatment and assessment protocol is described in Figure 9.1.
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The ethics committee Sri Deepti Rheumatology Centre approved the study and all 
participants gave written consent to participate.
9.4 Assessments
Before the anti-TNF treatment was started, baseline assessments of RA disease, its 
treatment and CV risk measurements were recorded. These assessments are described in 
chapter 4. The assessments were repeated three and six months after etanercept 
treatment had been withdrawn. Concomitant medication history was taken at each 
evaluation. The patients included in this study have active disease as defined by a DAS 
28 of >5.1.
9.5 Anti-TNF treatment
All eligible patients used etanercept 25 mg subcutaneously twice a week for two months 
then the dose was reduced to 25 mg / week for another two months then the drug was 
withdrawn. The patients were allowed to adjust the dose and stop NSAIDs and 
glucocorticosteroid if their joint disease was controlled. DMARDs were allowed to be 
altered if needed. At the time of tapering the etanercept dose leflunomide at a dose of 10 
mg / day was added to the drug therapy.
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Figure 9.1 Treatment and assessment protocol
Etanercept stopped
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Baseline 3 months 6 months
since since
stopping stopping
etanercept etanercept
9.6 Analysis
The CV risk factor distributions and prevalence of elevated risk factors are described at 
baseline and 3 months after etanercept. The difference in risk factor distributions at 
these 2 time points were assessed using paired t tests for normally distributed data, 
Wilcoxon’s matched pair signrank test for non parametric data and chi squared for 
binomial data.
The analysis was then repeated in the subgroup that provided 6 months follow up data 
after etanercept was stopped.
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9.7 Results
9.7.1 General details
Forty one active rheumatoid arthritis patients with inadequate response to traditional 
DMARDS who could afford drug costs of etanercept were included. The cohort of 
patients included 36 females and five males. All forty one patients underwent a repeat 
analysis 3 months after stopping etanercept treatment and 25 of the original subgroup 
underwent a further assessment 6 months after etanercept therapy was withdrawn (Table 
9.1).
Table 9.1 Assessments before and after 3 and 6 months treatment with etanercept
All Females Males
n n n
Pre etanercept treatment 41 36 5
3 months after etanercept treatment 41 36 5
6 months after etanercept treatment 25 22 3
9.7.2 CV risk factors and RA disease variables pre and post etanercept treatment
9.7.2.1 RA disease variables before and 3 months post etanercept treatment
At the baseline assessment this cohort of RA patients had a median RA disease duration 
of 5 years. However, the cohort was quite heterogeneous with a range of disease 
durations spreading between 6 months and 26 years. Rheumatoid factor was positive in 
40 patients (97.6%). All patients had active disease as shown by the high median 
DAS28 scores of 7.7. The 28 tender and swollen joint counts were elevated and global 
disease visual analogue scale (VAS) was 100. The median ESR was 103 mm/ hr.
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After patients had been treated with etanercept, the assessment 3 months after 
etanercept was withdrawn revealed a significant reduction in the DAS 28 score from 
7.73 to 4.64 (p<0.001). The results in table 9.2 reveal that this reduction in DAS28 
score was due to reduced 28 joint counts and a marked reduction in global health and 
ESR.
Table 9.2 RA disease variables before and 3 months after etanercept treatment
Parameter Description Pre etanercept 
n=41
3 m post etanercept 
n=41
p value
Duration
RA (yrs)
median [IQR] 5 3, 11 5 3, 11 NS
RF +ve n(%) 40 97.6 40 97.6 NS
SJC median [IQR1 12 8, 15 2 0, 4 p<b.ooi
TJC median [IQR1 18 14, 24 4 2,6 p<0.001
Global dis
VAS
median [IQR] 100 80, 100 30 20, 40 p<0.001
ESR median [IQR] 103 85, 125 42 30, 56 p<0.001
DAS28 median [IQR] 7.73 7.08,8.28 4.64 3.64,5.39 pO.OOl
IQR- inter quartile range, n-number, RF+ve~ rheumatoid factor positive, SJC- swollen joint 
count, TJC- tender joint count, Global dis VAS- global disease visual analogue scale, ESR- 
erythrocyte sedimentation rate, DAS 28- disease activity score of 28 joints.
The concomitant medicines used by the cohort are given in Table 9.3. At baseline all of 
the patients reported use of NSAIDs and steroid use was reported by 38 (92.7%). All 
but one patient reported current use of Methotrexate (97.6%). The dose of methotrexate 
ranged between 10-15 mg / week and prednisolone was used in a physiological dose of 
< 7.5 mg /day. Leflunomide use was reported in 34.2% of patients whereas 
hydroxychloroquine and sulphasalazine were both infrequently used. Combinations of 
DMARD drugs were used by 41% of the cohort at baseline.
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Three months after etanercept was withdrawn, NS AID use by the cohort was reduced 
significantly from 100% to 73.2%) (p<0.001). In addition, use of any steroid 
medications was also significantly reduced from 92.7% to 43.9%. Whilst all patients 
were started on Leflunomide as the dose of etanercept was reduced, not all patients 
remained on this medication. At the 3 month assessment only 22 (53.7%) were still 
taking leflunomide in addition to their other DMARD therapies.
Table 9. 3 Concomitant medicines before and 3 months after etanercept treatment
Parameter Description Pre etanercept 3 m post 
etanercept
p value
NSAIDs n(%) 41 100 30 73.2 PO.OOl
Steroids n (%) 38 92.7 18 43.9 PO.OOl
Etanercept n (%) 0 0 0 0 NS
Methotrexate n (%) 40 97.6 40 97.6 NS
Leflunomide n(%) 14 34.2 22 53.7 p=0.08
Hydroxychloroquine n(%) 4 9.8 7 17.1 NS
Sulphasalazine n(%) 1 2.4 2 4.9 NS
NS: Not significant p values after significance testing with Chi squared test.
9.7.2.2 General demographics in patients before and 3 months after etanercept 
treatment
The baseline median age of the patients was 48.9 years. Thirty six out of 41 patients 
(87.8%) were females. Vegetarian diet was reported by 16 (39%). None of the patients 
were smokers. The most frequently observed co morbidity was DM (29.3%) followed 
by HTN (12.2%). None of the patients had co morbid CVD. Patients with known CVD 
on treatment were excluded.
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9.7.2.3 Blood pressure before and 3 months after etanercept treatment
The median diastolic blood pressure remained constant during the course of the study. 
The baseline systolic blood pressure was 130 mm of Hg and dropped to 120 mm of Hg 
3 months after etanercept see Table 9.4.
High systolic BP (>140 mm of Hg) was observed in 29.3% of patients. Three months 
after etanercept treatment there was a significant reduction in the number of patients 
having a high systolic BP (p=0.01). Whilst the number of patients with elevated 
diastolic BP dropped from 12 to 8 this difference did not reach statistical significance.
Table 9.4 Blood pressure before and 3 months after etanercept treatment
Parameter Description Pre etanercept 3 m post etanercept fChi2 p value
Systolic
BP
median
[IQRl
130 120, 140 120 110, 130 0.03
Diastolic
BP
median
nQRi
80 80, 90 80 80, 80 NS
Elevated systolic BP
Systolic
BP >140
n(%) 12 29.3 3 7.3 6.6 0.01
Diastolic
BP >90
n(%) 13 31.7 8 19.5 1.60 0.21
9.7.2.4 Anthropometric measurements
The median height of the cohort was 157 centimetres and the median weight was 65 
kilograms. The median BMI was 25.2 and median waist: hip ratio was 0.9. There was 
no significant change in the BMI or waist: hip ratios after etanercept treatment. The 
proportions with high waist: hip ratios and BMI in the overweight/obese categories did 
not show any change during the course of the study.
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9.7.2,5 Fasting blood glucose and lipid parameters
The median fasting blood glucose was 87mg / dl and there was no significant change 
during the course of the study. None of the patients had elevated blood glucose greater 
than 126 mg/dl. The median baseline total cholesterol was 164 mg / dl and was constant 
3 months after exposure to etanercept. Median baseline HDL cholesterol was 48 mg/dl 
and triglyceride was 126 mg/ dl. Though the total cholesterol remained same there was 
a trend for a slight reduction in triglycerides (126 mg/dl to 118mg/ dl) and HDL 
cholesterol (48 mg/dl to 47 mg/ dl) levels, 3 months after etanercept treatment was 
withdrawn see Table 9.5.
Table 9.5 Fasting blood glucose and lipid parameters before and 3 months after 
etanercept treatment
Parameter Description Pre etanercept 3 m post 
etanercept
fChi2 p value
T- Choi median [IQR] 164 151, 188 164 152, 186 0.92
HDL-Chol median [IQR] 48 44,51 47 44, 50 0.72
TG median [IQR] 126 91, 171 118 98, 152 0.51
FBS median [IQR] 87 81,98 85 75, 92 0.28
Elevated lipids and fasting blood glucose
T-Chol >200 n(%) 8 19.5 5 12.2 0.82 0.36
HDL-Chol<40 n(%) 1 2.4 2 4.9 0.35 0.55
T-Chol:HDL 
ratio >4.5
n(%) 6 14.6 3 7.3 1.12 0.28
TG >150 n(%) 15 36.6 11 26.8 0.90 0.34
FBS >100 n(%) 8 19.5 6 14.6 0.34 0.56
FBS in DM 
range >126
n(%) 0 0 0 0 - -
Wilcoxon’s Rauksum test used to explore for significant differences between median lipid values
f Chi squared used to compare proportion with elevated risk factor after 3 months with pre treatment value
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9.7.2,6 Composite ten year risk of CHD event by JBS
The calculated median ten year predicted risk of a CHD event by joint British societies 
CHD risk score calculator at baseline was 3.3% based on systolic BP and 3.9% when 
calculated using diastolic BP. There was an insignificant trend for an increase in the 
CHD risk score 3 months after etanercept treatment. There was an insignificant trend 
for an initial reduction of CV risk factors three months after therapy see Table 9.6. 
Reduction in the number of patients with a high (>15%) CPID risk score was seen 3 
months after treatment with etanercept (7.3% to 0%).
Table 9.6 Composite ten year risk score of CHD event
Parameter Description Pre
etanercept
3 m post 
etanercePt
fChi2 p value
CHD risk (Systolic) median [IQR] 3.3 1.3, 6.9 3.8 1.5, 5.7 0.91 NS
CHD risk (diastolic) median [IQR] 3.9 1.1, 7.2 4.5 1.5, 6.9 0.92 NS
Elevated 10 year CHD risk
* 10 year CHD risk
>10%(systolic)
n(%) 6 14.6 4 9.8 0.46 p=0.50
*10 year CHD risk 
>15% (systolic)
n(%) 3 7.3 0 0 3.11 p=0.08
*10 yearCHD risk
>10% (diastolic)
n(%) 8 19 5 12.2 0.82 p=0.36
*10 year CHD risk 
>15% (diastolic)
n(%) 3 7.3 2 4.9 0.21 p=0.64
t Chi squared used to compare proportion with elevated risk factor after 3 months with pre treatment value 
NS:Not significant result
9.7.3 Influence on CV risk factors and RA disease variables six months after 
etanercept treatment
In a sub group of twenty five patients from the cohort of forty one patients started on 
etanercept a repeat analysis was done six months after the drug withdrawal.
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9.7.3.1 RA disease variables before and 6 months after etanercept treatment
The baseline disease variables in the sub group were as follows RA disease duration 
was 7 years (see Table 9.7). The disease duration in this sub group was longer than the 
original cohort (5 yrs). RF positive disease was seen in 96%. Compared to baseline 
values a significant sustained effect of etanercept on disease activity was observed six 
months after etanercept was withdrawn. All disease activity parameters showed a 
statistically significant improvement (p<0.001). The follow-up of the 25 patients 
demonstrated that there was a significant reduction in DAS28 which was maintained, 6 
months after etanercept treatment (7.87 - 4.47).
Table 9.7 RA disease variables before and 6 months after etanercept treatment
Parameter Description Pre etanercept 
n= 25
6 m post 
etanercept 
n=25
p value
Duration RA
(yrs)
median [IQR] 7 3, 13 7 3, 13 NS
RF +ve n(%) 24 96 24 96 NS
SJC median [IQR] 14 7, 16 1 0,4 pO.OOl
TJC median [IQR] 19 16, 26 4 1,6 pO.OOl
Global dis
VAS
median [IQR] 100 75,100 30 20, 30 pO.OOl
ESR median [IQR] 102 80, 125 44 28, 52 pO.OOl
DAS28 median [IQR] 7.87 7.08, 8.37 4.47 2.99,5.04 pO.OOl
NSAID use was reported by 100% of the patients before etanercept was started six 
months after the drug was withdrawn there was significant reduction in the requirement 
(56% (pO.OOl)).
Requirement of steroids dropped from 96% to 32% (p<0.001). The dose of 
methotrexate was between 10-15 mg / week and prednisolone was used in a 
physiological dose of < 7.5 mg /day. A slightly higher proportion of this subgroup
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remained on leflunomide than that seen in the whole cohort observed at 3 months.
Leflunomide use rose from 28% pre etanercept to 72% six months after etanercept see 
Table 9.8.
Table 9.8 Concomitant medicines before and 6 months after etanercept treatment
Parameter Description Pre etanercept 6 in post 
etanercept
p value
NSAIDs n(%) 25 100.0 14 56.0 p=<0.001
Steroids n(%) 24 96 8 32.0 p=<0.001
Etanercept n (%) 0 0 0 0 NS
Methotrexate n (%) 24 100.0 24 100.0 NS
Leflunomide n(%) 7 28.0 18 72.0 p=0.002
Hydroxychloroquine n (%) 2 8 3 12 NS
Sulphasalazine n(%) 0 0 0 0 NS
NS: Not significant p value
9.T.3.2 General demographics in patients before and 6 months after etanercept 
treatment
The mean age of this sub group of patients was 51.3 years and increased to 52.3 years. 
Eighty eight percent of the group was females forty percent were vegetarian. None of 
the participants were smokers. Co morbid hypertension was more frequently seen in 
36% of patients and diabetes in 20% see Table 9.9.
Table 9.9 Demographics, co morbidities and blood pressure before and 6 months 
after etanercept treatment
Parameter Description Pre etanercept 
n= 25
6 m post etanercept 
n=25
p value
Demographics
Age Mean (SD) 51.3 (9.6) 52.3 9.6 NS
Female gender n(%) 22 88.0 22 88.0 NS
Vegetarian n(%) 10 40.0 10 40.0 NS
Smoker n(%) 0 0 NS
Co morbidities
HTN n(%) 9 36.0 9 36.0 NS
DM n(%) 5 20.0 5 20.0 NS
CVD n(%) 0 0 0 0 NS
NS: Not significant p value
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9.T.3.3 Blood pressure before and 6 months after etanercept treatment
No change in blood pressure was observed before and 6 months after etanercept 
treatment. High systolic blood pressure > 140 mm of Hg was seen in 29.3 percent of 
patients at baseline and 24% six months after etanercept was withdrawn see Table 9.10.
Table 9.10 Blood pressure before and 6 months after etanercept treatment
Parameter Description Pre etanercept 6 m post etanercept JChi2 p value
Systolic
BP
median
[IQR1
130 120, 140 130 120, 130 NS
Diastolic
BP
median
[IQR]
80 80, 90 80 80, 90 NS
Elevated systolic BP
Systolic
BP >140
7 29.3 6 24.0 0.1 p=0.74
Diastolic
BP >90
7 28.0 12 48.0 2.1 p=0.15
| Chi squared used to compare proportion with elevated risk factor after 6 months with pre treatment value (in the 25 patients that had 6 month 
assessments)
NS: Not significant p value
9.7.3.4 Anthropometric measurements
The median height of the group was 157 centimetres. Baseline weight was 63 Kg, BMI 
was 24.8 and waist: hip ratio was 0.89 see Table 9.11. Six months after etanercept was 
withdrawn there was no significant change in the anthropometric measurements though 
there was an insignificant trend for mild increase in weight, BMI and waist 
measurements.
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Table 9.11 Anthropometric measurements before and 6 months after etanercept 
treatment
Parameter Description Pre etanercept *6 m post 
etanercept
$Chi2 P
value
Height median [IQR] 157 153, 161 157 149, 163 NS*
Weight median [IQR] 63 57,71 64 58, 74 NS
BMI median [IQR] 24.8 22.8, 28.3 26.0 22.2,28.
7
NS
Waist cm median [IQR] 93 86,95 94 86, 98 NS
Hip cm median [IQR] 103.
5
96, 108 103 96, 106 NS
WaistHip
Ratio
median [IQR] 0.89 0.86, 0.95 0.91 0.86,
0.94
NS
Elevated waist:hip ratio and BMI
High
Waist: Hip 
ratio
11 (%) 5 20.0 3 12.0 0.6 0.44
BMI>25 n(%) 12 48.0 14 56.0 0.32 0.57
} Chi squared used to compare proportion with elevated risk factor after 6 months with pre treatment value (in the 25 patients that had 6 month 
assessments)
NS: Not significant p value
9.7.4.S Fasting blood glucose and lipid parameters
Baseline median total cholesterol was 173 mg/ dl, HDL cholesterol was 48mg/dl and 
triglyceride was 126 and fasting blood glucose was 89 mg/dl. There was an insignificant 
trend for increase in total cholesterol and HDL cholesterol. Triglyceride level was 
reduced six months after etanercept was withdrawn (126 mg / dl to 115 mg / dl). There 
was no change in the fasting blood glucose levels see Table 9.12 
Low HDL cholesterol <40mg/dl was not observed in any patient at baseline but after six 
months of stopping the drug there was a slightly significant increase in the number of 
patients with a low HDL cholesterol (p=0.07).
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Table 9.12 Fasting blood glucose and lipid parameters before and 6 months after 
etanercept treatment
Parameter Description Pre
etanercept
6 m post 
etanercept
|Chi2 p value
Total
Cholesterol
Units
median
[IQR]
173 159, 196 180 158, 195 0.83
HDL
Cholesterol
median
hqri
48 46, 52 49 43,52 0.97
Triglycerides median
nQRi
126 100, 171 115 92, 139 0.22
FBS median
nQRi
89 81,98 89 86, 94 0.81
Elevated lipids and fasting blood sugar
T C >200mg/dl n (%) 6 24 5 20.0 0.12 0.73
HDLC<40mg/d
1
n (%) 0 0 3 12.0 3.19 0.07
TC:HDL ratio 
>4.5
n(%) 4 16.0 3 12.0 0.17 0.68
TG >150mg/dl n (%) 8 32.0 6 24.0 0.40 0.53
FBS >100mg/dl n(%) 6 24 4 16.0 0.50 0.48
FBS in DM 
range >126 
mg/dl
n(%) 0 0 0 0
t Clii squared used to compare proportion with elevated risk factor after 6 months with pre treatment value (in the 25 patients that had 6 month 
assessments)
NS: Not significant p value
9.T.4.6 Composite ten year risk of CHD event by JBS
The median 10 year CHD risk score for the probality of a CHD event calculated by JBS 
was 3.5 (systolic) and 3.9 (diastolic). There was an insignificant trend of reduction in 
elevated CV risk factors. The CHD risk score was same before and 6 month after 
etanercept was withdrawn see Table 9.13.
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Table 9.13 Composite ten year risk score of CHD event
Parameter Descriptio
n
Pre
etanercept
6 m post 
etanercept
$Chi2 p value
CHD risk 
(Systolic)
median
riQRi
3.5 2.2, 3.5 4.3 2.6, 6.9 0.66
CHD risk 
(diastolic)
median
noRi
3.9 2.7, 10.4 5.7 3.3, 9.0 0.69
*10 year CHD 
risk >10% 
(systolic)
n (%) 5 20.0 5 20.0 0 1.0
*10 year CHD 
risk >15% 
(systolic)
n (%) 3 12.0 2 8.0 0.22 0.63
*10 year CHD 
risk >10% 
(diastolic)
n(%) 7 28.0 5 20 0.44 0.51
*10 year CHD 
risk >15% 
(diastolic)
n (%) 2 8.0 2 8.0 0.22 0.64
J Chi squared used to compare proportion with elevated risk factor after 6 months with pre treatment value (in the 25 patients that had 6 month 
assessments)
Wilcoxon’s sign rank test used to compare median CHD risk scores
In the repeat analysis comparing 6 months after etanercept we see that the association 
with reduced prevalence of systolic hypertension was lost see Table 9.10. However, the 
numbers are smaller as fewer patients had 6 month data. The only association that 
remains significant at 6 months is the reduced exposure to steroids.
9.8 Discussion
This small cohort of RA patients demonstrated a significant reduction in their DAS 28 
with a short course of etanercept. The requirement of NSAIDs and steroids was 
reduced. However there was no significant change in the cardiovascular risk factor 
profile apart from a modest reduction in systolic BP at the 3 month assessment which 
was not sustained when the analysis was repeated 6 months after etanercept was 
withdrawn. It appears from this study that short term use of etanercept does not lead to
216
sustained improvement in CV risk factors after the drug is withdrawn. Non blinded 
nature of this study was in accordance with routine clinical practice and was not 
foreseen to impact the outcome.
There are several possible explanations for this modest improvement in systolic BP 
after short term exposure to anti-TNF therapy. One explanation might be that as disease 
activity was improved in the months after etanercept was used this may have lead to less 
chronic pain. We know from physiological studies that severe pain is associated with a 
rise in blood pressure although this is more marked in the acute setting with increased 
sympathetic drive (Chawla PS, 1999). The fact that disease activity was reduced and 
patients were less dependent on NSAIDs may also have contributed to the modest 
reduction in BP. We know that NSAID use can lead to a rise in BP through effects on 
the kidney causing salt and fluid retention. By the 3 month assessment 27 % of the 
cohort had managed to stop using any NSAIDs and this reduction in NSAID use may 
have been responsible for the improvement in systolic BP. Unfortunately it was not 
possible, because of the small cohort size to stratify the group into those dependant on 
NSAIDs and repeat the analyses. What was interesting was that the increased use of 
leflunomide during the months following withdrawal of etanercept was not associated 
with increase in BP. As hypertension is one of the commonly described side effects of 
leflunomide therapy (Rozman et ah, 2002), we have not seen any marked increase in BP 
with use of this drug at the 10 mg dose in this cohort. This reflects the results presented 
in chapter 8 section 8.7 the leflunomide chapter where addition of leflunomide was not 
seen to be associated with any increase in hypertension.
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It is rather interesting to note that three months after etanercept there was a moderate 
but not statistically significant reduction in the number of patients having a high (>15%) 
CHD risk score but this reduction did not persist 6 months after therapy. It is likely that 
the reduction in systolic blood pressure resulted in the initial reduction in CHD risk 
score.
Surprisingly there is a mild increase in number of patients with a low HDL < 40 mg/ dl. 
The exact reason for this is not known. Anti TNF treatment has been demonstrated to 
increase HDL cholesterol (Popa C 2005, Spanakis E 2006). However, these studies 
were carried out on predominantly Caucasian patients and it is possible that 
dyslipidaemia in Indian RA patients may respond in a different way though, the number 
of patients having a reduced HDL is small it is worth exploring this finding in studies 
with larger patient cohorts.
A modest beneficial effect of leflunomide on atherogenic index was seen in the study 
presented in chapter 8. It is possible that any effect of etanercept on HDL level has been 
reduced by the concomitant addition of low dose leflunomide in this study. In order to 
try and separate out the effect of etanercept on lipid profiles, repeating this study in a 
more controlled environment without the addition of leflunomide would help to explore 
whether short courses of etanercept have any significant adverse effects on HDL levels 
in Indian RA patients.
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Most of the published literature, reporting a beneficial effect of anti TNF treatment on 
lipid profile is with prolonged use of anti TNF alpha (Dahlqvist et ah, 2006), There are 
conflicting reports about the effect of anti TNF therapy on lipid profile. Studies 
reporting a short term effect of the drug have evaluated patients after a short duration of 
drug use but, those patients were still continuing anti TNF treatment .One study has 
observed an increase in HDL cholesterol and T-Chol but no change in atherogenic index 
(Seriolo et al., 2006) another study (Soubrier M, 2008 ) failed to observe any effect on 
lipid profile in patients treated with anti TNF agents. However, these studies did not 
observe the lipid profile after stopping anti TNF treatment to see the sustained benefit. 
To our knowledge this is the first study looking at the CV risk factors after the anti TNF 
treatment was withdrawn.
To our knowledge this is also the first study in South Asian Indian RA patients with a 
biologic response modifier - etanercept looking at the traditional CV risk factors and 
subjecting the patients to repeat evaluations after stopping etanercept and observing the 
change in response after the drug was withdrawn. Rather surprisingly there was no 
significant increase in disease activity even 6 months after stopping the drug. This 
finding is important in a developing country like India where patients are mostly self 
funded for their treatment and not many patients can be benefited from the costly 
treatments even when they have active disease. This approach may not alter the CV risk 
profile but is effective in disease control as demonstrated in this study. The encouraging 
finding of a sustained response can motivate rheumatologists of developing countries to 
give a short course of a biologic to induce remission / reduction in disease activity and
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maintain the response by increasing the dose of existing DMARDs or the addition of an 
additional DMARD like leflunomide. This concept of treatment is not described in 
literature.
In the western countries where biologic response modifiers are used for an indefinite 
periods this concept of induction of remission can be used and the cost of treatment can 
be significantly reduced and the drug can be made available to larger number of patients 
by cutting the per patient cost of therapy.
With the advent of biosimilar drugs the treatment scenario especially in developing 
countries may change. The biosimilars reduce the treatment costs significantly. 
However, it would be a concern as a difference in impurity and breakdown products can 
have serious health complications. Testing procedures based on a thorough 
demonstration of comparability of the similar product to an existing approved product 
are needed (Genazzani et ah, 2007). These drugs are referred to as follow on biologies 
by the FDA and subsequent entry drugs in Canada. The US FDA has been given 
authority to approve bio similar drugs as per “Patient protection and affordable care act” 
(March 23, 2010). The European medicines agency has drafted guidelines that may 
expand the market for biosimilar compounds.
There are a number of limitations with this study. The major limitation was that it was 
not possible to assess CV risk in patients whilst they were treated with etanercept and 
before leflunomide was added. This was the original plan for the study but as most
220
patients “save up” for etanercept exposure to optimize their disease control to help with 
significant family events; most patients were unable or unwilling to attend the clinic for 
CV assessments at that time. Also as they would only have had 2 months treatment by 
that time this short period of drug exposure may not have had sufficient time to lead to 
any CV risk modification. Therefore the decision was taken to explore whether 
etanercept was associated with risk factor modification after drug was withdrawn. We 
were also unable to repeat the analysis six months after etanercept therapy in all patients 
due to uncontrollable factors. Some of the patients had gone abroad to meet their 
children and others were not residing in Hyderabad at that time and could not come for 
a repeat analysis at the 6 month assessment. This was an observational study and no 
placebo arm was used. However as discussed in chapter 8 page 197, we would not 
expect this to change laboratory reports like ESR and lipids.
The other major weakness of the study was that large numbers of patients exposed to 
patients could afford the drug. If this study was to be repeated recruitment of patients 
from multiple similar rheumatology centres would be a way to increase the cohort size. 
Studies with larger numbers and longer follow up are needed in South Asian Indian RA 
patients to demonstrate the effect on traditional CV risk factors and also to support the 
concept of induction of remission with biologic response modifiers.
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Chapter 10 - Discussion
This chapter discusses results obtainedfrom this study as a whole, in the light of 
present literature. Public health messages, regarding life style modification and the 
needfor treating physicians, rheumatologists and cardiologists to be made aware of the 
gravity ofproblem are highlighted. Finally, the potential for future studies in this 
population to further investigate this are described.
10.1 Main findings of the study
This study, which explored the prevalence of traditional cardiovascular risk factors in 
South Asian Indian patients, has revealed interesting findings that impact not only on 
the population studied, but also a wider scale. I observed a dramatic increase in the 
prevalence of all traditional CV risk factors in this cohort; with a fourfold increased 
composite 1 Oyear CHD risk score of a CV event. The fact that the RA patients in my 
cohort were younger than the participants in most other studies, the increased traditional 
CV risk factors and composite CHD risk scores is rather alarming and has major public 
health implications. In contrast to other studies, smoking was rarely described by either 
cases or controls. The number of smokers overall was too small to detect an association 
with RA.
The median BMI in the two groups was in the overweight /obese range (25 kg/m2). 
Even though the cases and controls displayed an increased prevalence of obesity, a high 
waist to hip ratio was strongly associated with having RA. Co-morbidities such as 
hypertension, diabetes and hypothyroidism also had an association with a diagnosis of
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RA, with hypertension the most frequently observed co-morbidity. The diagnosis of RA 
was associated with dyslipidaemia, in the form of elevated total cholesterol, high 
triglycerides and low HDL. All of the factors constituting the metabolic syndrome also 
had an association with being a case of RA with almost half of the participants in the 
RA cohort meeting the diagnostic criteria for metabolic syndrome.
Traditional CV risk factors were not found to have a strong relation with disease 
activity. Furthermore, the finding of low/moderate disease activity being associated 
with high triglycerides was not expected and needs further exploration. Despite the fact 
that majority of the study participants were females, the significantly increased 10 year 
risk of a CHD event in RA cases highlights an urgent need for mortality studies in this 
population of South Asian Indian patients and a greater public health awareness.
In contrast to common the general perception in the past, leflunomide was not 
associated with increase in blood pressure in my cohort. Indeed, this drug appeared to 
reduce blood pressure in hypertensive individuals — an observation that needs further 
exploration in a bigger cohort with longer follow up.
Finally, whilst a short course of the biologic response modifier etanercept did not have a 
sustained effect on traditional CV risk factors, the sustained effect on disease activity is 
encouraging and may set a trend for inducing reduction ofRA disease burden. Although 
this study was not powered to explore the long term effect of etanercept on DAS 28 my 
finding needs to be further explored.
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10.2 Individual CV risk factors
When CV risk factors were examined individually, a strong association with being a 
case of RA was detected. There was a trend for elevated blood pressure to be more 
frequently seen in patients with RA. A high diastolic blood pressure of >95 mm Hg 
was associated with RA. My cohort had particularly active disease, with patients taking 
NSAIDSs and glucocorticosteroids. Although it is known that these agents are 
associated with hypertension, I am not aware of reports of these drugs mediating a 
selective rise in diastolic blood pressure. The stress related to having RA and its 
associated adverse impact on life is also not likely to have a selective effect on diastolic 
blood pressure. This finding of diastolic hypertension being associated with RA 
therefore needs to be addressed in future studies.
When compared to controls, RA was strongly associated with elevated fasting blood 
glucose and co morbid type 2 DM. It is possible that the effect of active disease in 
reducing mobility may have resulted in glucose intolerance. It is also possible that 
rheumatoid cachexia, which results in increased fat mass and reduced lean muscle mass, 
with increased abdominal girth and increased waist hip ratio may have played a role. 
Whilst I did not measure body composition formally in this study, I did record waist and 
hip measurements and observed that the waist to hip ratio was higher in RA cases, 
despite similar BMI between cases and controls - suggesting an unfavourable body 
composition in the RA cases.
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The observation that dyslipidaemia, in the form of high total cholesterol and low HDL 
cholesterol, resulting in an unfavourable atherogenic index, was intriguing. As the RA 
cases had active disease, I would have expected them to have low total cholesterol and 
low HDL cholesterol, as tends to be observed in inflammatory states. The finding of an 
unfavourable atherogenic index in the context of RA was particularly interesting, 
because the background South Asian population is known to have increased prevalence 
of CVD. The active inflammatory disease in RA should was expected to result in lower 
levels of triglycerides - however, I observed that hypertriglyceridaemia was associated 
with being a case of RA. Indian patients with RA often report a vegetarian diet. The 
effect of diet on triglycerides in RA was not explored. This should be considered in 
further studies, together with the potential effects of individual drug therapies in a 
controlled manner.
I found that RA patients displayed an increased composite CHD risk score four times 
that of controls. This observation is especially alarming. Male gender, age and smoking 
are the important constituents of CHD risk estimation - our RA cohort had a majority of 
female participants who were younger and reported infrequent smoking, yet had an 
increased CHD risk. Longer term studies could investigate the effects of this on CV 
events and mortality. However, the data I have generated suggests that public health 
measures should be set in place now, to protect this high-risk population for the future.
All the risk factors that cluster in metabolic syndrome were frequently reported in cases 
and controls, though the frequency was much higher in patients with RA. The strongest
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association with being a case of RA was metabolic syndrome. The increased prevalence 
of metabolic syndrome reported in South Asian Indians, compounded with a diagnosis 
of RA and therefore further magnifying CY risk needs to be better understood and acted 
upon. Potential mechanisms that might underlie this should also be investigated in 
further studies that might uncover novel strategies to target this therapeutically.
Disease activity was not found to be associated with traditional CV risk factors. At first 
sight this may appear to be counter intuitive. It was also surprising to note that low/ 
moderate disease activity was associated with high triglyceride levels. Increased 
triglyceride levels are known to be associated with active RA. My cohort was skewed to 
highly active disease, rendering comparisons with lower disease activity less practical. 
My finding of elevated triglyceride in low/ moderate disease activity should be explored 
further in a larger cohort that contains a higher proportion of patients with less severe 
disease activity and, ideally, patients in remission.
Though the addition of leflunomide and etanercept was not blinded, we did not 
anticipate any impact on study outcome nor any bias in patient examination. As the 
patients were responsible for the cost of their treatment and we do not expect the lack of 
blinding to affect the CV risk factors. Hence, the possibility of a placebo response is 
ruled out.
It was reassuring, if not somewhat surprising, to find that leflunomide was not 
associated with hypertension. Indeed, the hypertensive group displayed reduction in
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systolic BP when on leflunomide. This is an important finding, as blood pressure is an 
extremely important constituent of CHD risk estimation and a reduction in blood 
pressure results in reduction of CHD risk score. This finding may reduce current 
apprehensions with the perceived association between leflunomide with hypertension 
and, importantly, provide a cheaper option to treat refractory active RA in developing 
countries. I also observed a modest improvement in the atherogenic index with the use 
of leflunomide. However, the number of patients in the study was too small to draw 
firm conclusions and was not powered to investigate these aspects. Further studies with 
larger number of participants having disease for a longer duration are needed to address 
this finding of reduction of blood pressure in hypertensive individuals and improvement 
of atherogenic index. CHD risk prevention scores should be applied to these participants 
and the effect of leflunomide on the 10 year composite CHD risk score addressed.
Whilst my observation that just a short course of the TNF inhibitor, etanercept, 
produced a sustained reduction in disease activity was encouraging, the fact that this did 
not reveal a sustained effect on traditional CV risk factors was not expected. This may 
be explained by a number of potential factors. I have already discussed that elevation of 
disease activity was not associated with a rise in traditional CV risk factors. It is 
possible that the duration of exposure to etanercept may have been too short to detect 
significant changes in the parameters that I measured. In addition, my patient cohort 
was recruited from a tertiary care centre, a potentially skewed population. As patients in 
India are self-funded, there is a possibility that those with reduced disease activity may 
visit the clinic less frequently. I also was not able to record the details of the patients
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who refused participation — potentially missing those patients who were happy with 
their mildly active disease and therefore not wanting further evaluation. I could not 
compare the active RA patients with those with a low DAS 28 as all the participants in 
the RA cohort had active disease. I was also unable to collect all information from 
participants on etanercept, as this was not possible in the routine clinical setting of this 
study. Few Indian patients can afford biologic response modifiers, due to their 
prohibitively high cost. These drugs tend to be reserved for use at the time of an 
important family or social event and not all patients could make the repeat clinic visit at 
the required time.
10.3 The study findings in light of published literature
The strong association between RA and metabolic syndrome found in my study 
population has been reported in literature (Karvounaris et ah, 2007, Elisa Gremese 
2011, Sidiropoulos et ah, 2008) and the association also observed in individuals without 
a history of CVD (Crowson et ah, 2011). The prevalence of metabolic syndrome was 
increased in RA compared to osteoarthritis and the normal population (Dessein et ah, 
2002). Chronic inflammation is frequently associated with metabolic syndrome (Julie P 
Sutherland, 2004). A meta-analysis has reported that metabolic syndrome is associated 
with a two fold increase in the risk of CVD, CV mortality, myocardial infarction and 
stroke (Mottillo S, 2010). In addition to the increased background of inflammation and 
increased risk of CVD, the chronic inflammation in RA may result in further 
magnification of the risk. Patients with metabolic syndrome have an increased risk of
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having moderate to severe RA and disease activity was found to correlate with the 
presence of the number of metabolic syndrome parameters (Karvounaris et ah, 2007).
South Asian Indians are known to have clustering of CV risk factors which constitute 
the metabolic syndrome (Misra and Khurana, 2011). Raised inflammatory markers were 
also observed in South Asian Indians (Indulekha et al., 2011). A recent study in urban 
Indians without inflammatory arthritis has observed a prevalence of metabolic 
syndrome in females as high as 58% (Das, 2011). The fact that having RA was 
associated with an 80% increased risk of having metabolic syndrome is a matter of 
concern, as this group has an increased risk of developing type 2 diabetes and may have 
a high risk of future CV events. Contrary to the assumption that use of treatments for 
RA may reduce the factors constituting metabolic syndrome, it was found that RA 
patients with metabolic syndrome had a lower possibility to achieve good response to 
treatment (Elisa Gremese 2011). The patients in my cohort taking leflunomide and 
etanercept did not experience a change in their features of metabolic syndrome. 
However this finding needs to be explored in future studies. At this juncture it is 
difficult to establish a relation between RA, metabolic syndrome and the treatments 
used to treat RA.
I used the NCEP ATP III criteria to assess metabolic syndrome, using a high cut off. A 
lower cut off has been proposed for different ethnic populations. The cut off for BMI 
and waist:hip ratio is also lower, but their predictive value in identifying T2 DM and 
CVD compared to earlier cut offs has been debated (Misra and Vikram, 2008).
229
The DMARD, hydroxychloroquine, is associated with a decreased risk of diabetes and 
improved glycaemic control (Bili et ah, 2011), Earlier studies have also demonstrated 
improvement of lipid profile with the use of this drug (Munro R, 1997). It may be worth 
studying the effects of hydroxychloroquine on the features of metabolic syndrome in 
this high-risk population in the future.
An increased prevalence of diastolic hypertension in South Asians compared to 
Caucasians has been documented in an earlier study (Ajjan et ah, 2007). The RA cohort 
in this study had increased frequency of diastolic hypertension when compared to 
controls. This is a matter of concern and needs to be addressed urgently.
Type 2 diabetes was found to be more prevalent in RA as per an earlier meta-analysis 
addressing traditional CVD risk factors (Boyer et al., 2011). South Asians Indians are 
known to the highest prevalence of diabetes in the world (Gupta R, 2007) and diabetes 
is known to occur a decade earlier than Caucasians and other Asians (Mather HM, 
1998). Though there was no difference in BMI between the two cohorts, a high 
waistrhip ratio was associated with being a case of RA. This could be an explanation for 
the increased prevalence of diabetes found in the RA cohort. In the context of RA, the 
twenty times increased prevalence of elevated fasting blood sugar is a serious matter 
and requires immediate attention.
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The typical pattern of dyslipidaemia with high total cholesterol, high triglycerides, high 
atherogenic index and low total cholesterol is also an important finding. It reported in 
the literature that active disease is associated with low total cholesterol, low HDL 
cholesterol (White et ah, 2006) and low triglycerides (lannello S, 2003). A study from 
north India demonstrated a negative association between disease activity, total 
cholesterol and disease modification with 3 months of DMARDs, with modest elevation 
of total cholesterol and no signification association with HDL cholesterol and 
triglycerides. (Hadda V., 2007). In contrast, I observed a modest improvement of 
atherogenic index with three months use of leflunomide. These observations need to be 
studied further.
The increased prevalence of traditional CV risk factors has resulted in increased 
composite CHD risk score of a probability of a CHD event in 10 years to be strongly 
associated with being a case of RA. The CHD risk score was high in RA cases, both by 
Framingham risk score and JBS; but a higher CHD risk score (>15%) was observed 
with the JBS scoring system. Most of the studies in South Asian Indian RA patients 
have used the Framingham risk score for prediction of a CHD event. JBS may also be 
used in future studies. The relative sensitivity of these scores in predicting a CHD event 
and choice of optimal score for the future can be identified by following these two 
cohorts over time to address the occurrence of events and mortality.
The EULAR guidelines suggest that RA should be treated as a condition with high risk 
of CVD (Peters et al., 2010) - the increased risk being attributed to traditional CV risk
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factors and RA disease activity. Aggressive treatment of disease activity is rightly 
recommended, but in a country like India, where the patient is responsible for the cost 
of the treatment, the choice of medicines is considerably limited. The majority of Indian 
RA patients cannot afford biologies. The advent of biosimilars with lower cost may 
hopefully change the picture. The modest improvement of the atherogenic index and no 
increase in blood pressure with leflunomide is an encouraging finding in our scenario. 
The EULAR guidelines suggest an annual CV risk assessment that can be performed 
less frequently in patients who do not have a high risk. The suggestion of a 1.5 
multiplication factor in calculating CV risk for RA patients is also made. There is 
already a suggestion of further multiplication of CV risk in ethnic populations. My 
study suggests that, in the context of a South Indian population, this should be 
considered urgently, with additional data to inform this potentially gained from further 
follow up of my cohort. Pending development of better local guidelines, it is even more 
important that EULAR guidelines should be followed.
RA is known to occur ten years earlier in Indians (Chandrasekaran and Radhakrishna, 
1995). Diabetes occurs ten years earlier and CVD is also seen at a younger age (Enas et 
al., 1992). My RA cohort had active disease without particularly long disease duration. 
As the RA patients were younger compared to most of the published literature, the 
effect of the increased prevalence of CV risk factors should be explored in a future 
mortality study. It would also be interesting to know if RA is a risk factor for CVD in 
this population.
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10.4 Public health message and avenues for future research
My work has identified the urgent need for a fresh focus on RA and new public health 
messages for India. In light of my findings of increased prevalence of traditional CV 
risk factors in RA, life style modification measures in patients with RA are needed. 
Most of the elevated risk factors like diabetes, hypertension, dyslipidaemia and high 
waisfhip ratio, all clustering to increase the prevalence of metabolic syndrome can 
potentially be successfully improved by lifestyle modification with for example patients 
being especially encouraged to increase mobility and exercise (Turesson and Matteson, 
2007). The successful implementation of this will, however, be a considerable 
challenge. It was rather surprising to know the response of patients when they were 
made aware of their elevated/high composite 10 year CHD risk score. Some patients 
were concerned about their increased risk of a CHD event, some were angry that 
another problem is anticipated which would further increase their expenditure. Few 
patients responded by saying that since they were not productive and were a burden to 
their family members it was good that they would die. Hence patient education is of 
outmost importance. The patients should be encouraged to have health insurance which 
is not very commonly observed in individuals living India. I am not aware of a CV 
event in the RA cases or controls when this study data was analysed.
Physicians, rheumatologists and cardiologists should be made aware of the gravity of 
the problem and be particularly proactive in identifying and treating CV risk factors in 
RA. Co morbidities should be identified and treated. Blood pressure measurements 
should be performed at every clinic visit and patients with elevated blood pressure and
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those with existing hypertension should be advised to adhere to antihypertensive 
medication and monitor their blood pressure regularly.
Blood glucose monitoring should also be done frequently. Anthropometric 
measurements of the patients should be taken periodically and evaluation of criteria for 
metabolic syndrome should become routine. An annual lipid profile should be 
performed and interventions made as indicated. After conducting this study my 
colleagues and I in Hyderabad have changed our practice and, for example, have started 
checking lipid profiles in our patients.
The unexpected finding of sustained reduction of disease activity with just a short 
course of the biologic response modifier etanercept is reassuring that this approach is 
effective from a disease suppression angle. This approach can be potentially applied in 
developing countries, where active RA patients are unable to afford expensive drugs for 
more than short periods of a time at best. The advent of biosimilar drugs may help drive 
the costs of such treatments down, particularly benefiting active RA patients in 
countries such as.
Lifestyle modification, in the form of increased activity and diet modification should be 
repeatedly emphasised at regular intervals. This should become a routine practice at 
times such as giving a fresh prescription for medicines. The landmark INTERHEART 
case control study, looking at 15,000 patients in 52 countries with first presentation of 
myocardial infarction, has suggested that traditional CV risk factors should not be
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neglected in South Asians. High waist:hip ratio was found to be related to population 
attributable risk to an even greater than that associated with smoking (Salim Yusuf and 
John Varigos, 2004, Joshi P, 2007).
Aggressive treatment of RA to reduce the inflammatory burden should be advocated. 
There is a case to promote more extensive use of the traditional DMARD 
hydroxychloroquine, due to its beneficial effects on lipids and blood glucose. 
Dyslipidaemia should be treated. In addition to treating dyslipidaemia, statins are 
known have anti-inflammatory effects and to be associated with reduced CV events in 
individuals with elevated CRP levels in the absence of dyslipidaemia (Ridker, 2002). 
The JUPITER (Justification for the Use of Statins in Primary Prevention: An 
Intervention Trial Evaluating Rosuvastatin) placebo controlled trial, evaluating the 
effect of statins in reducing CV events and strokes in persons with normal cholesterol, 
demonstrated a reduction in the levels of hs CRP and LDL in patients on statins. There 
was also a modest reduction in the risk of CV events and stroke (Ridker PM, 2008). 
Other drugs known to have a beneficial effect on the CV system are angiotensin 
converting enzyme inhibitors and folic acid.
The need for addressing CV risk factors in RA by increasing awareness of the need for 
aggressive intervention as in diabetes and established CVD (Kumar and Armstrong, 
2008) is pressing. As the CVD risk in RA is similar to that observed in diabetes, RA 
should be considered as an individual risk factor for CVD (Peters et al., 2009) in its own 
right.
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10.5 Urgent need for studies in South Asian Indian RA patients
India is the second most populated country in the world with a population 1.21 billion 
(as per 2011 census). The Indian population amounts to 17.31% of the world 
population. One out of six persons in the world is from India. The world health 
organisation (WHO) has reported that cardiovascular disease is rising in Indians at an 
alarming speed and, by the year 2020, CVD will be the largest cause of disability and 
death in Indians (WHO 2005). The prevalence of rheumatoid arthritis in Indians is 
0.75%, which equates to more than 9 million patients with RA - yet there is paucity of 
data for so many aspects of RA in India. I have created the largest RA case control 
database in the country. My study has confirmed the increased prevalence of traditional 
CV risk factors in South Asian Indians and a strong association of RA with metabolic 
syndrome. Whether RA truly is an independent risk factor for CVD in this population 
should be investigated by following these patients, observing the CVD event rate and 
exploring if this is affected by CV risk factors.
If the composite CHD risk prediction scores are valid in these patients, I anticipate that 
this increased CHD risk will correlate with an increased CHD event rate in the RA cases 
as these patients are followed up. As yet, no CVD morbidity or mortality studies have 
been conducted in RA cohorts in India. Possible barriers to this type of study include 
difficulty in obtaining accurate cause-specific mortality data because of a lack of 
population-based mortality registers in this country. However, if assumptions are made, 
based on the CHD risk scores predicting absolute risk of CHD events, I estimate that in 
the 90 RA patients with risk in excess of 15% some 14 patients would be expected to
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have a significant CHD event. If the same approach were applied to the controls, only 7 
would be expected to have a significant event. This would equate to a 2 fold increase in 
CVD events described in the RA cardiovascular literature (Wolfe and Michaud, 2008) 
(van Halm et ah, 2009) (Solomon et al., 2003). This, together with the fact that there is 
an overall increased prevalence of CV risk in the general population of India, suggests 
that my work has been particularly timely and may lead to fundamental changes in 
consideration of CV risk in South Asian Indian RA patients for the future.
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